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Abstract 
Pre-treatment with polyunsaturated fatty acids or bioactive lipid mediators has 
been shown to reduce neuronal injury in rodent models of focal ischaemia, 
but the molecular mechanisms underlying this neuroprotection are unclear. In 
this study, we aimed to investigate whether systemic administration of alpha 
linolenic acid (ALA) leads to changes in the profile of mouse brain 
phospholipid and bioactive lipid mediators in both mouse brain and plasma 
within the previously determined neuroprotection time window. Mass 
spectrometry (MS) and tandem mass spectrometry (MS/MS) allowed us to 
detect and identify 47 phospholipids in mouse cerebral cortex, including 
several phospholipid species not previously reported in brain lipidomic 
studies. These included a phosphatidylethanolamine species with m/z 720 
that has been associated with retinal stem cells. No widespread changes in 
cerebral cortex phospholipid composition were observed following 
intravenous ALA. Several significant changes in lipid mediators (P<0.05 with 
two-way ANOVA and post hoc Dunnett‟s t test) were detected in ALA-treated 
animals compared to untreated and vehicle-injected animals. Many of the 
affected lipid mediators are ligands for prostanoid receptors which have been 
demonstrated to play a role in the development of brain injury following 
cerebral ischaemia, implying that changes in bioactive lipid mediators or 
modulation of prostanoid receptors may occur following ALA pre-treatment in 
mice. This study illustrates the potential of advanced lipidomic analysis as a 
novel tool for neurochemists. 
Key words: mouse, fatty acids, brain, cortex, phospholipid, plasma, tandem 
mass spectrometry, neuroprotection 
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1. Introduction 
 
1.1. General introduction on lipids and their physiological 
roles 
 
 
 
There is no universal definition of a lipid, but broadly speaking, lipids 
constitute a diverse group of compounds traditionally characterized by their 
physicochemical properties, most notably their high solubility in organic 
compounds such as chloroform and hexane, and their low solubility in water. 
There is a great variety in the structure and physicochemical properties of 
lipids. They can be divided into simple lipids, which yield two or fewer 
properties when hydrolysed, and complex lipids that give rise to three or more 
components when hydrolyzed. Simple lipids include fatty acids and 
cholesterol. Examples of complex lipids are mono–, di– and tri–glycerides, 
ceramides, waxes, phospholipids and glycolipids. 
 
1.2. Fatty acids  
 
1.2.1. Structure and nomenclature of fatty acids 
 
The simplest lipids are fatty acids, which are long chain (i.e. acyl chain) 
monocarboxylic acids. The acyl chain may contain no double bonds in the 
case of saturated fatty acids (SFA), one double bond if they are 
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monounsaturated fatty acids (MUFA), or more than one double bond if they 
are polyunsaturated fatty acids (PUFA). The nomenclature of fatty acids is 
dependent on the length of the carbon chain and the position and 
conformation of the CC double bonds. Systematic prefixes for fatty acids 
depend on the acyl chain length, as described in Table 1.1. 
 
Table 1.1 Systematic chain length nomenclature of fatty acids  
Carbon chain length Prefix 
12 Dodeca - 
14 Tetradeca - 
16 Hexadeca- 
18 Octadeca - 
20 Eicosa - 
22 Docosa - 
24 
24 
Tetracosa - 
 
The variety in the number, positions and conformations of double bonds 
mean that fatty acids exist in many isomeric forms. For example, positional 
isomers of fatty acids have different locations of double bonds and epimeric 
fatty acid isomers have differing conformations of groups. A CC double bond 
is denoted by Δ, followed by the carbon position of the double bond e.g. Δx 
indicates that a double bond is located on the xth C atom from the carboxyl 
group. The rigid nature of the CC double bond gives rise to cis and trans 
isomers of some fatty acids (also known as Z and E isomers, respectively) 
where the orientation of groups in space differ between two isomers. Cis 
isomers are those where both ends of methyl chain are located on the same 
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side of the double bond and trans isomers have the ends of the methyl chain 
on opposing sides of the double bond. 
 
The position of the double bond from the methyl carbon end can be denoted 
by describing a fatty acid as an n-x (or -x) fatty acid, where the double bond 
is on the xth carbon atom from the methyl carbon end of the chain. Hence, n-3 
fatty acids have a double bond located at the 3rd carbon atom from the methyl 
end, n–6 fatty acids have a double bond located at the 6th carbon atom from 
the methyl end and n–9 fatty acids have a double bond located at the 9th 
carbon atom from the methyl end. PUFA can also be described using a 
shorthand form, as in Figure 1.1. 
 
 
Figure 1.1 Shorthand nomenclature of PUFA 
 
 
Shorthand nomenclature of PUFA describes the number of C atoms in its structure, the 
number of C=C double bonds and the position of the C=C bond furthest away from the 
COOH group 
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In addition to systematic nomenclature, many fatty acids have trivial names, 
which are commonly used in literature. Table 1.2 shows the systematic, trivial 
and shorthand names of common saturated and unsaturated fatty acids.  
 
Table 1.2 Nomenclature of long chain fatty acids (adapted from 
www.cyberlipid.com)  
Systematic name Trivial name Shorthand 
Saturated fatty acids   
Dodecanoic Lauric 12:0 
Tetradecanoic Myristic 14:0 
Hexadecanoic Palmitic 16:0 
Octadecanoic Stearic 18:0 
Omega – 9 fatty acids   
cis 9-octadecenoic Oleic 18:1(n-9) 
All cis 5,8,11-eicosatrienoic Mead 20:3(n-9) 
Omega – 6 fatty acids   
All cis 9,12-octadecadienoic Linoleic 18:2(n-6) 
All cis 6,9,12-octadecatrienoic γ-Linolenic 18:3(n-6) 
All cis 8,11,14-eicosatrienoic Dihomo-γ-
linolenic 
20:3(n-6) 
All cis 5,8,11,14-eicosatetraenoic Arachidonic 20:4(n-6) 
All cis 7,10,13,16-docosatetraenoic - 22:4(n-6) 
All cis 4,7,10,13,16-docosapentaenoic - 22:5(n-6) 
Omega – 3 fatty acids   
All cis 9,12,15-octadecatrienoic α-Linolenic 18:3(n-3) 
All cis 6,9,12,15-octadecatetraenoic Stearidonic 18:4(n-3) 
All cis 8,11,14,17-eicosatetraenoic - 20:4(n-3) 
All cis 5,8,11,14,17-eicosapentaenoic - 20:5(n-3) 
All cis 7,10,13,16,19-docosapentaenoic - 22:5(n-3) 
All cis 4,7,10,13,16,19-docosahexaenoic - 22:6(n-3) 
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1.2.2. Biosynthesis of fatty acids 
 
It has long been known that lipids form an essential part of a balanced diet. In 
the 1920s, Burr and Burr described a deficiency disease in rats when fat was 
strictly excluded from the diet, which could be cured by addition of a few daily 
drops of lard (Burr & Burr, 1929). More recent work on dietary lipids led to the 
use of the term “essential fatty acids” to describe the two polyunsaturated 
fatty acids (PUFA) linoleic acid (LA) and α- linolenic acid (ALA). The essential 
fatty acids are so called because they are required by mammals, and yet they 
cannot be synthesised by mammalian cells (Nicolaou & Kokotos, 2004).  
 
Figure 1.2 The essential fatty acids 
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Mammals can synthesise long chain saturated fatty acids de novo by 
elongation of a short-chain precursor (typically acetyl CoA) by 2 carbon units 
until the carbon chain length reaches C16 or C18 (Gurr et al., 2002). Palmitic 
acid (C16:0) and stearic acid (C18:0) can then be used as a starting point for 
the production of many other fatty acids using a variety of elongases and 
desaturases. The biosynthesis of LA and ALA from saturated fatty acids 
requires a Δ– 12 desaturase (also known as ω-6 desaturase) and a ω–3 
desaturase respectively (James, 1963; Harris & James 1965). These 
enzymes can be found in plant cells and cyanobacteria but not in mammalian 
cells, which means that LA and ALA must be supplied from the diet (Ursin, 
2003). Other long-chain PUFA can either be supplied from the diet or 
biosynthesised from dietary essential fatty acids by the pathways illustrated in 
Figure 1.3. The biosynthesis of long-chain polyunsaturated n-3 and n-6 PUFA 
in mammals occurs by two parallel pathways which have ALA and LA as their 
respective starting points (Sprecher, Luthria et al., 1995; Parker-Barnes, Das 
et al., 2000; Nakamura & Nara, 2003). LA is the precursor of many important 
n-6 PUFA, including arachidonic acid (AA), whilst several n-3 PUFA can be 
synthesised from ALA by animals and humans, including eicosapentaenoic 
acid (EPA) and docosahexaenoic acid (DHA) (Rapoport et al., 2001; Sinclair 
& Wesinger, 2004). The synthesis of long-chain PUFA in mammals is a multi-
step process involving elongases, desaturases and partial β-oxidation 
(Sprecher et al., 1995).  
 16 
Figure 1.3 Biosynthesis of polyunsaturated fatty acids
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Both Δ5-desaturase and Δ6-desaturase genes (FADS1 and FADS2, 
respectively) have been identified and cloned in mammalian cells (Cho et al., 
1999a; Cho et al., 1999b). The FADS-2 gene has recently been shown to 
possess Δ8-desaturase activity on both n-6 and n-3 fatty acids in yeast cells 
transfected with a baboon gene (Park et al., 2009) and Δ8-desaturation of 
20:2n-6 acid to 20:3n-6 has previously been reported in both rat and human 
tissue (Albert & Coniglio, 1977; Albert et al., 1979) 
 
Six fatty acid elongase genes (Elovl 1-6) have been identified in rats, mice 
and humans, which show differential expression in different tissue types and 
also have different substrate specificity (Wang et al., 2005). Elovl-1 is 
expressed in many tissue types, including liver, lung, kidney, skin, heart and 
brain, with a particularly high level expression in CNS myelin. Its substrates 
are saturated and monounsaturated fatty acids up to a chain length of C26, 
and its activity is essential for myelination since a reduction in Elovl-1 activity 
in the CNS results in animal models of myelination deficiency (Tvrdik et al., 
2000). Elovl-2 can be found in liver, brain and testes. It elongates C20 – C22 
polyunsaturated fatty acids and is believed to be important in the production 
of long-chain n-3 and n-6 PUFA. Elovl-3 is expressed in skin, sebaceous 
glands, heart and adipose tissue (Westerberg et al., 2006) and can act on 
monounsaturated and saturated fatty acids with chain lengths up to C24. 
Elovl-4 is only expressed in the retina and acts upon very long chain fatty 
acids (chain length longer than C26). A deficiency of Elovl-4 has been linked 
to juvenile macular degeneration, and a lack of very long chain phospholipids 
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in the retinal tissues (McMahon et al., 2007). Elovl-5 has a wide range of 
substrates, and can elongate most saturated, monounsaturated and 
polyunsaturated fatty acids in the range of C16 – C22. It is widely-expressed in 
many tissue types but is most prominent in liver, where it is the most 
abundant elongase type. Elovl-6 is predominantly found in liver, brain and 
adipose tissue. It is selective for C12 - C16 saturated and monounsaturated 
fatty acids and is regulated at transcription level by SBERP1, a key protein in 
the regulation of hepatic lipid synthesis (Matsuzaka et al., 2002). 
 
1.3. Phospholipids 
 
Phospholipids are complex lipids, which serve primarily as structural lipids in 
membranes. Phospholipids can be defined as compounds which consist of: 
 
(i) a short organic backbone (either glycerol or sphingosine) 
(ii) fatty acid moieties linked to the glycerol or sphingosine backbone 
by either acyl, alkyl or ether linkages at the sn-1 and sn-2 position 
(iii) a polar head group at the sn-3 position of the backbone 
 
Phospholipids which contain a glycerol backbone are termed 
glycerophospholipids and those with a sphingosine backbone are called 
sphingophospholipids. 
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Figure 1.4 Structure of glycerol and sphingosine 
 
 
1.3.1. Glycerophosphopholipids 
 
Glycerophospholipids are amphipathic compounds (i.e. contain both a polar 
and a non-polar moiety in their structure), as they include a glycerol backbone 
with a polar head group attached to a phosphate unit at the sn-3 position, and 
fatty acid chains at the sn-1 and sn-2 positions (denoted R1 and R2 in Figure 
1.5). Further variation in the structure of glycerophospholipids can be 
introduced by a variety of R groups at the sn-1 and sn-2 positions. The variety 
of acyl chain length and unsaturation, as well as the many different possible 
polar head groups, results in a broad range of glycerophospholipids in 
biological tissues. 
 20 
Figure 1.5 Glycerophospholipid structure 
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1.3.2. Sphingophospholipids 
 
Sphingophospholipids contain sphingosine, a long-chain hydrophobic 
molecule, as their backbone, with a phosphate group at the sn-3 position and 
a fatty acid chain at the sn-2 position (denoted R in Figure 1.6). 
 
Figure 1.6 Structure of sphingomyelin 
 
1.4. Cholesterol 
 
Cholesterol is a polycyclic compound that is widely found in all animal tissues 
(Figure 1.7). The fused rings in cholesterol‟s structure means that the 
molecule is planar, except for the iso-octyl side chain and the hydroxy and 
two methyl groups. The hydroxy and methyl groups are arranged in β 
conformation.  
 
Figure 1.7 Cholesterol 
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Cholesterol can either be synthesised de novo in all eukaryotic cells (except 
red blood cells), or can be obtained from the diet and transported into cells 
from the circulation. Uptake of dietary cholesterol from the circulation can 
occur directly by desorption from the plasma membrane or through receptor – 
mediated uptake from lipoproteins. The main site of cholesterol biosynthesis 
is the liver, where it occurs inside the endoplasmic reticulum, but cholesterol 
biosynthesis also happens in brain peroxisomes. Cholesterol is a major brain 
lipid but its amphipathic nature (due to the non-polar iso-octyl side chain and 
the polar hydroxy group in its structure) means that it cannot be readily 
transported across the tight junctions of the blood–brain barrier. The brain is 
therefore reliant on intracerebral de novo synthesis of cholesterol to fulfil its 
cholesterol requirements.  
 
 
The process of cholesterol biosynthesis from mevalonate is a complex multi–
step reaction (McMurry & Begley, 2005). The rate-limiting step in cholesterol 
biosynthesis is the reduction of 3(S)-Hydroxy-3-methylglutaryl CoA to (R)-
mevalonate by HMG-CoA reductase (HMGR), and regulation of HMGR 
activity and its expression is the primary means of controlling the rate of 
cholesterol biosynthesis. Cholesterol can directly cause feedback inhibition of 
HMGR, control HMGR gene expression and the rate of HMGR degradation. 
In addition, HMGR can be regulated by covalent modification; with 
phosphorylation of HMGR by AMP-activated protein kinase decreasing its 
activity. 
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Cholesterol can interact with membrane phospholipids and sphingolipids to 
form “lipid rafts”, transient microdomains approximately 100-200nm diameter 
that are enriched in cholesterol and sphingolipids. Sphingolipids have 
predominantly saturated fatty acyl chains and the glycerophospholipids 
located within lipid raft areas are more saturated than in non-raft domains, 
increasing the efficiency of and the degree of order in fatty acyl chain packing 
within the raft microdomain. The result is a decreased permeability in lipid raft 
regions compared to other membrane regions. Membranes which 
predominantly contain glycerophospholipids are fluid and easily permeable 
due to loose packing of the phospholipids, which occurs for two reasons. 
Firstly, some glycerophospholipids contain bulky head groups, which mean 
that they do not naturally pack together tightly to form a bilayer structure. For 
example, phosphatidylethanolamines have a conical shape and naturally form 
a hexagonal phase in aqueous solutions. Secondly, unsaturated CC bonds 
cause a kink in the fatty acyl chains and prevent close packing of acyl chains. 
Many glycerophospholipids contain polyunsaturated fatty acyl chains, which 
unlike saturated fatty acyl chains cannot be packed tightly together.  
 
Intercalation of cholesterol within lipid rafts also alters the physicochemical 
properties of the plasma membrane by stabilizing its structure. Hydrophilic 
interaction between the cholesterol molecule‟s hydroxy group and choline-
containing phospholipids inside the lipid raft increases the mechanical 
strength of the membrane without affecting its horizontal flexibility.  
 24 
Cholesterol can also have an effect on the activity of integral membrane 
proteins such as ion channels, receptors and enzymes either directly, by 
binding to them (for example, proteins with sterol-binding domains can be 
directly modulated by cholesterol), or indirectly, by causing changes in 
plasma membrane physico-chemical properties that affect the folding and 
function of the proteins. Many proteins linked to cell signalling have also been 
found to be enriched in lipid rafts. These include G proteins, MAP kinase, 
protein kinase C and the p85 subunit of PI 3-kinase. 
 
Figure 1.8 Cholesterol is a key component of lipid rafts, which have been 
implicated in many physiological functions, including cell signalling (adapted 
from http://cellbiology.med.unsw.edu.au/units/science/lecture0803.htm) 
 
Inner leaflet
Outer leaflet
Non-raft membrane     Lipid raft
Unsaturated fatty   Saturated fatty acyl  
acyl chains             chains
Cholesterol
Lipid raft associated 
transmembrane proteins
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1.5. Lipid mediators involved in cell signalling 
 
Eicosanoids are biologically active lipid mediators derived from C20 fatty acids 
(eicosa = “twenty” in Greek), including prostaglandins (PG), thromboxanes 
(TX), leukotrienes (LT), lipoxins (LX), isoprostanes (IsoP), isofurans (IsoF) 
and a host of hydroxy, hydroperoxy and epoxy eicostrienoic, eicosatetraenoic 
and eicosapentaenoic acids (Cracowski, 2004; Hong et al., 2003; Parker-
Barnes et al., 2000; Serhan et al., 2000; Serhan et al., 2004; Serhan et al., 
2006; Zhou & Nilsson, 2001). Eicosanoids are derived from C20 
polyunsaturated fatty acids, mainly dihomo-gamma-linoleic (20:3n-6), 
arachidonic (20:4n-6), and eicosapentaenoic (20:5n-3) acids, through the 
action of cyclo-oxygenases-1 and 2 (COX-1 and COX-2), lipo-oxygenases 
(LOX), cytochrome P450 monoxygenases and free radical-catalysed 
reactions. Analogous compounds can be derived from DHA, such as 
resolvins, neuroprotectins, neuroprostanes (NeuroP) and neurofurans 
(NeuroF) (Hong et al., 2003; Moriguchi et al., 2004; Roberts & Fessel, 2004). 
Figure 1.9 illustrates the wide variety of lipid mediator compounds that can be 
produced from PUFA by enzymatic and non-enzymatic pathways. 
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Figure 1.9 Production of lipid mediators from the essential fatty acids can take place by several pathways 
 
COX = cyclo-oxygenase 
EET = epoxyeicosatrienoic acid 
EETeTr = epoxyeicosatetraenoic acid 
F.R. = free radicals 
PG = prostaglandin 
HETE = hydroxyeicosatetraenoic acid 
HDHA = hydroxydocosahexaenoic acid 
IsoP = isoprostane 
LOX = lipo-oxygenase 
NeuroP = neuroprotectins 
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Prostaglandins and thromboxanes are an important class of lipid mediators 
which are involved in physiological and pathophysiological processes in 
practically every organ, tissue and cell. They play a role in vasomotor control, 
regulation of inflammation and the immune response, platelet aggregation 
and blood clotting, and initiation of labour (Lieberman et al., 2006). PGI2, 
PGD2 and PGE2 generally favour vasodilation and a decrease in platelet and 
leukocyte aggregation, and also reduce T cell proliferation and lymphocyte 
migration, whilst PGF2α causes vasoconstriction, bronchoconstriction and 
contraction of smooth muscle. The biologically-active TXA2 shares many 
functions with PGF2α, causing vasoconstriction, platelet aggregation, 
bronchoconstriction and lymphocyte proliferation. The biological functions of 
prostaglandins are mediated through prostanoid-specific receptors and 
intracellular signalling pathways, whilst their biosynthesis is inhibited by the 
action of nonsteroidal anti-inflammatory drugs (NSAID) such as ibuprofen and 
indomethacin on COX enzymes. However, some NSAID such as 
acetylsalicylic acid (aspirin) can also lead to the modification of COX-2, which 
leads to biosynthesis of modified eicosanoids which have anti-inflammatory 
properties, such as the aspirin-triggered lipoxins (Claria & Serhan, 1995). 
  
Leukotrienes are products of LOX and play a role in inflammation processes 
and in anaphylaxis. LTB4 acts on immune cells; promoting adhesion and 
chemotaxis of leukocytes, and aggregation, enzyme release and production 
of reactive oxygen species in neutrophils. The cysteinyl 4-series LTs (LTC4, 
LTD4 and LTE4) act on smooth muscle and endothelial cells, causing 
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bronchoconstriction and increased microvascular permeability (Samuelsson 
et al., 1987). 
 
Many hydroxy, hydroperoxy and epoxy fatty acids have biological functions 
affecting vasomotor control or inflammation, with the exception of the diol 
products of epoxy eicosatrienoic acids (which are biologically inactive). In 
general, n-3 hydroxy fatty acids are anti-inflammatory or pro-resolution, whilst 
n-6 compounds are generally vasoactive or pro-inflammatory. The hydroxy 
derivatives of EPA and DHA known as resolvins and protectins are examples 
of anti-inflammatory n-3 hydroxy fatty acids, and 20-HETE is an example of a 
vasoactive n-6 hydroxy fatty acid (Capdevila & Falck, 2002; Serhan et al., 
2000). 
 
Isoprostanes are considered reliable markers of oxidative stress status and 
have been linked to inflammation, ischaemia-reperfusion, cardiovascular 
disease, reproductive disorders and diabetes (Masoodi & Nicolaou, 2006). 
They have also been shown to have biological activity, for example, both 8-
iso- PGE2 and 8-iso-PGF2α can modulate platelet aggregation (Roberts & 
Morrow, 1997). IsoFs are biomarkers of oxidative stress in mitochondria and 
are produced in significant quantities under conditions of high oxygen 
pressure (Fessel & Roberts, 2005). Since IsoF production is greater than IsoP 
production in some tissues (such as brain and kidney), it has been suggested 
that a combined measure of IsoP and IsoF may be a more accurate measure 
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of oxidative stress than either of these compounds alone (Fessel & Roberts, 
2005). 
 
1.5.1 The cyclo-oxygenase enzymes and their lipid mediator products 
 
Two isoforms of cyclo-oxygenase (COX) exist, which differ in tissue 
expression patterns, pharmacalogical properties and physiological functions 
(Morita, 2002, Rouzer & Marnett, 2005). COX–1 is widely acknowledged to be 
a housekeeping gene, constitutively expressed in many tissue types (Morita, 
2002, Rouzer & Marnett, 2005). COX–2 is an inducible gene, which is 
regulated at the transcription level (Morita, 2002). A splice variant of the COX-
1 gene third isoform (COX-3) has also been reported, which has been 
designated COX-3 (Chandrasekharan et al. 2002; Shaftel et al. 2003). A 
splice variant of the COX-1 gene has also reported as a third isoform of COX, 
and designated COX-3 (Chandrasekharan et al., 2002). This splice variabt 
contains intron 1 of the COX-1 gene, which is highly-conserved between 
mammalian species, including dogs, mice and humans. COX-3 is believed to 
be constitutive, and gene expression studies have shown the presence of 
COX-3 mRNA in the majority of tissues in human, rat and mouse brains, with 
the highest expression observed in endothelial cells of the cerebral cortex 
(Chandrasekharan et al., 2002; Kis et al., 2004; Shaftel et al., 2003).  
 
The lipid products of COX enzymes are collectively known as prostanoids, 
and they include prostaglandins, leukotrienes and thromboxanes (Tapiero et 
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al. 2002). COX enzymes can undergo regiospecific oxidation of dihomo-γ-
linolenic acid (DHGLA), AA, or EPA to produce 1-series, 2-series or 3-series 
PGs respectively, the products differing in structure due to the different 
number of double bonds in the substrates. 
 
Figure 1.10 Prostaglandin products of dihomo γ – linolenic acid, arachidonic 
acid and eicosapentaenoic acid (adapted from Nicolaou & Kokotos, 2004)  
 
COOH
dihomo-γ-linolenic acid arachidonic acid eicosapentaenoic acid
(all-cis 8,11,14-eicosatrienoic acid) (all-cis 5,8,11,14-eicosatetraenoic acid)        (all- cis 5,8,11,14,17-eicosapentaenoic acid)
COOH COOH
OH
O
COOH
OH
PGE1 PGE2 PGE3 
OH
O
COOH
OH
OH
O
COOH
OH
OH
COOH
OH
OH
OH
COOH
OH
OH
OH
OH
OH
COOH
PGF1α PGF2α   PGF3α 
1-series prostaglandins 2-series prostaglandins                       3-series prostaglandins
 
 
The PG products of AA and EPA differ considerably in biological activity (Arita 
et al., 2005; Claria & Serhan, 1995). For example, the PG-2 series 
synthesised from AA are predominantly pro-inflammatory, whereas the PG-3 
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series produced from EPA have anti-inflammatory physiological effects 
(Nicolaou & Kokotos, 2004, Tapiero et al., 2002). The anti-inflammatory 
properties of PG-3 series compounds have been attributed to the difference 
of prostaglandin receptor (PG-R) binding to PG-2 series and PG-3 series 
compounds. PG-3 series compounds generally have a lower affinity to PG-R 
than PG-2 series compounds and they also do not result in activation of PG-
R. The presence of both PG-3 and PG-2 series compounds results in 
competitive antagonism, where both PG series compete for PG-R binding 
sites, reducing PG-2 series binding and hence reducing PG-R activation 
(Bagga et al., 2003; Wada et al., 2007). 
 
Acetylated COX–2 can also produce hydroxy acids from PUFA, such as 9-
hydroxyoctadienoic acid (9–HODE) and 13–hydroxyoctadienoic acid (13–
HODE) from LA, 11-hydroxyeicosatetraenoic acid (11–HETE) from AA, 11-
hydroxyeicosapentaenoic acid (11–HEPE) from EPA and 13–
hydroxydocosahexaenoic acid (13–HDHA) from DHA (Arita et al., 2005). It 
has been proposed that the acetylation of COX-2 can modify the enzyme‟s 
substrate –binding pocket, resulting in production of positional and 
stereochemical isomers of the previously mentioned HETEs and HEPEs 
(Serhan et al., 2000). COX-2 reduces production of 9-HODE, 11R–HETE, 
11R–HEPE and 15R-HEPE and increases that of 15(R)–HETE, 15(R)–HEPE, 
18(R)–HEPE and 17(R)–HDHA (Arita et al., 2005, Claria & Serhan, 1995, 
Serhan et al., 2000). Some of these hydroxy fatty acids, such as 18(R)–
HEPE, are bioactive lipids that reduce inflammation and assist in the 
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resolution of inflammation (Chen & Bazan, 2005, Hong et al., 2003, Lagarde, 
2003, Mukherjee et al., 2004). Others can compete with other bioactive 
compounds for receptor binding positions, resulting in a biological effect. For 
example, 18(R)–HEPE competes with LTB4 for binding to human LTB4 
receptor expressed in HEK293 cells, resulting in reduced PMN migration 
following injury (Serhan et al., 2000). 
 
1.5.2 The lipooxygenase enzymes and their lipid mediator products 
 
LOX enzymes can synthesise a wide range of products which participate in 
the development or the resolution of inflammation, including hydroperoxy and 
hydroxy fatty acids, LTs and LXs (Arita et al., 2005; Claria & Serhan, 
1995;Hong et al., 2003; Mukherjee et al., 2004). In a similar manner to COX 
enzymes, LOX enzymes can produce both 4–series and 5–series LTs, which 
have different physiological functions. The 4–series leukotrienes are pro-
inflammatory lipid mediators; LTA4 is a potent platelet,-aggregating factor and 
LTB4 stimulates the chemotaxis and activation of neutrophils. 5–series 
leukotrienes, however, do not share these properties. LTA5 inhibits the 
production of TXA2, reducing blood clotting, and LTB5 is a weak chemotactic 
agent. The 5–series LTs exert their anti-inflammatory effects by directly 
competing with the 4–series LTs for LT receptor binding. 
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Figure 1.11. Biosynthesis of leukotrienes from polyunsaturated fatty acids by 
5- lipooxygenase. Other enzymes (leukotriene B hydrolase and glutathione S-
transferase) are responsible for the conversion of leukotriene A to other 
leukotriene species. 
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AA= arachidonic acid 
EPA= eicosapentaenoic acid 
HEPE= hydroxyeicosapentaenoic acid 
HETE= hydroxytetraenoic acid 
HPEPE= hydroxyperoxyeicosapentaenoic acid 
HPETE= hydroxyperoxytetraenoic acid 
LOX= lipo-oxygenase 
LTA= leukotriene A 
LTB= leukotriene B 
LTC= leukotriene C 
LTD= leukotriene D 
LTE= leukotriene E 
 
LOX enzymes can also hydroxylate PUFA in a regiospecific and 
stereospecific manner, catalysing the oxidation of fatty acids to produce 
hydroperoxy and/or hydroxy fatty acids (Arita et al., 2005; Brash, 1999; Jisaka 
et al., 2005; Kuhn et al., 2002; VanRollins & Murphy, 1984). Most of the 
compounds produced are in the (S) configuration, although a few LOX 
enzymes which produce (R) products have been recognised (Brash, 1999). 
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Figure 1.12 Hydroxylation of polyunsaturated fatty acids by LOX enzymes 
produces a wide range of hydroxy and hydroxyperoxy fatty acids 
LA AA EPA DHA
LOX enzymes
5(S)-HETE 5(S)-HEPE 4(S)–HDHA
5–HPETE 12-HPETE 7(S)–HDHA
8(S)–HETE 15-HPETE 11(S)–HDHA
12(S)–HETE 13(S)–HDHA
15(S)-HETE 14(S)–HDHA
17(S)-HDHA
13-HODE
 
AA= arachidonic acid 
DHA= docosahexaenoic acid 
EPA=eicosapentaenoic acid 
HDHA= hydroxydocosahexaenoic acid 
HEPE= hydroxyeicosapentaenoic acid 
HETE= hydroxyeicosatetraenoic acid 
HPETE= hydroperoxyeicosatetraenoic acid 
HODE= hydroxyoctadienoic acid 
LA= linolenic acid 
LOX= lipo-oxygenase 
 
The term “lipoxin” was introduced to describe anti–inflammatory lipid 
mediators synthesised from AA by sequential reactions of more than one type 
of LOX enzymes (Serhan et al. 1984). LX contain three hydroxy groups and 
are conjugated tetraenes (Δ 6,8,10,12). The two LX compounds were designated 
LXA (5(S),6(R),5(S)–trihydroxytetraeicosanoic acid) and LXB 
(5(S),15(R),16(S)–trihydroxytetraeicosanoic acid). LXA and LXB can be 
synthesised by one of two biochemical pathways that require interaction of 
two different LOX enzymes located in different cell types. One pathway 
involves interaction of 15–LOX–1 in reticulocytes and 5–LOX in neutrophils 
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and the other, interaction of 5–LOX in neutrophils and 12–LOX in platelets 
(see figure 1.13). 
 
Figure 1.13 Production of lipoxins from arachidonic acid is a multiple step 
process and requires LOX enzymes from different cell types 
 
Arachidonic acid
15-HPETE
5,15di-HPETE
15–HP–5,6 epoxy 
tetraene
LTA4
LXA4 LXB4
LXA hydroxylase LXB hydroxylase
12–LOX 12-LOX
15–LOX
5–LOX
5–LOX
5–LOX
LXA4 LXB4
 
HPETE=hydroperoxyeicosatetraenoic acid 
LOX=lipo-oxygenase 
LT= leukotriene 
LX= lipoxin 
 
15–epi–lipoxins have also been isolated from cell cultures, which are (R) 
epimers of LXA and LXB. These compounds arise from the oxidation of 
15(R)–HETE produced by acetylated COX–2 enzymes in the manner 
previously described. The 15–epi–lipoxins are also known as aspirin–
triggered lipoxins (ATL), and their biosynthesis requires interaction between 
acetylated COX–2 and 5–LOX. ATL have been shown to be anti-
inflammatory. ATL are unstable and have very short half-lives in vitro and in 
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vivo, which made their study difficult. However, more stable synthetic 
analogues of ATL which share their anti-inflammatory properties have been 
synthesized to allow the study and better understanding of ATL‟s biological 
actions (Chiang et al., 2005; Petasis et al., 2005).  
 
1.5.3 The cytochrome P450 enzymes and their lipid mediator 
products 
 
Numerous isoforms of cytochrome P450 monoxygenases exist in plants and 
mammals, for example, humans have over fifty P450 genes (Lewis, 2004). 
The P450 monoxygenases involved in oxidation of eicosanoids and PUFA 
are members of the CYP2 and CYP4 families (Lagarde 2003). Of the PUFA, 
AA is the most widely acknowledged PUFA substrate for P450 oxidation, but 
EPA is also an efficient substrate for these enzymes (Barbosa-Sicard et al., 
2005). The reactions catalysed by the P450 monoxygenases are based on 
three main mechanisms (Capdevila et al., 2000), which are: 
 
i. Bis–allylic hydroxylation of fatty acids (LOX–like reaction mechanism) 
ii. Hydroxylation of fatty acids at or near the ω–position  
iii. Epoxidation of fatty acids  
 
The first mechanism produces hydroxyeicoasatetraenoic acids (HETEs) from 
AA, the second produces HETEs from AA and hydroxyeicoasapentaenoic 
acids (HEPEs) from EPA, and the third produces epoxyeicosatrienoic acids 
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(EETs) from AA and epoxyeicosatetraenoic acids (EETeTrs) from EPA 
(Barbosa-Sicard et al., 2005; Capdevila et al., 2000; Capdevila & Falck, 2000; 
Lagarde, 2003). 
 
Figure 1.14 Cytochrome P450 metabolism of arachidonic acid occurs by 
three reaction mechanisms 
 
EET=epoxyeicosatrienoic acid HETE=hydroxyeicosatetraenoic acid 
 
Many of the oxidized PUFA products generated by P450 enzymes are known 
to possess biological activity, with the exception of the hydrolysed diol 
products of EETs (Capdevila & Falck, 2002). Most of these compounds have 
been reported to exert vascular or inflammatory effects, for example, 15-
HETE has been reported to vasoconstrict the renal vascular bed (Capdevila & 
Falck, 2002) and 5,6-EET and 8,9-EET are potent angiogenic agents (Pozzi 
et al., 2005). Both 5-HETE and 12–HETE have been known to mediate 
inflammatory effects in the vascular system (Natarajan and Nadler, 2004). 
However, some lipid mediators have anti-inflammatory effects, such as 18(R)-
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HETE (Chiang et al., 2005, Serhan et al., 2000) and 11,12–EET (Arita et al, 
2005). In addition, the EETs as a group can alter the flow of ions in the heart 
and kidney (Lagarde, 2003) and 20-hydroxy–14,15–EET is a high affinity 
endogenous ligand for PPARα (Cowart et al., 2001). 
 
1.5.4 Bioactive lipids produced by non–enzymatic (free radical–
catalysed) pathways 
 
Isoprostanes (IsoPs) are PG–like compounds derived from AA in vivo by 
nonenzymatic (free radical induced) peroxidation (Roberts & Morrow, 1997, 
Montine et al., 2004). They can be detected and quantified at physiological 
levels in tissues or in plasma, urine and other biological fluids and they are 
considered reliable biomarkers of inflammation (Cracowski, 2004, Cracowski 
et al., 2005). Initially the isoprostanes were divided into four classes, one to 
represent each regioisomer formed, but more recently, a nomenclature 
system based on their structure has been developed (Morrow et al., 1990, 
Taber et al., 1997). 
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Figure 1.15 A representative isoprostane (8c-iso prostaglandin F2α). The 
nomenclature of isoprostanes is dependent on their structure and is 
described in detail below. 
Side chain hydroxyl group is at C8 Side chain hydroxyl is in S configuration
Ring hydroxyl 
groups are 
down
Side chains from cyclopentane ring are cis 
Ring and side chain hydroxyl groups 
are cis
 
Isoprostane letter  Based on prostaglandin of which it is an 
epimer (e.g. F2, E2 and D2) 
Number prefix to name Location of side chain hydroxyl group 
Default absolute configuration of side 
chain hydroxyls 
(S) Compound with (R) configuration is 
denoted as “ent” (for enantiomer)  
Default absolute configuration of ring 
hydroxyls 
Down (α) Compounds where hydroxyls are 
in an upwards configuration are denoted as 
“ent” 
Position of side chains relative to 
cyclopentane ring  
Normally cis Lower number C is designated 
as “epi” if trans conformation  
Position of side chains relative to 
cyclopentane ring hydroxyls 
Cis/ trans – subscript c/t is used 
 
IsoPs display potent biological activities. They have a constrictor effect in 
many vascular beds (including cerebral arterioles and retinal blood vessels) 
and a bronchoconstrictor effect on human tissue in vitro and guinea pig in 
vivo (Cracowski, 2004). In vitro experiments have shown increased F2-IsoP 
production during oxidation of low–density lipoprotein (LDL), which is a key 
event in the formation of artherosclerotic plaque (Montuschi et al., 2004). 
IsoPs may also have a role in the pathology of neurodegenerative diseases 
where oxidative stress is known to play a part e.g. Alzheimer‟s disease, since 
their formation in membranes may alter membrane biophysical properties, 
resulting in alteration or impairment of neuronal function, and they have been 
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suggested as a biomarker of neuronal inflammation (Nourooz-Zadeh et al., 
1999; Roberts et al., 1998). Some 3-series isoprostanes can also be 
produced from eicosapentaenoic acid (Gao et al., 2006). Similarly, the 
neuroprostanes are free radical-catalysed oxidation products of 
docosahexaenoic acid (DHA) that are analogous to IsoPs (Moriguchi et al., 
2004, Roberts & Fessel, 2004). NeuroPs can be considered as suitable 
biomarkers of neuronal inflammation owing to the high concentration of DHA 
in the CNS compared to other regions of the body (Montine et al., 2004).  
 
Isofurans (IsoFs) are compounds similar in structure to IsoPs, but they have a 
furan ring instead of a cyclopentane ring (Roberts & Fessel, 2004). IsoFs are 
produced from the peroxidation of AA (Montine et al., 2004) and are more 
likely to be formed under conditions of oxidative stress or high pO2, since the 
mechanism of their biosynthesis involves attack by oxygen on a double bond 
of an intermediate compound (Roberts & Fessel, 2004), leading to 
speculation that production of IsoFs may be a reliable indicator of oxidative 
stress (Fessel et al., 2003). The nomenclature system of IsoFs is similar to 
that of the IsoPs (Taber et al., 2004), and is described in Figure 1.16. 
Neurofurans (NeuroFs) analogous to IsoFs have recently been identified 
(Taber & Roberts, 2005) and it is conceivable that they may also be suitable 
biomarkers of CNS inflammation. NeuroPs and NeuroFs share a 
nomenclature system that is analogous to that of IsoPs and IsoFs. 
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Figure 1.16 A representative isofuran (syn 8-cis-6,15,18-epi isofuran). The 
nomenclature of isofurans is dependent on their structure and is described in 
detail below. 
 
First C in 
tetrahydrofuran 
ring is C8
Alkyl groups of 
tetrahydrofuran 
ring are syn
Allylically-oxygenated alkenes have a 
Z configuration: denoted 15,18 epi
Isolated alkene with E 
configuration: 
designated 6-epi
Side chain hydroxyls 
have S configuration
Isolated alkene with Z
configuration
 
Isofuran number  Number of first C atom in 
tetrahydrofuran ring 
Position of alkyl groups of tetrahydrofuran 
ring 
syn / anti (S/A) 
Position of ring hydroxyl relative to adjacent 
alkyl group 
cis / trans (C/T) 
Default absolute configuration of side chain 
hydroxyls 
(S) – compounds with an (R) 
configuration are denoted as “ent”  
Default geometry of isolated alkenes  Z – compounds with an E configuration 
are denoted as “epi” 
Default geometry of allylically – oxygenated 
alkenes 
E – compounds with a Z configuration 
are denoted as “epi” 
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1.6. Polyunsaturated fatty acids and the brain 
 
Lipids, PUFA in particular, are known to be essential for the development of 
the brain (Wilson & Sargent, 1993; Uauy et al., 2000; Wainwright, 2002). 
They may be incorporated into structural lipids, for example, DHA and AA are 
both important constituents of phospholipids in neuronal membranes (Williard 
et al., 2001; Zhou & Nilsson, 2001), or used as substrates for the production 
of lipid mediators that participate in numerous physiological functions 
(Yehuda et al., 1998; Tapiero et al., 2002). Some of the biological roles of 
PUFA are outlined in Figure 1.17. 
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Figure 1.17 Diagram of the multiple roles of PUFA in physiological functions, some of which may be inter-
related  
PUFA 
GENE EXPRESSION
PUFA and their 
metabolites can gene 
expression, including 
inflammatory genes and 
PPARα (see Section 
1.6.5) 
INTRACELLULAR 
SIGNALLING
PUFA act as 2nd 
messengers in many 
signalling systems. For 
example, PKC and 
MAP kinases are 
affected by PUFA (see 
Section 1.6.4)
EICOSANOID 
PRECURSORS
PUFA released from 
membranes by PLA2 or 
PLC and DAG kinase may 
be used as substrates for 
the production of 
eicosanoids, which have 
different effects e.g. LTs 
derived from AA promote 
inflammation whereas LTs 
derived from EPA suppress 
inflammation (see Section 
1.6.5)
METABOLISM
PUFA are substrates for  β-
oxidation. They can also 
regulate lipid biosynthesis by 
inhibition feedback.
MEMBRANE 
COMPONENTS
The PUFA content of 
membrane bilayer 
phospholipids can 
influence a membrane‟s 
biophysical properties  and 
hence the conformation 
and activity of membrane-
bound proteins
 
 
 
AA= arachidonic acid MAP= mitogen-activated protein PLC= phospholipase C 
DAG= diacylglycerol PKC = protein kinase C PPAR= peroxisome proliferator-activated receptor 
EPA= eicosapenatenoic acid PLA2= phospholipase A2 PUFA= polyunsaturated fatty acid 
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1.6.1. PUFA occurrence and metabolism in the brain 
 
 
It has been estimated that lipids account for over half of the brain‟s dry weight 
(Simopoulos, 1991; Calvani & Benatti, 2003). Brain composition analysis has 
shown that lipids account for more than half of the grey matter, and the 
majority of grey matter lipids contain PUFA in their structure (Sinclair & 
Wesinger, 2004).  
 
Tracer studies using carbon-14 radiolabelled PUFA suggest that PUFA can 
cross the blood–brain barrier (BBB) (Rapoport et al., 2001; Sinclair & 
Wesinger, 2004). Moreover, rats fed deuterated LA and ALA showed 
accumulation of the radiolabelled fatty acid in brain and plasma lipids (Liu & 
Salem, 2007). The kinetics of fatty acid transport from the blood to the brain 
varies between lipid species, and more than one model has been proposed 
for the uptake of PUFA by the brain.  
 
The lipophilic nature of fatty acids means that they may be rapidly 
incorporated into and easily dissociated from membrane structures. This has 
led to the suggestion by Hamilton (1998) that fatty acids diffuse down a 
concentration gradient across the BBB. It was proposed that un-ionized fatty 
acids can slot into the outer leaflet of the BBB, rapid diffuse through the lipid 
bilayer, and then dissociate from the inner leaflet of the membrane, the whole 
process occurring almost instantaneously. Other models of fatty acid 
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transport have also been proposed, such as active transport using carrier 
proteins. Work in the 1990s led to the cloning of a family of five proteins 
known as the fatty acid transporter proteins (FATP1 - 5). It has been 
suggested that these act as carrier proteins, transporting fatty acids across 
the BBB using facilitated diffusion or active transport (Schaffer & Lodish 1994; 
Abumrad et al., 1998; Hirsch et al., 1998). The exact mechanism of fatty acid 
transport across the BBB has not been elucidated, although a highly-
conserved AMP-binding site has led to the suggestion that fatty acids may be 
actively transported.  
 
It is also possible that different PUFA are uptaken by different mechanisms, 
for example, plasma AA correlates directly to the amount of AA in brain 
tissues, whereas plasma DHA does not correlate directly to the amount of 
DHA in brain tissues (Blank et al., 2002), implying that DHA may be actively 
uptaken by brain or there may be another source of DHA available. This 
suggestion has also been echoed by Abumrad and colleagues (1998), who 
proposed that at high concentrations of free fatty acids, simple diffusion may 
be the most important transport mechanism, whilst at physiological 
conditions, the role of FATP is more important than that of diffusion. 
 
Elovl-1, Elovl-2, Elovl-5 and Elovl-6 gene expression have all been 
demonstrated in the brain, and of these elongases, both Elovl-2 and Elovl-5 
are capable of elongating 18:2n-6 and 18:3n-3 to produce C20 and C22 PUFA 
(Wang et al., 2005). However, biosynthesis of long-chain PUFA in the brain is 
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not believed to be a significant source of EPA and DHA, despite the presence 
of fatty acid elongases in the brain (Igarashi et al., 2007). It has been 
postulated that a signalling system exists for the delivery of DHA to the 
central nervous system (CNS) from the liver, which could be activated when 
extra DHA is required in the CNS e.g. following neuronal membrane damage 
(Scott & Bazan, 1989). Rapoport and colleagues (Igarashi et al., 2007) 
reported that dietary n-3 PUFA deficiency upregulated elongase and 
desaturase expression in the liver, but not in the brain, supporting the theory 
that the liver supplies the majority of the brain‟s PUFA requirements. 
 
1.6.2. PUFA as membrane components 
 
 
Phospholipids are a major component of neuronal membranes and they 
incorporate esterified PUFA in their structures in the sn-2 position and 
sometimes also the sn-1 position (Figure 1.3). Insufficiency of PUFA, whether 
caused by diet or by metabolic disorders (for example, peroxisomal disorders) 
can result in abnormal fatty acid metabolism. These can result in changes in 
brain lipid composition (Uauy et al., 2000; Wainwright, 2002; Barcelo-Coblijn 
et al., 2003; DeMar et al., 2004). Changes in the lipid content of the diet, in 
particular n-3 PUFA, can alter the phospholipid composition of membranes in 
many tissues, including the brain (Gerbi et al., 1999; Blank et al., 2002; 
Barcelo-Coblijn et al., 2003).  
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Changes in the lipid environment can also influence the functional properties 
of enzymes that are incorporated into the membrane structure. For example, 
the Na+/ K+-ATPase α2 isoenzyme in rats fed a sunflower oil diet (which is low 
in n-3 PUFA) showed a higher affinity for sodium than in rats fed a soybean 
oil diet (which is rich in n-3 PUFA) (Gerbi et al., 1999). The biophysical 
properties of membranes (fluidity, flexibility and permeability) are affected by 
their phospholipid and cholesterol content (Chen & Bazan, 2005) and 
changes in the composition or biophysical properties of membranes may lead 
to changes in receptor conformation and ion channels‟ activity (Barcelo-
Coblijn et al., 2003). Alternatively, some PUFA may be endogenous ligands 
for ion channels, for instance, AA, DHA and ALA can bind to and activate the 
TREK-1 K+ channel (Lauritzen et al., 2000). 
 
1.6.3. PUFA and gene expression 
 
 
Many genes have been reported to be affected by changes in dietary lipids, 
including genes that are involved in cytoskeleton and membrane association, 
signal transduction, ion channels, metabolism and regulatory proteins (Kitajka 
et al., 2002; Barcelo-Coblijn et al., 2003). Fatty acids can regulate several 
genes at transcription level, including peroxisome proliferator-activated 
receptors (PPARs), of which PPARα is the most widespread, retinoid X 
receptor (RXR), sterol regulatory element binding protein (SREBP) and 
nuclear factor kappa B (NFκB) (Jump et al., 2005).  
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Rats fed perilla oil (rich in ALA) or fish oil (rich in DHA and EPA) show 
differences in gene expression in the brain compared to those fed a standard 
diet (Kitajka et al., 2002; Barcelo-Coblijn et al., 2003), Animals which received 
a diet enriched in n-3 fatty acids had an increase in the expression of 
synucleins, which are involved in synapse formation (Kitajka et al., 2002). The 
addition of oxidised n-3 fatty acids to in vitro cell cultures reduced the 
expression of pro-inflammatory genes (Mishra et al., 2004). A study on the 
effects of dietary n-3 fatty acids showed that plasma levels of several 
inflammatory biomarkers, such as C-reactive protein (CRP), interleukin-6 (IL-
6), E-selectin, inflammatory cell adhesion molecule-1 (ICAM-1) and secreted 
vascular cell adhesion molecule-1 (sVCAM-1) was inversely related to dietary 
intake of n-3 fatty acids in women (Lopez-Garcia et al., 2004). This lends itself 
to the suggestion that a deficiency in n-3 fatty acids may lead to increased 
susceptibility to pathophysiological inflammatory states. Similarly, a high 
intake of n-3 fatty acids may protect against inflammatory conditions such as 
cardiovascular disease or cerebrovascular disease. 
 
1.6.4. PUFA in cell signalling  
 
 
The vast majority of lipids in the brain are esterified and incorporated into 
complex lipids but the hydrolysis of phospholipids at the sn-2 position by 
phospholipase A2 (PLA2) results in the release of PUFA as free fatty acids 
(FFA), which form a substrate pool for the formation of numerous lipid second 
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messengers that can regulate and/or interact with intercellular signalling. 
Some PUFA can themselves affect the synthesis and/or release of 
neurotransmitters and brain peptides. In addition, the production of bioactive 
lipid mediators such as prostaglandins, hydroxy-polyunsaturated fatty acids 
and isoprostanes from FFA may further affect cell signalling mechanisms 
(Rouzer & Marnett, 2005; Serhan, 2005).  
 
1.6.5. Production of lipid mediators from PUFA 
 
 
Eicosanoids are well–known for their pro-inflammatory effects but recently it 
has been pointed out that “not all eicosanoids are bad guys” (Serhan, 2005). 
Although it has been traditionally held that eicosanoids and their derivatives 
are pro-inflammatory compounds, both anti-inflammatory and pro-resolution 
(promoting tissue repair) lipid mediators have been described (Serhan et al., 
2000; Hong et al., 2003; Serhan et al., 2004; Sethi et al., 2004; Bannenberg 
et al., 2005). For example, 18(R)– hydroxyeicosapentaenoic acid (18(R)–
HEPE), a metabolite of EPA, reduced the migration of neutrophils following 
cell injury in HEK 293 cell cultures that express leukotriene (LT) receptors by 
competing with LTB4 for binding sites (Serhan et al., 2000). Mouse models of 
peritonitis showed a reduction in leukocyte infiltration mediated by two 
metabolites of DHA, 4(S)-hydroxydocosahexaenoic acid and 10(S),17(S)-
docosatriene (Marcheselli et al., 2003). The latter also caused a 
neuroprotective effect in mouse models of focal brain ischemia-reperfusion, 
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reducing the volume of the infracted tissue and increasing the strength of 
electronic signal from the hippocampus following a simulated stroke 
(Marcheselli et al., 2003). Aspirin-triggered lipoxins (ATL) have also been 
reported to show anti-inflammatory properties in many rodent models of 
inflammation, including peritonitis and ischaemia-reperfusion injury of the lung 
(Bannenberg et al., 2004; Chiang et al., 1999). 
 
1.6.6. Adaptive cytoprotection (Preconditioning and brain 
tolerance) 
 
Tolerance is an adaptive cytoprotective response initiated in response to a 
sublethal insult which gives increased resistance to a subsequent potentially 
lethal insult. The process of inducing tolerance is termed preconditioning. 
Many types of stimuli have a preconditioning effect, for example, thermal 
stress, tissue injury, oxidative agents and ischaemia.  
 
Ischaemic preconditioning was first demonstrated twenty years ago by Murry 
and colleagues (1986), who showed that a short period of ischaemia in 
canine myocardium led to increased survival after a subsequent prolonged 
period of ischaemia. This phenomenon has since also been reported in rabbit 
and swine myocardium, inferring that this phenomenon is common to many 
mammalian species (Schott et al., 1990; Cohen et al., 1991). A retrospective 
study on patients admitted to hospital following myocardial infarction showed 
that patients who had experienced episodes of prodromal angina in the 24 
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hours prior to myocardial infarction had smaller infarct sizes than those who 
had not, implying that human myocardium may also be responsive to 
preconditioning (Ottani et al., 1995). Preconditioning is not unique to the 
heart, and many other organs, including the brain, have also been reported to 
be protected by ischaemic preconditioning (Kitagawa et al., 1990; Kitagawa et 
al., 1991; Liu et al., 1992; Matsushima & Hakim, 1995).  
 
The occurrence of prodromal transient ischaemic attacks (TIA) were linked to 
less severe strokes and improved outcome in stroke patients (Weih et al., 
1999), prompting speculation that ischaemic preconditioning could also occur 
in the human brain. A later multi-centre study supported this theory by 
showing that patients who had experienced prodromal TIA had smaller infarct 
volumes following a stroke than patients with no prior ischaemic events, 
despite showing a comparable reduction in cerebral blood flow and cerebral 
blood volume (Wegener et al., 2004). This study demonstrated that the 
protective effects of prodromal TIA were due to an intrinsic neuroprotective 
effect rather than alterations in cerebral blood flow caused by enhanced 
vascularisation. 
 
Preconditioning has a time-dependent effect and only offers temporary 
protection against a subsequent noxious stimulus. This time frame has been 
described as the „window of protection‟ and has been widely studied in order 
to assess the potential benefits of preconditioning and also to gain insight into 
the molecular mechanisms behind preconditioning (and idenitifcation of 
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pharmacological targets). It was found in rodents that two stages of 
preconditioning exist:  „early preconditioning‟, which takes effect immediately 
after the sublethal noxious stimulus and lasts for up to 24 hours, and „delayed 
preconditioning‟, which only develops at least 24 hours after the initial noxious 
stimulus, peaking approximately 72 hours after the preconditioning event, and 
lasting for several days in total. Figure 1.18 illustrates the time effect of the 
two forms of preconditioning.  
 
Figure 1.18 Preconditioning is a time-dependent phenomenon, which exists 
in two forms: (i) early preconditioning and (ii) delayed preconditioning. Both 
forms are believed to be the result of different cellular processes (adapted 
from Dirnagl et al., 2003). 
 
The ability of one type of preconditioning treatment to induce tolerance to 
other forms of cellular stress is known as cross–tolerance. For example, 
whole body hyperthermia is neuroprotective against brain ischaemia (Wada et 
al., 1999). The existence of cross-tolerance opens the possibility of using 
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different treatments or procedures to induce ischaemic tolerance, of which 
some may have potential applications in treating human diseases such as 
heart disease and ischaemic stroke.  
 
Two main strategies have emerged in stroke treatment and the induction of 
neuroprotection. These are: (a) enhancing direct effects of a neuroprotective 
agent on pharmacological targets, and (b) induction of prophylactic 
neuroprotection by causing adaptive changes in cell biology. 
 
Figure 1.19 Neuroprotective agents have been postulated to work by either 
having direct or prophylactic effects on brain tissue. 
 
 
 
Extensive research has been carried out into pharmacological methods of 
reducing neuronal death after an ischaemic insult, including animal studies on 
platelet-activating factor (PAF) receptor antagonists and LOX inhibitors 
(Belayev et al., 2008; Belayev et al., 2009; Jatana et al., 2006) and clinical 
trials on N-methyl D-aspartate (NMDA) receptor antagonists (Grotta et al., 
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1995; Lees et al., 2000). LOX inhibitors showed a reduction in post-ischaemic 
inflammation in rodent models of stroke and exerted their actions by 
preventing the activation of NFκB and INOS (Jatana et al., 2006). The novel 
PAF receptor antagonist, LAU-0901 also provided neuroprotection in rodent 
models of stroke by reducing the inflammatory effects of PAF (Belayev et al., 
2008; Belayev et al., 2009). However, despite extensive effort, there has 
been no success in drug development for a single pharmacological target for 
stroke treatment. 
 
Prophylactic strategies have not received as much attention, although  
PPARα has been pointed out as a potential target for development of anti-
ischaemic drugs, due to the ability of PPARα ligands (e.g. fenofibrate and 
WY-14643) to reduce infarct size in animal models of ischaemia-reperfusion 
(Inoue et al., 2003; Lee et al., 2003). Some PUFA, including LA and ALA, are 
also endogenous ligands of PPARα, with optimal binding to PPARα occurs in 
fatty acids that have chain lengths of C16- C20 and several double bonds in the 
carbon chain (Forman et al., 1997; Cullingford et al., 1998; Lee et al., 2003). 
Treatment of animals with PPARα activators prior to brain ischaemia has 
been shown to confer a neuroprotective effect which is dependent upon 
PPAR activation (Deplanque et al., 2003; Lee et al., 2003; Gelé, 2004). It 
has been suggested that fibrates exert their effect through a combination of 
reducing oxidative stress and inflammation, and the modulation of lipid 
metabolism (Gelé, 2004). It can therefore be deduced that the reduction of 
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post-ischaemic inflammatory processes results in a better outcome following 
focal ischaemia in animal models, with animals treated with anti-inflammatory 
compounds receiving lower infarct volumes and a higher neurological score 
(Belayev et al., 2008; Belayev et al., 2009; Deplanque et al,. 2003; Gelé, 
2004; Inoue et al., 2003; Jatana et al., 2006). 
 
PUFA have been reported to exert a neuroprotective effect in rat models of 
ischaemic stroke and epilepsy (Lauritzen et al., 2000; Blondeau et al., 2002). 
Intracerebroventricular or intravenous administration of PUFA resulted in 
increased survival of hippocampal neurons in rats subjected to a period of 
global forebrain ischaemia or exposure to kainate (Lauritzen et al., 2000; 
Blondeau et al., 2002). Many n–3 and n–6 PUFA including LA, ALA, AA and 
DHA were protective, but ALA appeared to be the most efficient of the 
compounds tested (Lauritzen et al., 2000; Blondeau et al., 2002). Saturated 
fatty acids did not show a neuroprotective effect on neuronal survival, 
implying that neuroprotection is specific to PUFA rather than all fatty acids 
(Lauritzen et al., 2000). A more recent study by the same group showed that 
neuroprotection was also seen in rats subjected to MCAO. Intravenous 
injection of one of several n-3 or n-6 PUFA to rats 24 – 96 hours prior to an 
ischaemic challenge resulted in reduced infarct size and increased neuronal 
survival compared to vehicle–injected animals (Blondeau et al., 2002). PUFA 
administration was also neuroprotective in mice, even when administrated 
after the MCAO period, as seen in Figure 1.20 (Heurteaux et al., 2006; 
Blondeau et al., 2009). 
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Figure 1.20 Post-ischaemia ALA treatment of C57/BL6 mice resulted in a 
statistically significant (* P<0.05, ** P<0.01) reduction in infarct volume 
following 1h MCAO (from Heurteaux et al., 2006) 
 
 
Treatment of rats with DHA conjugated to albumin significantly improved their 
neurological scores 72 hours after MCAO (Rodriguez de Turco et al., 2002; 
Belayev et al., 2005). This effect was dose-dependent, with a greater 
improvement seen in rats administered a low dose (0.62mg/kg of DHA–
albumin) than in those given a higher dose of 1.25 mg/kg DHA–albumin 
(Belayev et al., 2005). Lipidomic analysis of the treated rats‟ brains showed 
accumulation of 10,17S–docosatriene in the ipsilateral hemispheres of rats 
treated with DHA-albumin but not in those rats treated with albumin or saline 
(Belayev et al., 2005). More recently, the same group unequivocally 
demonstrated the neuroprotective effects of low or medium intravenous 
doses of DHA administrated shortly after MCAO onset, leading to the theory 
that DHA could be beneficial to patients after ischaemic stroke (Belayev et al., 
2009). 
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Metabolites of PUFA have also been implicated in neuroprotection, namely 
the neuroprotectins and resolvins. Intracerebroventricular infusion of the DHA 
metabolite 10,17S-docosatriene (also known as “neuroprotectin D1” or 
NPD1), has been reported to reduce the volume of the infarction in mice 
exposed to focal ischaemia by MCAO, and to improve neurological test 
scores following MCAO (Marcheselli et al., 2003; Mukherjee et al., 2004; 
Belayev et al., 2005). As it has been pointed out, inflammation and resolution 
are not direct opposites, and „anti-inflammation‟ and „pro-resolution‟ differ 
slightly in their meaning (Serhan & Chiang, 2008). The molecular 
mechanisms behind the neuroprotective effect of NPD1 appear to be its pro-
resolution qualities, rather than inhibition of the inflammatory response 
(Serhan & Chiang, 2008). The resolution of inflammation in rodent models of 
stroke is promoted by NPD1 through inhibition of neutrophils infiltration into 
brain tissue, reduction of expression of pro-inflammatory proteins (such as 
NFκB and COX-2) and apoptotic proteins (such as Bax and Bad), and up-
regulation of anti–apoptotic protein expression, such as members of the Bcl 
family (Marcheselli et al., 2003; Lukiw et al., 2005).  
 
1.7. Introduction to lipidomics 
 
 
Lipidomics can be defined as the study of all lipid species present in a 
biological system. It comprises both the identification of lipid species present 
in the system and the study of their biochemical properties.  
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The isolation, localisation, characterization and quantification of known lipid 
species and the identification of novel lipid molecules in the cell plays a major 
role in lipidomics (van Meer 2005; Wenk 2005). Advances in lipid analytical 
techniques during the past twenty years, most notably the development of the 
electrospray ionisation (ESI) interface, and the increased processing power of 
online mass spectrometry software, have made it feasible to carry out 
“shotgun lipidomic” studies, where a broad range of lipid classes in biological 
samples can be simultaneously investigated (Pulfer & Murphy, 2003; Han & 
Gross, 2005; Houjou et al., 2005; Taguchi et al., 2005). The use of 
bioanalytical techniques to study diverse classes of lipids such as 
glycerophospholipids, sphingophospholipids, eicosanoids, isoprostanes, fatty 
acids and hydroxy fatty acids is essential for the other part of lipidomics, 
which is to develop an understanding of the influences of lipids on biological 
systems, including their roles in membrane architecture, transcriptional and 
translational modification, cell signalling and interaction between cells 
(Watson, 2006). Our study will utilise either high-performance liquid 
chromatography (HPLC) coupled to electrospray ionisation interface tandem 
mass spectrometry system to identify a variety of lipid mediators in mouse 
plasma and cerebral cortex, and direct infusion of the analyte to an 
electrospray ionisation interface tandem mass spectrometry system to identify 
glycerophospholipids in mouse cerebral cortex tissue. 
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1.7.1. High-performance liquid chromatography 
 
 
Liquid chromatography (LC), in particular high-performance liquid 
chromatography (HPLC) is a popular bioanalytical technique which is widely 
available. Compounds are separated on the basis of their physicochemical 
properties, based on their elution time out of an organic-phase packed 
column back into the more polar mobile phase (or in the case of reverse-
phase HPLC, from a polar packed column into a non-polar (organic) mobile 
phase).  
The sample is injected into the mobile phase, which flows through the HPLC 
equipment and into the column. The sample adsorbs onto the surface of the 
beads packed into the column and is flushed out of the column by the 
continuous flow of mobile phase, its constituents separated on the basis of 
their elution time out of the column. The analyte is passed through a detector 
(most commonly an ultraviolet (UV) spectrometer, although other detection 
techniques, such as fluorescence or refractive index measurement, may be 
used), where an absorption peak is recorded. The detection equipment may 
be linked to a computer which uses software to calculate the area beneath 
the chromatogram peak to produce a quantifiable result. Figure 1.21 
illustrates a schematic diagram of HPLC, showing its main components and 
the route the analyte takes through the analytical set-up (shown by arrows).  
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Figure 1.21 Schematic diagram of HPLC  
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HPLC is particularly suitable for high-throughput analysis due to its speed and 
the availability of automated sample injectors. Furthermore, it is a sensitive 
and accurate analytical method which does not require large samples and 
does not destroy the sample during analysis; meaning that it can be coupled 
to other analytical equipment, such as a mass spectrometer, instead of a 
detector.  
 
1.7.2. Principles of electrospray ionisation 
 
Electrospray ionization (ESI) is a “soft” ionization technique which allows the 
production, detection and identification of molecular ions. Biomolecules 
generally possess complex chemical structures, often with high molecular 
mass, and they may also be polymers. The ability of ESI to form molecular 
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ions rather than ion fragments is advantageous for the analysis of biological 
molecules, since the production of small- sized ion fragments would not give 
much information on the overall structure of the analysed compound 
(Hoffman, 2005).  
 
It is essential that compounds to be analysed by ESI-MS are ionized in 
solution. The sample, dissolved in organic solvent, is introduced to the 
electrospray needle from a coupled liquid chromatography (LC) system or 
directly from a syringe pump. The sample comes out of the needle in a fine 
spray. A potential difference is applied across a cone surrounding the 
electrospray needle to facilitate the formation of ions inside the sample 
droplets. An internal heat source is applied to the analyte source and the 
cone surrounding the electrospray needle to assist the evaporation of solvent, 
and nitrogen gas is used as a desolvation gas to vaporize the droplets of 
volatile organic solvent. As the solvent evaporates, the surface tension of the 
charged droplets increases to such an extent that the highly-charged droplets 
disintegrate during what is known as “Coulombic expansion” to produce 
droplets that are much smaller in size. The solvent evaporates from the  
droplets, leaving behind the ionized analyte.
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Figure 1.22 Diagram of the electrospray ionisation (ESI) interface. The sample is dissolved in volatile solvent and injection 
through a fine needle inside a cone that has a voltage set across it. Large ionized droplets are formed which are reduced 
in size by evaporation of solvent, assisted by a flow of N2 gas in the cone. The highly-charged droplet disintegrates as the 
similar charges repel each other (Coulombic expansion), leaving behind ionized analyte which passes through a vacuum 
to the analyser. 
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The formation of ions in solution necessary for ESI-MS may prove difficult for 
non-polar lipids. However, the formation of lipid species molecular ions in 
solution can be facilitated by adding ammonium hydroxide to the mass 
spectrometry solvent. It is alternatively possible to add ammonium sulphate to 
the mass spectrometry solvent to aid the ionization and separation of acidic 
lipids (Christie, 2003). 
 
The production of molecular ions rather than ion fragments is advantageous 
in lipid analysis, since many lipids have a complex chemical structure 
containing more than one component. For example, sphingophospholipids 
contain a sphingoid base and fatty acyl chains and glycerophospholipids 
comprise of a polar head group, glycerol backbone and fatty acyl chains. If 
only ion fragments of the analysed compound could be recovered, then it 
would not be possible to calculate the overall structure of many lipid species 
in a biological sample. ESI-MS produces mainly molecular ions, which 
provides information on the molecular weight of a species but not on its 
structure. Phospholipids are difficult to separate using ESI-MS alone because 
the variation in head group, chain length and saturation of phospholipids 
means that more than one phospholipid species can have the same 
molecular weight. In the past, researchers have used chromatography 
methods coupled to mass spectrometry, for instance, gas chromatography–
mass spectrometry (GC-MS) or liquid chromatography–mass spectrometry 
(LC-MS). However, the recent arrival of electrospray tandem mass 
spectrometry (ESI-MS/MS) for analysis of biological samples has provided a 
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highly sensitive method of phospholipid analysis. GC-MS, LC-MS and MS/MS 
share many advantages: they are high-resolution, sensitive, and rapid 
(analysis takes minutes), require only a small volume of sample and allow 
both qualitiative and quantitative analysis. However, MS/MS poses an 
advantage over other methods in that no derivatization of fluorescent lipid 
products or fatty acid methyl esters (FAME) from fatty acids is necessary.  
 
1.7.3. Tandem mass spectroscopy (MS/MS) 
 
Tandem mass spectrometry may be carried out using a triple quadrupole 
mass spectrometer. A quadrupole consists of four metallic rods, two set at a 
positive voltage and the other two at a negative voltage. The quadrupole has 
both electrical and radio voltage components, and the ratio of electrical and 
radio potential difference determines the mass of the ions which can pass 
through the quadrupole at the resonance frequency. The first and third 
quadrupoles in a triple quadrupole mass spectrometer are detection 
chambers and the second quadrupole is a collision chamber, where high–
energy collision of ions leads to fragmentation of ions; this is known as 
collision–induced dissociation (CID). Figure 1.23 illustrates the three modes 
of ion scan that can be carried out using tandem mass spectrometry 
(MS/MS).  
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Figure 1.23 Tandem mass spectrometry (MS/MS) ion scanning modes  
(Q = quadrupole) 
Product ion scanning 
The daughter ions produced 
in the collision cell are 
scanned in quadrupole 3.
Q2Q1 Q3
Quadrupole 1 is set to allow 
only ions with a selected m/z 
value into the collision cell.
The selected ions are 
fragmented into daughter 
ions inside the collision cell.
Product ion scanning
Collision cell
The selected ions are 
fragmented into product ions 
inside the collision cell.
The product ions produced in 
the collision cell are scanned 
in quadrupole 3.
 
Precursor ion scanning 
Precursor ion scanning
Quadrupole 3 is set to 
detect fragments with a 
selected m/z value.
Quadrupole 1 scans to find the m/z of 
the precursor ions that produced the 
fragment selected in Q3.
Collision-induced 
fragmentation occurs 
inside the collision cell.
Q1 Q2 Q3
 
Neutral loss scanning 
m/z = [A] m/z = [A - ]
Precursor ions are identified using the loss of a specified mass between the ions scanned in 
quadrupoles 1 and 3, which corresponds to the loss of a specific fragment during CID.
Neutral loss scanning
Q1 Q2 Q3
recursor ions are identified using the loss of a specified mass between the ions scanned in quadrupoles
1 and 3, which corresponds to the loss of a specific fragment during collision-induced dissociation (CID) in 
quadrupole 2.
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The use of different settings on quadrupoles 1 and 3 allow three types of ion 
scan to be carried out using MS/MS: 
 
a) Product ion scanning, where quadrupole 1 is set to allow only ions with a 
selected m/z value into the collision cell. The selected ions are fragmented 
into daughter ions, which are scanned in quadrupole 3. 
b) Precursor ion scanning, where quadrupole 3 is set to detect fragments 
with a selected m/z value and quadrupole 1 scans to find the m/z of the 
precursor ions that produce that fragment upon CID in the collision cell. 
c) Neutral loss scanning, where precursor ions are identified using the loss of 
a specified mass between the ions scanned in quadrupoles 1 and 3, which 
corresponds to the loss of a specific fragment during CID. 
 
1.7.4. Hybrid analytical techniques 
 
A combination of two or more analytical techniques can be used to produce a 
hybrid analytical technique (also known as „hyphenated‟ analytical techniques 
due to their shorthand nomenclature) to detect and/or separate compounds 
from a sample. Over the past 25 years, hyphenated analytical techniques 
(such as GC-MS and LC-MS) have been developed and become widely used 
for the analysis of pharmaceutical and biological compounds, including 
forensic and toxicological analysis. More recently, hyphenated analytical 
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techniques have been explored as analytical tools to building a molecular 
profile of biological systems, as seen in proteomics and lipidomics.  
 
Gas chromatography and liquid chromatography are often coupled to another 
analytical technique because of their ability to analyse a sample without 
destroying the analyte, and the use of GC and LC coupled to tandem mass 
spectrometry has been developed over the past twenty years. GC-MS and 
LC-MS share the advantages of high sensitivity and high specificity, and both 
methods also provide information-rich detection. The use of a 
chromatographic method coupled to a mass spectrometer provides 
information on both the retention time and the fragmentation pattern of a 
compound, meaning that two compounds which share the same m/z value 
but have differing retention times can be identified without need for 
fragmentation studies. Tandem MS coupled to GC or LC offers even higher 
sensitivity and specificity than MS coupled to one of these methods. For 
example, HPLC-MS/MS can be used to detect glycerophospholipids and 
eicosanoids in the picomolar range. 
 
LC-MS offers an additional advantage over GC-MS in that it is not limited to 
volatile compounds, so compounds with molecular weight of >500Da can also 
be analysed using this method. Complex lipids such as glycerophospholipids 
and ceramides are generally not volatile and tend to have heavier molecular 
weights. The use of LC-MS for their analysis rather than GC-MS means that 
derivatization of fatty acid methyl esters (FAME) from glycerophospholipids is 
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not necessary and that the entire structure of the compound, including 
information on the positioning of the fatty acyl chain can be determined. LC-
MS systems also have lower maintenance requirements than GC-MS 
systems, which allows continuous analysis of large sample batches. 
  
1.8 Aims and Objectives 
 
Stroke is the third most common cause of death in the United Kingdom and is 
the most common cause of severe disability (http://www.stroke.org.uk). 
Research efforts in the past were concentrated on the discovery of a 
pharmacological target which could be blocked in order to reduce neuronal 
injury following a stroke, but more recent efforts have placed greater 
emphasis on preventative treatment to make the brain more resistant to the 
deletrious effects of a reduction in blood supply.  
 
It has been demonstrated that intravenous injections of PUFA can lead to 
neuroprotective effects in models of ischaemic stroke and epilepsy in rodents 
(Blondeau et al., 2002, Lauritzen et al., 2000) and that pre-treatment with 
bioactive lipid mediators can reduce neuronal injury in rodent models of focal 
ischaemia, but the molecular mechanisms underlying this neuroprotection are 
unclear.  
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We speculate that intravenous PUFA treatment may lead to changes in the 
lipid profile of the mouse. These changes may occur in structural lipids (e.g. 
glycerophospholipids) or in bioactive lipid mediators (e.g. prostanoids) and 
may be systemic or limited to the area of protection (i.e. the cerebral cortex). 
To assess whether intravenous PUFA injection causes changes in the 
lipidomic profile of the mouse and to determine whether these effects are 
systemic or localised, we propose to  (i) create a profile of cerebral cortex 
phospholipids in the mouse using mass spectrometry (MS) and tandem mass 
spectrometry (MS/MS), (ii) investigate whether intravenous fatty acid (ALA) 
leads to changes in cerebral cortex phospholipid composition at 3, 24, 72 and 
168 hours after its administration, (iii) profile lipid mediators (including 
prostanoids and hydroxy fatty acids) in mouse cerebral cortex and plasma, 
and (iv) assess the effects of ALA treatment on lipid mediator profiles in 
mouse cerebral cortex and plasma within the previously determined 
neuroprotection time window. 
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2. Materials and Methods 
 
2.1. Experimental strategy  
 
The purpose of this study was to obtain an accurate picture of the lipidomic 
profile in the living animal. In order to ensure that this result was achieved, we 
must consider the source of our samples, the methods used for sample 
collection, sample storage conditions, sample processing methods and 
analytical methods. This section explores these issues and explains how we 
developed an experimental strategy for the collection, processing, storage 
and analysis of tissue and plasma samples that prevented the formation of 
artefacts from post-mortem metabolic changes and minimised the 
degradation of glycerophospholipids and lipid mediators. 
 
2.1.1 Use of animals 
 
The growth of three-dimensional brain cell aggregate cultures which contain a 
mixture of differentiated cell types has been reported using both murine and 
human tissue (Seeds, 1971; Pulliam et al., 1988). Embryonic cells were used 
as the source for both of these examples of an in vitro model of the 
developing brain. However, despite developments in cell culture methods and 
in computer modelling (leading to in silico models), a satisfactory model of the 
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adult brain has not yet been achieved, and as a result, our work necessiates 
the use of animal models.  
 
Extensive work has been carried out on both the effects of essential fatty 
acids such as linolenic acid (LA) and α-linolenic acid on rodents and rodent 
models of brain ischaemia (Lauritzen et al., 2000; Blondeau et al., 2002; 
Belayev et al., 2005). The neuroprotective effects of PUFA in rat models of 
ischaemia were demonstrated by Lazundski‟s group (Lauritzen et al., 2000; 
Blondeau et al., 2002) and more recent work by the same group also showed 
a neuroprotective effect of PUFA in mice (Heurteaux et al., unpublished 
work).  
 
The small size of mice confer them many advantages over rats for our 
purposes. They are cheaper to acquire and to house than the same number 
of rats, are easier to kill rapidly and humanely without the use of specialist 
equipment (e.g. a guillotine), and their smaller-sized brains can be 
metabolically inactivated more rapidly than the larger rat brains. The small 
sample size required for lipidomic analysis means it is not necessary to 
collect a large amount of brain tissue for analytical purposes, and each 
mouse yielded enough brain tissue to allow both phospholipid analysis and 
lipid mediator analysis, keeping the number of animals required to a 
minimum.  
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The C57/BL6 mouse strain was selected because this is the strain that is 
commonly used for mouse models of stroke and cerebrovascular disease, 
and only male mice were used to eliminate the possibility of sex differences. 
This is also the same strain and sex that were used for the study on the 
neuroprotective effects of PUFA in mice (Heurteaux et al., unpublished work).                        
2.1.2. Metabolic inactivation of the brain 
 
It has been known since the 1970s that rapid post-mortem changes occur in 
brain lipids (Bazan, 1970), including the autolysis of phospholipids, an 
increase in free fatty acids, and oxidation of lipids (Lee & Hajra, 1991). 
Ischaemia leads to failure of ion-exchange pumps, causing anoxic 
depolarisation. This process leads to a massive influx of Ca2+ ions entering 
the neuronal cell via receptor-linked ion channels. The Ca2+ ions activate 
calcium – dependent phospholipases and kinases, such as phospholipase A2 
(PLA2), which hydrolyses phospholipids at the sn-2 position. Free fatty acids 
(FFA) are released from the hydrolysed phospholipids, which serve as a 
substrate pool for bioactive lipid mediators. As shortly as 90s after cessation 
of blood supply to the brain, concentrations of FFA and diacylglycerols (DAG) 
in the brain can rise dramatically whilst the concentration of phospholipids 
falls (Lee & Hajra, 1991).  
 
In order to ensure that an accurate picture of the living brain‟s lipidomic profile 
is obtained, sample collection and processing methods were selected to 
73 
 
result in minimal post-mortem changes and to prevent the formation of 
artefacts. Metabolic inactivation of the brain (also referred to as fixation of the 
brain, since the tissue‟s metabolic status is kept in a fixed state) was used 
during sample collection, and samples were processed in such a way as to 
minimise the degradation of glycerophospholipids and lipid mediators. 
 
The brain is known to be a difficult organ to metabolically inactivate, owing to 
its encasement in bone, high metabolic demands, and susceptibility to rapid 
changes in metabolic status during ischaemia, in particular following anoxic 
depolarisation. Two conventional ways of metabolic inactivation of the brain, 
heating (using microwave irradiation) and cooling (freezing), have been well-
documented since the 1970s. More recently, an alternative method of brain 
metabolic inactivation by inactivation of metabolic processes was reported 
(Bazan & Birkle, 1988). Figure 2.1 provides a summary of the brain fixation 
methods available and the advantages and limitations of each fixation 
method. 
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Figure 2.1 Brain metabolic processes can be inactivated by cold, heat or chemical inactivators – each method has advantages and 
limitations 
Microwave 
irradiation (Heat 
inactivation)
Rapid freezing 
(Cold 
inactivation)
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inactivation
Freezing in situ
Rapid freezing of 
tissue 
postmortem
Focused 
irradiation of 
animal’s head
Irradiation of 
brain tissue slices
Cardiac perfusion 
of metabolic 
inactivators
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still alive, so no 
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Requires deep 
anaesthesia
Labour-intensive 
brain dissection
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Allows blood 
collection
Labour-intensive 
brain dissection
Rapid and 
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fixation
Easy to dissect 
unfrozen brain
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equipment
Risk of distress 
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hazardous 
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Pontén et al. 
(1973)
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Cenedella et al. 
(1975)
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(1988)
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2.1.2.1. Heat inactivation 
 
The most rapid method of brain fixation using heat is focused high-power 
microwave irradiation. Microwaves are directed onto an unanaesthetised 
animal‟s head, causing rapid heating of the brain tissue and leading to the 
metabolic fixation of the brain and rapid death of the animal. Brain fixation 
using microwaves prevents all post-mortem metabolic changes and the brain 
is quickly and irreversibly fixed (Cenedella et al., 1975; Murphy, 2009). It also 
has the advantage of keeping the tissue‟s histological structure intact. An 
alternative to irradiation of the live animal is rapid killing of the animal, 
dissection of the brain out of the skull and irradiation of tissue slices. 
 
A disadvantage of heat inactivation of brain tissue is that, many naturally-
occurring lipids, in particular PUFA, are susceptible to oxidation at high 
temperatures. This raises the issue of whether PUFA oxidation at high 
temperatures would occur during microwave irradiation, which could cause 
the production of hydroxy fatty acids that have bioactive properties 
themselves, or alternatively lead to the depletion of substrate for production of 
bioactive lipid mediators. However, previous work on analysis of lipid 
mediators in the brain did not show an increase in PUFA metabolites in 
animals killed by microwave irradiation compared to those killed by 
decapitation (Bazinet et al., 2005; Farias et al., 2008), suggesting that the 
brief heating of the brain during focussed microwave irradiation does not lead 
to heat degradation of lipids. 
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2.1.2.2. Cold inactivation (freezing) 
 
Many methods of brain fixation by cooling are also available, of which the 
most widely reported is freezing of the brain in situ. This method allows the 
freezing of the surface tissues whilst still allowing blood flow to deeper 
tissues, preventing ischaemia and anoxic depolarisation occurring in the 
deeper tissues whilst the surface tissue is being frozen. It has been 
successfully been used in rats and in mice, as well as larger experimental 
animals, such as cats (Yang et al., 1983).  
 
There are method variations within in situ freezing of the brain, such as 
“funnel freezing”, carried out by anaesthetizing the animal, making an incision 
in the skin on the head and pouring liquid nitrogen directly onto the skull 
(Pontén et al., 1973), “freeze blowing”, where high-pressure airflow through 
two cranial probes is used to eject brain tissue from a conscious animal into a 
pre-cooled chamber (Veech et al.,1973) and the “box method”, where a 
Styrofoam box fitted around an animal‟s head is filled with liquid nitrogen and 
used to rapidly cool the brain (Yang et al., 1983).  
 
Freezing of the brain in situ is of particular use in larger animals, where 
freezing the whole head takes considerably longer than in mice due to larger 
brain volume and the insulating effect of a thicker skull. The “box method” can 
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be used to freeze brain surface tissues of even large experimental animals 
(Obrenovitch et al., 1988). 
 
Another possibility in our study due to the small size of the mouse‟s brain is to 
drop the whole animal into liquid nitrogen without the use of anaesthesia. This 
brings instant death and freezes the brain in under a minute, rapid enough to 
prevent ischaemic artefacts from occurring (Swaab, 1971). To ensure minimal 
pain and distress, as required by the Animals (Scientific Procedures) Act 
1986, the animal would have to be anaesthetised prior to sacrifice and tissue 
freezing. However, although blood could be collected from the heart after 
recovering the animal from the liquid nitrogen, the blood would have 
undergone haemolysis, meaning that only whole blood could be analysed 
rather than plasma. An alternative to dropping the whole animal into liquid 
nitrogen is to sacrifice the anaesthetised animal by decapitation, letting the 
head fall into a Dewar flask of liquid nitrogen whilst collecting blood into 
anticoagulant-containing centrifugation tubes on ice. This method allows rapid 
freezing of the mouse brain, yet still allows easy collection of a blood sample. 
An advantage of this method over immersion into liquid nitrogen is that the 
lipid profile of plasma can be analysed, since the blood sample is not frozen 
and therefore does not haemolyse. 
 
Another option is to anaesthetize and decapitate the mouse, dissect the brain 
from the head on ice and dropping the dissected tissue into liquid nitrogen to 
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freeze it. It is possible to dissect the brain from the head in fewer than two 
minutes and once immersed in liquid nitrogen, the cortex would be expected 
to freeze in seconds. However, since anoxic depolarisation occurs as shortly 
as ninety seconds after death, this method may not freeze the brain quickly 
enough to avoid ischaemic artefact and achieve reliable data.  
 
2.1.2.3. Chemical inactivation 
 
Birkle and Bazan (1988) described an alternative to heat or cold metabolic 
inactivation of the brain, where cardiac perfusion with a cocktail of metabolic 
inhibitors and calcium chelators was used to chemically fix brain tissue. Two 
inhibitors of PLA2, p–bromophenylacylbromide (pBPB) and diisopropyl 
fluorophosphate (DFP) were used to inactivate PLA2, ethylditetraacetate 
(EDTA) was used to chelate free intracellular Ca2+ ions and 
nordihydroguaiaretic acid (NDGA), an antioxidant and an inhibitor of 
lipooxygenase (LOX), was used to prevent the oxidation of cerebral lipids. 
The described method could be modified to allow blood collection by cardiac 
puncture before perfusing the heart with the chemical mixture. The brain 
retains its histological structure and its dissection from the perfused animal is 
a rapid and simple process in contrast to the dissection of frozen brain tissue. 
 
2.1.2.4. Selection of a metabolic inactivation method 
 
The importance of selecting an appropriate method of brain fixation to prevent 
the occurrence of artefacts was illustrated by a study by Farias and 
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colleagues on LC-MS/MS analysis of brain lipids (Farias et al., 2008). Groups 
of mice were subjected to one of three brain sample collection methods: (i) 
focused microwave irradiation of animal‟s head, followed by dissection of 
brain (ii) decapitation of animal, followed by dissection of brain, and (iii) 
decapitation of animal, exposure to the environment for 5 min, followed by 
focused microwave irradiation and then dissection of the brain. The use of 
microwave irradiation prior to brain dissection resulted in a significantly lower 
brain prostaglandin D2 (PGD2) concentration compared to the other two 
sample collection methods but there was no significant difference in brain 
PGD2 between the groups of animals that were decapitated, indicating that 
the fixation process did not stimulate production of brain PGD2 (Farias et al., 
2008). The authors concluded that the elevated level of brain PGD2 observed 
in animals not subjected to microwave irradiation was due to ischaemic 
artefacts, and that microwave fixation was an effective method of preventing 
artefacts in brain lipid analysis. This study would support our theory that 
dissection of mouse brain on ice would not be rapid enough to prevent 
ischaemia-induced metabolic changes in the brain and that an improved 
method of fixation is required. 
 
Heat fixation using microwave irradiation has been described as a humane 
method of euthanasia for small rodents if the instrument used is capable of 
inducing rapid unconsciousness (Animal Procedures Committee report, 
2006). High-energy microwave irradiation using powerful equipment can fulfil 
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this condition, quickly and irreversibly deactivating enzymes in the brain. 
However, the high temperatures achieved in an animal‟s brain, even when 
subjected to only a brief period of microwave irradiation raises the question of 
whether heat-labile compounds, such as PUFA, would be degraded by the 
fixation process. The use of high-powered microwave irradiation does not 
appear to be commonplace, especially in the United Kingdom, and the use of 
low-power equipment could lead to a slower death, potentially causing 
distress and suffering to the animal. Therefore, the lack of access in our 
laboratory to suitably high-powered microwave irradiation equipment 
effectively precludes the use of microwave irradiation as a method of fixing 
brain tissue in this study. 
 
Chemical inhibition of brain tissue metabolism initially appears to have many 
advantages as a brain fixation method. Firstly, no specialist equipment is 
required for this method, secondly, blood can also be collected unlike as in 
freezing of the whole animal and thirdly, dissection of the fixed brain is easy 
and rapid compared to that of frozen tissue. However, this method has the 
disadvantage of requiring hazardous chemicals, including an acute 
neurotoxin and a chronic mutagenic agent. Rodent toxicity studies on the 
anti-cholinesterase DFP have shown a very low LD50 in both rats and mice 
through oral, inhalation or transdermal routes (www.sciencelab.com/xMSDS-
Diisopropyl_Fluorophosphate-9927520). DFP is harmful if absorbed in large 
quantities through the skin, can cause severe damage to mucosal tissues 
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including eyes and the respiratory tract and can even be lethal if swallowed 
(https://fscimage.fishersci.com/msds/41368). NDGA is an irritant to mucosal 
tissues, including the respiratory tract and is potentially harmful if ingested or 
absorbed through the skin (http://www.caymanchem.com/msdss/70300). BPB 
is also very destructive of mucosal tissues and can be fatal if inhaled. 
 
The toxicity and potential mutagenic properties of some of these chemical 
metabolic inactivator compounds poses questions as to whether their use can 
be justified. Although the health risks posed to users of animal laboratory 
facilities can be minimised by thorough decontamination of the laboratory 
area and occupational health screening, the use of departmental shared 
facilities for tissue sectioning means that there is a risk of exposing other 
personnel to traces of these compounds during the processing of tissue 
samples. Since there are alternative brain fixation methods available which 
do not require the use of such hazardous chemicals, the use of chemical 
inactivators for metabolic inactivation were deemed unacceptable under the 
School of Life Sciences‟ COSHH guidelines, and so brain fixation by cardiac 
perfusion of brain metabolic inhibitors could not be considered for this study. 
 
This essentially leaves freezing as the only available method of brain fixation 
for this study. Freezing in situ involves freezing the outer layers of brain tissue 
whilst still allowing blood to penetrate the deeper layers of tissue, preventing 
anoxic depolarisation from occurring in deep tissue layers before they can be 
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frozen. This method also allows the removal of a blood sample while the brain 
is being frozen or after the process has been completed.  
 
However, since mice are small enough to be able to freeze the whole head of 
the animal in under a minute, the brain does not necessarily need to be 
frozen in situ to prevent anoxic depolarisation occurring in deeper brain 
tissues. The whole animal or the head of an anaesthetised animal could be 
frozen by immersion in liquid nitrogen instead, removing the need for a 
complicated experimental set-up as in freezing in situ. However, if plasma is 
to be analyzed, unfrozen blood must be collected, which rules out dropping 
the whole animal into liquid nitrogen. 
 
Our need for the collection of unfrozen blood and rapid post-mortem freezing 
of brain tissue means that decapitation can be considered as a method of 
animal sacrifice. This method allows easy collection of blood from the carotid 
arteries and if the animal‟s head is immediately dropped into liquid nitrogen, 
ensures rapid freezing of the brain before anoxic depolarisation can take 
place. The dissection of the cerebral cortex out of the frozen head, whilst 
laborious, is a straightforward process compared to the dissection of frozen 
cerebral cortex from an animal with its brain frozen in situ or the collection of 
blood from an animal in a stereotactic frame setup for freezing in situ.  
83 
 
The following figure illustrates the decision-making process which led to the 
choice of a method for the collection of blood and brain samples and the 
fixation of brain tissue. The preferred method was sacrifice of an 
anaesthetised animal by decapitation, followed by rapid post-mortem freezing 
of brain tissue. This method requires no specialist equipment, does not 
involve the use of toxic chemicals and is an efficient method of fixing brain 
tissue. It also has the advantage of allowing the collection of a blood sample 
as well as brain tissue from the same animal, reducing the total number of 
mice required for studies on both brain and plasma lipids, in accordance with 
the principles of the 3Rs (“Reduce, Refine, Replace”) promoted by the 
National Centre for the Replacement, Refinement and Reduction of Animals 
in Research (http://www.nc3rs.org.uk/). 
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Figure 2.2 Selection of brain metabolic inactivation method was carried out by a process of elimination 
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2.1.3. Tissue storage, processing and analytical issues 
 
Care was taken during the extraction process to ensure that minimal 
degradation of the samples occurred, because lipid mediators are particularly 
vulnerable to free radical-mediated oxidation upon exposure to UV radiation. 
Exposure of samples to direct sunlight was minimised using blinds on the 
laboratory windows and by carrying out extractions earlier during the day 
(when the sun was not directly upon the west-facing laboratory‟s windows). 
Homogenisation of brain samples was carried out on ice and samples were 
kept on ice at all times unless they were undergoing extraction processes that 
could not be carried out in an ice box, for example, vortexing, centrifugation 
and solid phase extraction. During centrifugation, the temperature of the 
centrifuge was set to 4°C. Extraction solvents were gently dried off under 
nitrogen gas in a dark environment to prevent oxidation of phospholipids and 
lipid mediators. Amber glass vials were used to store samples that contained 
extracted lipid mediators to minimise exposure of eicosanoids to light. Butyl 
hydroxy toluene (BHT), an antioxidant, was added to the extraction solvents 
to prevent oxidation and to enable storage of lipids for up to a month at -20°C. 
However, to minimise the risk of sample oxidation after extraction and before 
lipidomic analysis, sample extraction was carried out no more than a week 
prior to analysis where possible. Figures 2.3 – 2.5 illustrate the processes 
involved the collection, storage, extraction and phospholipid analysis of 
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mouse cerebral cortex samples, and collection, storage, extraction and lipid 
mediator analysis of mouse cerebral cortex and plasma. 
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Figure 2.3 Collection, processing and phospholipid profiling of mouse cerebral cortex 
Killing of animal
Whole head of animal 
quickly frozen in liquid 
nitrogen 
Frozen head transferred to  
-20°C freezer for 30-60 
minutes
Hemispheres dissected 
from frozen whole head 
and dipped in liquid 
nitrogen 
White matter removed 
from hemispheres to leave 
behind cerebral cortex
Cerebral cortex pieces 
transferred to plastic 
cryotubes and stored at -
80°C until required for lipid 
extraction
Brain samples removed 
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immediately prior to 
extraction of lipids
Homogenisation of brain 
samples in appropriate 
solvent containing 
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Phospholipid extraction is 
carried out at room 
temperature with  sunlight 
minimised
Solvent used in 
phospholipid extractions is 
dried off under nitrogen 
gas in dark conditions
Dried extracted lipids are 
dissolved in 2:1 
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Figure 2.4 Collection, processing and lipid mediator profiling of mouse cerebral cortex 
Killing of animal
Whole head of animal 
quickly frozen in liquid 
nitrogen 
Frozen head transferred to  
-20°C freezer for 30-60 
minutes
Hemispheres dissected 
from frozen whole head 
and dipped in liquid 
nitrogen 
White matter removed 
from hemispheres to leave 
behind cerebral cortex
Cerebral cortex pieces 
transferred to plastic 
cryotubes and stored at -
80°C until required for lipid 
extraction
Brain samples removed 
from -80°C freezer 
immediately prior to 
extraction of lipids
Homogenisation of brain 
samples in appropriate 
solvent
SPE of lipid mediators is 
carried out at room 
temperature with  
protection from direct 
sunlight
Solvent used in SPE is dried 
off under nitrogen gas in 
dark conditions
Dried extracted lipids are 
dissolved in ethanol and 
transferred to sealed 
amber HPLC vials
Extracted lipids are stored 
at  -20°C for up to a week 
prior to LC-MS/MS analysis
Analytes are kept in cool,  
dark conditions during LC-
MS/MS run
Processed samples are 
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storage
Sample collection process shaded in green Sample analysis process shaded in red
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Figure 2.5 Collection, processing and lipid mediator profiling of mouse plasma 
 
Killing of animal
Whole blood collected in tube 
containing anticoagulant and 
kept on ice
Plasma separated from red blood 
cells by centrifugation
Plasma removed and transferred 
to plastic  cryotubes
Plasma is stored at -80°C until 
required for lipid extraction
Plasma samples defrosted 
immediately prior to extraction of 
lipid mediators
SPE of lipid mediators is carried out 
at room temperature with  
protection from direct sunlight
Solvent used in SPE is dried off 
under nitrogen gas in dark 
conditions
Dried extracted lipids are dissolved 
in ethanol and transferred to 
sealed amber HPLC vials
Extracted lipids are stored at -20°C 
for up to a week prior to LC-
MS/MS analysis
Analytes are kept in cool, dark 
conditions during LC-MS/MS run
Processed samples are returned to 
-20°C for storage
Sample collection process shaded in green Sample analysis process shaded in red
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2.2. Animal treatments 
 
2.2.1. Care and welfare of animals 
 
Young adult male C57/BL6 mice (aged 8 – 16 weeks) obtained from Harlan 
(Bicester, Oxfordshire, UK) were used throughout. All procedures were 
carried out in designated premises under Home Office licensing in 
accordance with the Animals (Scientific Procedures) Act (1986), and with 
ethical approval from the University ethical review process. Animals were 
housed in a controlled environment (21 ± 2 °C, 40-60% relative humidity) in 
consecutive 12 hour cycles of light and dark, and had free access to food and 
water. All animals were fed on a standard laboratory rodent diet (Harlan 
Teklad, Bicester, Oxfordshire, UK). 
 
2.2.2. Preparation of alpha linoleic acid or vehicle 
 
α-Linolenic acid (18:3n-3, ALA), like many other PUFA, is thermally labile and 
is also sensitive to light. Care was taken to minimise exposure of the 
compound to light, including the selection of amber glass vials were selected 
for preparation of an ALA solution or vehicle. A 1 M solution of ALA was 
prepared by dissolving 139 mg of free fatty acid (Sigma-Aldrich, Poole, 
Dorset, UK) in 0.5ml of ethanol (Fisher Chemicals Ltd,Loughborough, 
Leicestershire, UK) in an amber glass vial (Sigma-Aldrich, Poole, Dorset, UK). 
This stock solution was sonicated for two minutes to ensure that all the fatty 
acid had thoroughly dissolved, then subsequently used to prepare a 50 μM 
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ALA solution in 0.9% NaCl, through serial dilution, with an overall dilution 
factor of 1:20,000. The ALA solution for injection was prepared immediately 
prior to use in order to ensure that minimal degradation of the compound 
occurred.  
2.2.3. Intravenous injection of alpha linoleic acid or vehicle 
The tail vein injections were carried out in a darkened room with a spotlight 
lamp located next to a purpose–made mouse restrainer (Vet Tech Solutions 
Ltd, Congleton, Cheshire, UK). Light was concentrated on the area where the 
mouse entered the restrainer so that exposure of ALA to light could be 
minimised. The brightness of the light also encouraged the mouse to enter 
the darker environment of the tube-shaped restrainer.  
 
Male C57/BL6 mice were placed inside a purpose – made restrainer and a 
local anaesthetic (5% EMLA cream, Astra Pharmaceuticals, Kings Langley, 
Hertfordshire, UK) was spread over each mouse‟s tail. The moisture of the 
EMLA made the tail vein easier to see on the black mice and also caused 
vasodilation, making the injection process easier for the researcher and less 
distressing for the mice. 0.0139mg/kg of ALA was injected into the tail vein of 
the mouse using a disposable syringe (Terumo, Leuven, Belgium)and a 27 
gauge winged infusion set (Vygon UK, Cirencester, Gloucestershire, UK). The 
corresponding vehicle (0.005% v/v ethanol in 0.9% NaCl) was used as 
controls for drug-treated animals. 
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2.2.4. Sample collection  
Anaesthesia was induced in the mouse by exposure to 5% halothane in 2:1 
N2O:O2 for 3 minutes, and the anaesthetized animal was then rapidly killed by 
decapitation. The head was allowed to fall into a Dewar flask of liquid nitrogen 
and blood from the severed neck arteries was collected into centrifugation 
tubes containing an anticoagulant solution of 0.1 ml sodium EDTA in 0.5 M 
NaOH (both from Sigma-Aldrich, Poole, Dorset, UK) and kept in an ice 
bucket. The blood samples were centrifuged at 3000 rpm at 4°C for 20 min 
and the plasma (supernatant layer) was pipetted into cryotubes using glass 
Pasteur pipettes. Each plasma sample had a volume of approximately 300-
400µL and they were stored in plastic cryotubes at –80°C until required for 
analysis.  
 
The frozen mouse heads were allowed to remain in the liquid nitrogen for 
approximately 5 minutes after the animal‟s death, and were then transferred 
to a –20°C freezer for approximately 45 min to allow their temperature to 
equilibrate at around –20°C. Once the temperature of the mouse heads had 
increased sufficiently to make dissection of the brain from the head feasible, 
they were collected from the –20°C freezer and the cerebra were dissected 
from the heads in a cooled environment using metal tools that had been 
cooled by dipping in liquid nitrogen. The dissected-out cerebra were 
frequently dipped into a small vessel of liquid nitrogen to ensure that they 
remained frozen throughout the dissection process. Once removed from the 
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liquid nitrogen, room-temperature tools were used to scoop out the white 
matter out of the cerebra, leaving behind the cerebral cortex. At optimum 
dissecting temperature, the consistency of the white matter is that of hard ice 
cream, whilst the grey matter is frozen solid. The grey matter left behind after 
dissecting out the white matter was placed in cryotubes that had been cooled 
by dipping inside the liquid nitrogen vessel and stored at –80°C until 
extraction. Figure 2.6 demonstrates the different processes undertaken in 
preparing plasma and cerebral cortex samples for storage prior to lipid 
extraction. 
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Figure 2.6 Brain and blood sample collection and preparation for lipid 
extractions 
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2.3. Lipid extraction 
 
2.3.1. Liquid/liquid extraction of phospholipids 
 
Phospholipids were extracted from mouse cerebral cortex samples using a 
modification of the Folch method (Folch et al., 1957). All organic solvents 
used in this process were purchased from Fisher Chemicals Ltd 
(Loughborough, Leicestershire, UK) and other chemicals were bought from 
Sigma-Aldrich (Poole, Dorset, UK). Samples of mouse brain tissue were 
homogenised in 0.5 ml water and 3 ml of 2:1 v/v chloroform-methanol mixture 
containing 0.01% BHT. The samples were each vortexed for 5 min, and then 
centrifuged at 2000 rpm for 5 min at 4°C to separate the aqueous and organic 
phases. The organic phase was removed and the remainder was re-extracted 
with 0.5 ml water and 4 ml of 2:1 v/v chloroform-methanol mixture containing 
0.01% BHT. Each sample was again vortexed for 5 min and centrifuged at 
2000 rpm for 5 min at 4°C. The organic extracts from both cycles of extraction 
were combined and washed twice with 2 ml of 0.5 KCl in 50% v/v methanol-
water. After washing, the combined extracts were dried over anhydrous 
sodium sulphate and filtered through Pasteur pipettes packed tightly with 
cotton wool. The filtered extracts were dried gently under a stream of nitrogen 
gas until no liquid remained, and the residue dissolved in 1ml of 2:1 
chloroform-methanol solution with 0.01% w/v BHT added. The vials were then 
flushed with nitrogen gas and wrapped with parafilm to ensure that the vials 
containing the extracts were airtight. The extracted sample in storage solvent 
could be stored at – 20°C or -80°C until required for analysis.  
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2.3.2. Solid phase extraction (SPE) of lipid mediators 
 
All organic solvents used in this process were purchased from Fisher 
Chemicals Ltd (Loughborough, Leicestershire, UK) and other chemicals were 
bought from Sigma-Aldrich (Poole, Dorset, UK). Brain tissue samples were 
homogenised (approximately 50 up and down strokes) in deionised water 
using a glass Dounce mini homogeniser with a tight-fitting pestle (Wheaton 
Micro-homogeniser kit, VWR, Lutterworth, Leicestershire, UK). The tissues 
were kept on ice during the homogenisation process. The homogenate was 
adjusted to 15% v/v methanol and a final volume of 3ml. 2.8ml deionised 
water was added to 200µl aliquots of plasma to achieve a total sample 
volume of 3ml. 530 µl of methanol and 40µl of 1ng/ml PGB2-d4 (Cayman 
Chemicals, Ann Arbor, MI) dissolved in ethanol were added to each sample. 
The samples were kept on ice for 30 min, then centrifuged at 3000 rpm for 5 
min to remove precipitated proteins. The supernatant was removed to a clean 
glass vial and pH adjusted to pH 3.0 using 0.025M HCl. The acidifed sample 
was added to SPE cartridges (Strata C18-E, Phenomenex, Manchester, UK) 
which had been preconditioned with 20ml of methanol, followed by 20ml of 
deionised water and allowed to pass through drop-wise. 
 
After the samples had run through the cartridges, 20ml of 15% (v/v) methanol 
was run through the SPE cartridges, followed by 20ml of deionised water and 
10ml of hexane. Finally, 10ml of methyl formate was run through the SPE 
cartridges to extract the lipid mediators and collected in glass extraction 
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tubes. The extracted eicosanoids were dried under a gentle stream of 
nitrogen gas until no visible liquid remained. 100μl of ethanol was added to 
the glass tube, taking care to dissolve the lipid residue thoroughly in the 
ethanol. The ethanolic solution was transferred to a 100μl glass vial insert 
that was placed inside a 2ml HPLC amber glass vial (both from Sigma-
Aldrich, Poole, Dorset, UK), and then stored at -20°C until required for 
analysis. 
 
2.4. Lipdomic Analysis 
 
2.4.1. ESI-MS/MS of phospholipids 
 
Analysis of phospholipids was carried out using a triple quadrupole (3Q) mass 
spectrometer (Quattro Ultima model, Waters, Manchester, UK) with 
MassLynx 4.0 software. An aliquot of 100μl extracted sample was mixed with 
200μl of 70:20:10:3 chloroform: methanol: 10% ammonium hydroxide (aq): 
water. 
 
General scans of phosphatidylcholine, sphingomyelin and 
phosphatidylethanolamine species were carried out in ES+ mode and general 
scans of phosphatidylserine and phosphatidylinositol species in ES – mode, 
using the instrument parameters described in Table 2.1. The acquisition time 
for each scan was 24 seconds.  
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Table 2.1 Instrument parameters for general scanning in ES+ and ES- modes 
Instrument (3Q) parameter ES –  ES + 
Polarity ES – ES + 
Capillary voltage (kV) 2.60 2.30 
Cone voltage (V) 55.0 60.0 
RF Lens 1 7.6 5.0 
Aperture 0.0 0.0 
RF Lens 2 1.0 1.0 
Source temperature (° C) 80 80 
Desolvation temperature (° C) 150 150 
Cone Gas Flow (L/hr) 60 60 
Desolvation Gas Flow (L/hr) 380 380 
LM (Low mass ion) Resolution MS1 14.8 14.8 
HM (High mass ion) Resolution 
MS1 
14.5 14.5 
Ion Energy 0.5 0.3 
Entrance 14 15 
Collision Energy (eV) 0 0 
Exit 17 20 
LM (Low mass ion) Resolution MS2 13.5 13.5 
HM (High mass ion) Resolution 
MS2 
13.5 13.5 
Ion Energy 2 2.0 0.6 
Multiplier (gain) 610 610 
  
In addition to a general scan, two types of fragmentation scans were carried 
out on each sample: (a) neutral loss scans, where the precursor ions are 
detected on the basis of a loss of a fragment with a specified m/z value during 
CID, and (b) precursor ion scans, which reports the m/z value of precursor 
ions whose fragmentation leads to production of ion fragments with a 
specified m/z value. The scanning parameters are dependent on the polar 
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head group of the phospholipid class. Phosphatidylcholines and 
sphingomyelins are identified through the production of a choline ion (with an 
m/z of 184) lost from the head group of both classes of phospholipids. 
Fragmentation of phosphatidylinositol species in the ES- mode results in the 
production of inositol, which has an m/z value of 241. The loss of 
ethanolamine from phosphatidylethanolamine species results in the 
production of a daughter ion with a m/z value 141 less than the parent ion. 
Similarly, the loss of serine from a phosphatidylserine upon fragmentation of 
the molecular ion results in a product ion with its m/z value 87 less than the 
original molecular ion.  
 
Table 2.2 Tandem mass spectrometry parameters for the analysis of 
phospholipid classes in mouse brain tissue 
 
Phospholipid class Scanning mode 
Phosphatidylcholine Precursors of m/z 184 (ES+) 
Phosphatidylethanolamine Neutral loss of m/z 141 
(ES+) 
Phosphatidylinostol Precursors of m/z 241 (ES-) 
Phosphatidylserine Neutral loss of m/z 87 (ES-) 
Sphingomyelin Precursors of m/z 184 (ES+) 
 
The instrument parameters for fragmentation ion scanning vary slightly 
according to the class of phospholipid which is to be fragmented, and are  
detailed in Table 2.3.
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Table 2.3 Instrument parameters for phospholipid analysis by tandem mass spectrometry 
Instrument parameter Phosphatidyl 
choline (PC) 
Sphingomyelin (SM) Phosphatidyl 
ethanolamine (PE) 
Phosphatidyl 
serine (PS) 
Phosphatidyl 
inositol (PI) 
Polarity ES + ES + ES + ES – ES – 
Capillary voltage (kV) 2.30 2.30 2.30 2.60 2.60 
Cone voltage (V) 60.0 60.0 60.0 55.0 55.0 
RF Lens 1 7.6 7.6 7.6 5.0 5.0 
Aperture 0.0 0.0 0.0 0.0 0.0 
RF Lens 2 1.0 1.0 1.0 1.0 1.0 
Source temperature (° C) 80 80 80 80 80 
Desolvation temperature (° C) 150 150 150 150 150 
Cone Gas Flow (L/hr) 60 60 60 60 60 
Desolvation Gas Flow (L/hr) 380 380 380 380 380 
LM (low mass) 1 Resolution 15.0 15.0 15.0 14.8 14.8 
HM (high mass) 1 Resolution 15.0 15.0 15.0 14.5 14.5 
Ion Energy 1 0.3 0.3 0.3 0.5 0.5 
Entrance 1.0 1.0 1.0 -1 -1 
Collision Energy (eV) 30 30 25 25 25 
Exit 2.0 2.0 2.0 2.0 2.0 
LM (low mass) 2 Resolution 14.0 14.0 14.0 13.5 13.5 
HM (high mass) 2 Resolution 14.0 14.0 14.0 13.5 13.5 
Ion Energy 2 0.6 0.6 0.6 1.0 1.0 
Multiplier (gain) 500 600 600 480 600 
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Results were quantified by processing spectrometric data from each 
sample using MassLynx data analysis software, and importation of 
numerical data into a Microsoft Excel spreadsheet. A macro for Excel 
developed by collaborators at the University of Southampton (Professor 
A.Postle and colleagues) was used to calculate the percentage 
abundance of the phospholipid species detected in each phospholipid 
class.  
 
The ions detected at above 1% percentage abundance in each 
phospholipid class using fragmentation scanning were further subjected 
to precursor ion scans in the negative (ES-) mode to identify the fatty 
acyl, plasmogen or ether groups that made up the remainder of the 
phospholipid‟s structure. A 100μl aliquot of extracted sample was mixed 
with 200 μl of 70:30 chloroform:methanol with 0.02% formic acid. The 
formic acid facilitated the production of negative fatty acyl ions from the 
phospholipid structure. The instrument parameters for this analysis 
were as described in Table 2.4. 
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Table 2.4 Instrument parameters for tandem mass spectrometry analysis of 
phospholipids: identification of fatty acyl chains 
 
2.4.2. ESI-LC-MS/MS analysis of prostaglandins  
 
ESI-LC-MS/MS analysis was performed on a HPLC pump (model 2695, 
Waters, Manchester, UK) coupled to an electrospray-interface triple 
quadrupole mass spectrometer (Quattro Ultima, Waters, Manchester, UK) 
using MassLynx 4.0 software. Chromatographic analysis was carried out on a 
C18 column (Luna, 5μm, 150 x 5mm, Phenomenex, Manchester, UK) 
maintained at ambient temperature. Sample injections were performed using 
Instrument parameter PC SM PE PS PI 
Polarity ES – ES – ES – ES – ES – 
Capillary voltage (kV) 2.60 2.60 2.60 2.60 2.60 
Cone voltage (V) 55.0 55.0 55.0 55.0 55.0 
RF Lens 1 5.0 5.0 5.0 5.0 5.0 
Aperture 0.0 0.0 0.0 0.0 0.0 
RF Lens 2 1.0 1.0 1.0 1.0 1.0 
Source temperature (° C) 80 80 80 80 80 
Desolvation temperature (° C) 150 150 150 150 150 
Cone Gas Flow (L/hr) 60 60 60 60 60 
Desolvation Gas Flow (L/hr) 380 380 380 380 380 
LM (low mass) 1 Resolution 14.8 14.8 14.8 14.8 14.8 
HM (high mass) 1 Resolution 14.5 14.5 14.5 14.5 14.5 
Ion Energy 1 0.5 0.5 0.5 0.5 0.5 
Entrance -1 -1 -1 -1 -1 
Collision Energy (eV) 25 30 30 20 20 
Exit 2.0 2.0 2.0 2.0 2.0 
LM (low mass) 2 Resolution 13.5 13.5 13.5 13.5 13.5 
HM (high mass) 2 Resolution 13.5 13.5 13.5 13.5 13.5 
Ion Energy 2 1.0 1.0 1.0 1.0 1.0 
Multiplier (gain) 500 600 600 480 600 
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an autosampler (model number 2690, Waters, Manchester, UK) with the 
temperature of the sample chamber set at 8 ± 2°C. 200µl of a 2pg/µl cocktail 
of standards in ethanol were prepared containing prostaglandin D1 (PGD1), 
prostaglandin E1 (PGE1), prostaglandin F1α (PGF1α), 6-keto-prostaglandin F1α 
(6-keto-PGF1α), prostaglandin B2 (PGB2), prostaglandin B2-d4 (PGB2-d4), 
prostaglandin D2 (PGD2), prostaglandin E2 (PGE2), prostaglandin F2α (PGF2α), 
prostaglandin J2 (PGJ2) , 15-deoxy- Δ 
12,14-prostaglandin J2 (PGJ2), 
prostaglandin D3 (PGD3), prostaglandin E3 (PGE3), prostaglandin F3α (PGF3α), 
thromboxane B2 (TXB2), thromboxane B3 (TXB3), 8-iso-PGE2, 8-iso-PGF2α, 
13,14-dihydro-PGE1, 13,14-dihydro-PGF1α, 13,14-dihydro-PGF2α, 13,14-
dihydro-15-keto PGE1, 13,14-dihydro-15-keto-PGF1α, 13,14-dihydro-15-keto-
PGE2 and 13,14-dihydro-15-keto-PGF2α (all purchased from Cayman 
Chemicals, Ann Arbor, MI).  
 
A range of standard solutions was produced by adding 40µl of 2ng/ml of the 
internal standard PGB2-d4 and 50µl, 40µl, 30µl, 20µl, 10µl or 5µl of the 
cocktail of prostanoid standards in ethanol, then diluting with ethanol to 
produce a final volume of 100µl. This process produced a range of standard 
solutions with prostanoid cocktail concentrations of 1pg/µl, 0.8pg/µl, 0.6pg/µl, 
0.4pg/µl, 0.2pg/µl and 0.1pg/µl respectively. Calibration lines were set up for 
each of the prostanoid species in the cocktail of standards using the standard 
solutions, which were later used during for the quantification of prostanoid 
species in the biological samples. 
 
104 
 
The injection volume of the standards was 5μl and that of biological samples 
was 10μl. A gradient was set up between Solvent A (45:55:0.02 v/v/v 
acetonitrile: water: glacial acetic acid) and Solvent B (90:10:0.02 v/v/v 
acetonitrile: water: glacial acid) with a flow rate of 0.2 ml/min. The gradient 
was as follows: 100% Solvent A for 0.0 to 8.0 min, ramping to 50% Solvent A 
and 50% Solvent B from 8.0 to 8.1 min, 50% Solvent A and 50% Solvent B 
from 8.1 to 12.0 min, ramping to 30% Solvent A and 70% Solvent B from 12.0 
to 12.1 min, 30% Solvent A and 70% Solvent B from 12.1 to 20.0 min, 
ramping from 30% to 100% Solvent A over 20.0 to 20.1 min, remaining at 
100% Solvent A from 20.1 to 30.0 min. The mass spectrometer was used in 
the ES- mode, with the capillary voltage was set to 3500V and the cone 
voltage set to 35V. The source temperature was set to 120°C and the 
desolvation temperature to 360°C. Twenty one different MRM transactions 
were monitored over the course of each run with the collision energy of each 
transition set as described in Table 2.5.  
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Table 2.5 Collision energy settings for multiple reaction monitoring (MRM) 
used for the ESI-LC-MS/MS analysis of prostanoids (Masoodi & Nicolaou, 
2006) 
 
Compound MRM (m/z) Collision energy (eV) 
PGD1 353  317 15 
PGE1 353  317 15 
PGF1α 355  311 25 
6-keto-PGF1α 369  163 23 
PGB2 333  175 20 
PGB2-d4 337  179 20 
PGD2 351  271 17 
PGE2 351  271 17 
PGF2α 353  193 25 
PGJ2 333  271 15 
Δ12-PGJ2 333  271 15 
15-deoxy-Δ12,14 PGJ2 315  271 15 
PGD3 349  269 15 
PGE3 349  269 15 
PGF3α 351  193 25 
TXB2 369  169 17 
TXB3 367  169 15 
8-iso-PGE2 351  315 15 
8-iso-15-keto PGE2 349  113 23 
8-iso-PGF2α 353  193 25 
8-iso-15-keto PGF2α 351  315 15 
13,14-dihydro PGE1 355  337 15 
13,14-dihydro-15-keto PGE1 353  335 12 
13,14-dihydro PGF1α 357  113 38 
13,14-dihydro-15-keto PGF1α 355  193 32 
13,14-dihydro-15-keto PGE2 351  333 12 
13,14-dihydro PGF2α 355  311 30 
13,14-dihydro-15-keto PGF2α 353  113 28 
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2.4.3. LC-MS/MS analysis of hydroxy fatty acids 
 
LC-MS/MS analysis was performed on a HPLC pump (model 2695, Waters, 
Manchester, UK) coupled to an electrospray-interface triple quadrupole mass 
spectrometer (Quattro Ultima, Waters, Manchester, UK) using MassLynx 4.0 
software. Chromatographic analysis was carried out on a C18 column (Luna, 
5μm, 150 x 5mm, Phenomenex, Manchester, UK) maintained at ambient 
temperature. Sample injections were performed using an autosampler (model 
number 2690, Waters, Manchester, UK) with the temperature of the sample 
chamber set at 8 ± 2°C. A cocktail of standards were prepared using 
5S,12R,18R-trihydroxy-6Z,8E,10E,14Z,16E-eicosapentaenoic acid (Resolvin 
E1), 5S,8R,17S-trihydroxy-4Z,9E,11E,13Z,15E,19Z-docosahexaenoic acid 
(Resolvin D1), 10R,17S-dihydroxy-docosa-4Z,7Z,11E,15Z,19Z-hexaenoic 
acid (Protectin D1), 9-hydroxy-10E,12Z-octadienoic acid (9-HODE), 13-
hydroxy-9Z,11E-octadienoic acid (13-HODE), 5-hydroxy-6E,8Z,11Z,14Z,17Z-
eicosapentaenoic acid (5-HEPE),18-hydroxy-5Z,8Z,11Z,14Z,16E-
eicosapentaenoic acid (18-HEPE), 9-hydroxy-5Z,7E,11Z,14Z,17Z-
eicosapentaenoic acid (9-HEPE), 8-hydroxy-5Z,9E,11Z,14Z,17Z-
eicosapentaenoic acid (8-HEPE),15-hydroxy-5Z,8Z,11Z,13E,17Z-
eicosapentaenoic acid (15-HEPE),12-hydroxy-5Z,8Z,10E,14Z,17Z-
eicosapentaenoic acid (12-HEPE), 5-hydroxy-6E,8Z,11Z,14Z-
eicosatetraenoic acid (5-HETE), 8-hydroxy-5Z,9E,11Z,14Z-eicosatetraenoic 
acid (8-HETE), 11-hydroxy-5Z,8Z,12E,14Z-eicosatetraenoic acid (11-
HETE),15-hydroxy-5Z,8Z,11Z,13E-eicosatetraenoic acid (15-HETE), 12-
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hydroxy-5Z,8Z,10E,14Z-eicosatetraenoic acid (12-HETE), 9-hydroxy-
5Z,7E,11Z,14Z-eicosatetraenoic acid (9-HETE), Leukotriene B4 (LTB4), 17S-
hydroxy-4Z7Z,10Z,13Z,15E,19Z-docosahexaenoic acid (17S-HDHA) and 
12S-hydroxy-5Z,8Z,10E,14Z-eicosatetraenoic-5,6,8,9.11,12,14,15-d8 acid 
(12-HETE-d8). Protectin D1 and Resolvins E1 and D1 were obtained from the 
laboratory of C.N. Serhan (Centre of Experimental Therapeutics and 
Reperfusion Injury, Brigham & Women‟s Hospital, Boston, MA). All other lipid 
standards were purchased from Cayman Chemicals (Ann Arbor, MI). A range 
of standard solutions was produced by adding 40µl of 2ng/ml of the internal 
standard 12HETE-d4 and 50µl, 40µl, 30µl, 20µl, 10µl or 5µl of the cocktail of 
lipid standards in ethanol, then diluting with ethanol to produce a final volume 
of 100µl. This process produced a range of standard solutions with lipid 
cocktail concentrations of 1pg/µl, 0.8pg/µl, 0.6pg/µl, 0.4pg/µl, 0.2pg/µl and 
0.1pg/µl respectively. Calibration lines were set up for each of the lipid 
species in the cocktail of standards using the standard solutions, which were 
later used during for the quantification of lipid species in the biological 
samples. 
 
The mass spectrometer was used in the ES- mode, with the capillary voltage 
was set to 3500V and the cone voltage set to 35V. The source temperature 
was set to 120°C and the desolvation temperature to 360°C. Analysis was 
carried out using an isocratic system by mixing two solvents, A and B, at a 
ratio of 95:5 v/v. Solvent A was 80:20:0.02 v/v/v methanol: water: glacial 
acetic acid and Solvent B was 45:55:0.02 v/v/v acetonitrile: water: glacial 
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acetic acid. The injection volume of standards was 5μl and that of biological 
samples was 10μl. Twenty different MRM transactions were monitored over 
the course of each run with the collision energy of each transition set as 
described in Table 2.6.  
 
Table 2.6 Collision energy settings for MRM transitions of lipo-oxygenase, 
acetylated COX and P450 enzymes lipid mediator products (Masoodi et al., 
2008) 
Compound MRM (m/z) Collision energy (eV) 
9-HODE 295  171 25 
13-HODE 295  195 25 
5-HEPE 317  115 20 
18-HEPE 317  133 25 
9-HEPE 317  149 20 
8-HEPE 317  155 18 
15-HEPE 317  175 18 
12-HEPE 317  179 20 
5-HETE 319  115 20 
9-HETE 319  123 20 
8-HETE 319  155 20 
11-HETE 319  167 20 
 15-HETE 319  175 18 
12-HETE 319  179 20 
12-HETE-d8 328 185 17 
LTB4 335  195 17 
17S-HDHA 343 281 15 
RvE1 349  195 17 
PD1 359  206 15 
RvD1 375  141 15 
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2.5. Data collection and presentation 
 
The cerebral cortex collected from each mouse was split into two, so that 
each mouse produced three samples for lipidomic analysis: (i) a plasma 
sample for lipid mediator analysis, (ii) a cerebral cortex sample for lipid 
mediator analysis and (iii) another cerebral cortex sample for phospholipid 
analysis. For each sample type, the mice were divided into three main 
groups: (a) Control mice, who did not undergo any form of treatment prior to 
killing and sample collection, (b) PUFA-treated mice, which underwent tail 
vein injection of 50 μM ALA solution in 0.9% NaCl prior to killing and sample 
collection and (c) Vehicle-treated mice, which received a tail vein injection of 
the corresponding vehicle (0.005% v/v ethanol in 0.9% NaCl) prior to killing 
and sample collection. Mice in the ALA and the vehicle treatement groups 
were killed at four different timepoints (3h, 24h, 72h and 168h) following 
injection with ALA or vehicle.  
 
Statistical analysis was carried out for both phospholipids and lipid mediators 
between control and treatment groups, and between different treatment 
groups at the same timepoints using two-way analysis of variance (ANOVA) 
tests between control and treatment groups with post-hoc Dunnett‟s 
correction. A value of P<0.05 between a PUFA-treated group and both control 
and the corresponding VEH-treated groups was considered statistically 
significant and a P value of <0.01 highly significant. All statistical analysis was 
carried out using SPSS 16.0 for Windows (SPSS Inc, Chicago, IL). 
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3. Lipidomic analysis of cerebral cortex phospholipids 
in mice 
3.1. Profiling of phospholipids in mouse cerebral cortex: 
general scans 
 
A general scan of the lipid extract using MS provides an overview of the 
phospholipid species present. All species that are ionized by the ESI 
interface, with different mass/charge ratio (m/z) values prominent in the 
positive and negative ion modes, can be detected with a general scan. The 
spectrum produced by a general scan provides information on the total ion 
count, the presence (or absence) of prominent phospholipid species and the 
relative abundance of lysophospholipid species. This information can be used 
to determine whether a sample has been extracted, stored and processed in 
the correct manner. For example, a high ratio of lysophospholipids to 
phospholipids is indicative of sample degradation. Figures 3.1 and 3.2 shows 
representative general scan spectra of a tissue sample taken from the 
cerebral cortex of an untreated (control) mouse in both positive (figure 3.1) 
and negative (figure 3.2) modes. Although general scans using MS are useful 
to identify the overall number of C atoms and the number of C=C double 
bonds present in a phospholipid sample, they can not be used for quantitative 
analysis. It is for this reason that MS/MS fragmentation scans were used in 
order to identify which fatty acyl group corresponds to that on the sn-1 
position and which corresponds to the fatty acyl group on the sn-2 position.
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Figure 3.1 General ESI-MS scan of a representative sample of mouse cerebral cortex in the ES + mode, where positively-charged 
[M+H] + ions are produced 
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Figure 3.2 General ESI-MS scan of a representative sample of mouse cerebral cortex in the ES – mode, where negatively-charged 
[M – H] - ions are produced (a) General scan of murine cerebral cortex tissue in ES - mode
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3.2. Profiling of phospholipids in mouse cerebral cortex: 
MS/MS analysis 
 
In addition to a general scan, two types of fragmentation scans were carried 
out on each sample to identify phosphatidylcholine, sphingomyelin, 
phosphatidylethanolamine, phosphatidylserine and phosphatidylinositol 
species. These scans were: (a) neutral loss scans, where the precursor ions 
are detected on the basis of a loss of an ion fragment with a specified m/z 
value during collision-induced dissociation (CID), and (b) precursor ion scans, 
whose fragmentation leads to production of ion fragments with a specified 
m/z value. The scanning parameters differed according to the polar head 
group of the phospholipid class to be detected.  
 
Phosphatidylcholines and sphingomyelins were identified through the 
detection of choline ions (with an m/z of 184) lost from the head group of both 
classes of phospholipids. Phosphatidylinositol species were identified through 
the detection of an inositol ion (m/z 241) lost from the head group of this 
phospholipid class upon fragmentation in the ES- mode. 
Phosphatidylethanolamine species were detected through neutral loss 
scanning of 141, where the production of a fragment ion with m/z value 141 
less than the parent ion is detected. Similarly, the loss of serine from a 
phosphatidylserine upon fragmentation of the molecular ion results in a 
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product ion with its m/z 87 less than the original molecular ion, so 
phosphatidylserines were detected through neutral loss scanning of m/z 87. 
 
Figures 3.3 – 3.6 show representative spectra of fragmentation scans carried 
out to identify different classes of phospholipids (namely 
phosphatidylcholines, sphingomyelins, phosphatidylethanolamines, 
phosphatidylserines and phosphatidylinositols) in a single tissue sample 
taken from the cerebral cortex of an untreated (control) mouse. 
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Figure 3.3 Representative ESI-MS/MS spectrum in the ES+ mode showing phosphatidylcholine (PC) and sphingomyelin (SM) 
species in mouse cerebral cortex tissue; the scan used is a precursor ion scan of m/z 184 
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Figure 3.4 Representative ESI-MS.MS spectrum in the ES+ mode showing phosphatidylethanolamine (PE) species in mouse 
cerebral cortex tissue; the scan used is a neutral loss ion scan of m/z 141. 
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Figure 3.5 Representative ESI-MS/MS spectrum in the ES- mode showing phosphatidylserine (PS) species in mouse cerebral cortex 
tissue; the scan used is a neutral loss scan of m/z 87.  
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Figure 3.6 Representative ESI-MS/MS spectrum in the ES- mode showing phosphatidylinositol (PI) species in mouse cerebral cortex 
tissue; the scan used is a precursor ion scan of m/z 241. 
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3.3. Identification of phospholipid species in mouse cerebral 
cortex 
 
3.3.1. Phosphatidylcholine and sphingomyelin species  
 
 
Nineteen phosphatidylcholine (PC) and sphingomyelin (SM) species were 
identified in individual samples of mouse cerebral cortex using precursor ion 
scans for the choline headgroup (m/z 184), with the resulting data 
summarised in figures 3.7a-b. 
 
The majority of choline phospholipid species detected in the mouse cerebral 
cortex contained saturated and/or monounsaturated fatty acids, with the two 
most abundant phosphatidylcholines alone accounting for almost half of total 
choline phospholipids detected in the cerebral cortex of untreated mice. 
These two species had m/z values of 734 and 760 and were putatively 
identified using lipid analyser software as PC 32:0 and PC 34:1 respectively. 
The identities of these compounds in mouse brain were confirmed as PC 
16:0/16:1 and PC 16:0/18:0 in the fragmentation study (see section 3.4.) 
 
Highly-unsaturated phosphatidylcholine species contained either arachidonic 
acid (20:4) or docosahexaenoic acid (22:6), both which are known to be 
precursors for lipid mediators. 
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Figure 3.7a Phosphatidylcholine (PC) and sphingomyelin (SM) species identified in cerebral cortex samples of naive mice 
(n=8), grouped by fatty acyl chain components: docosahexaenoic acid (DHA)/ arachidonic acid (AA)/ monounsaturated 
fatty acid (MUFA) and saturafted fatty acid (SFA)  
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Figure 3.7b Nineteen phosphatidylcholine and sphingomyelin species (including two alkyl-linked PC species) were 
identified in mouse cerebral cortex samples using precursor ion scans for the choline headgroup (m/z184).The most 
abundant choline phospholipid species contained saturated and monounsaturated fatty acids. 
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3.3.2. Phosphatidylethanolamine species 
 
Many phosphatidylethanolamine (PE) species were identified in mouse 
cerebral cortex, including some trace species with higher m/z values than 
those observed in rat brain tissue. As a result, some PE species could not be 
identified using the lipid analyzer software. 
 
Highly-unsaturated lipids comprise the majority of this phospholipid class in 
the mouse cerebral cortex. The three most abundant species all contain a 
PUFA (either arachidonic or docosahexaenoic acid) in their structure, and 
they account for two thirds of phosphatidylethanolamines in mouse cerebral 
cortex. The three most abundant phosphatidylethanolamine species detected 
in mouse cerebral cortex had m/z values of 764, 768 and 792, and were 
putatively identified using a lipid analyser software calculator as PE 16:0/22:6, 
18:1/20:4 and 18:0/22:6 respectively. The identities of these compounds in 
mouse brain were confirmed using further fragmentation (see section 3.4). In 
contrast to PC and SM species, phospholipids containing solely saturated or 
monounsaturated fatty acyl chains are relatively rare in PE species, 
accounting for under a fifth of all PE species. 
 
 
..  
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Figure 3.8a Phosphatidylethanolamine species identified in cerebral cortex samples of naive mice (n=8), grouped by fatty 
acyl chain components ), grouped by fatty acyl chain components: docosahexaenoic acid (DHA)/ arachidonic acid (AA)/tri-
enoic and di-enoic/ monounsaturated fatty acid (MUFA) and saturafted fatty acid (SFA)  
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Figure 3.8b – Part I Twenty nine phosphatidylethanolamine species were identified in mouse cerebral cortex samples 
using neutral loss scans of 141 (equivalent to loss of the ethanolamine headgroup, which has a mass of 141). The most 
abundant phosphatidylethanolamine species contained arachidonic (20:4) or docosahexaenoic acid (22:6) 
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Figure 3.8b – Part II Twenty nine phosphatidylethanolamine species were identified in mouse cerebral cortex samples 
using neutral loss scans of 141. The most abundant phosphatidylethanolamine species contained arachidonic (20:4) or 
docosahexaenoic acid (22:6). Some PE species could not be identiied using lipid analyzer software  
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3.3.3. Phosphatidylserine species 
 
Sixteen phosphatidylserine species were identified in mouse cerebral cortex, 
including some species with m/z values differing from those observed in rat 
brain tissue. The two most abundant species in this lipid class accounted for 
approximately three quarters of all phosphatidylserine species in mouse 
cerebral cortex, and had m/z values of 788 and 834 The identity of these two 
phosphatidylserine species, based on the calculations by the lipid analyser 
software, were 18:0/18:1 for m/z = 788 and 18:0/22:6 for m/z = 834. These 
identities were confirmed by data from MS/MS analysis (see section 3.4) 
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Figure 3.9a Phosphatidylserine species identified in cerebral cortex samples of naive mice (n=8), grouped by fatty acyl 
chain components: docosahexaenoic acid (DHA)/ arachidonic acid (AA)/tri-enoic and di-enoic/ monounsaturated fatty acid 
(MUFA) and saturafted fatty acid (SFA)  
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Figure 3.9b Sixteen phosphatidylserine species were identified in mouse cerebral cortex samples using neutral loss scans 
of 87 (equivalent to loss of the serine headgroup, which has a mass of 87). The most abundant phosphatidylserine 
species contained either docosahexaenoic acid (22:6) or a monounsaturated fatty acid 
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3.3.4. Phosphatidylinositol species 
 
The three most abundant phosphatidylinositol species detected in mouse 
cerebral cortex all contained arachidonic acid (20:4), which has been 
implicated in cell signalling. The three most abundant PI species had m/z 
values of 857, 883 and 885 and were putatively identified as 16:0/20:4, 
18:1/20:4 and 18:0/20:4 respectively from rat brain data. Data from MS/MS 
analysis confirmed the putative identities of these phospholipids (see section 
3.4). 
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Figure 3.10a Phosphatidylinositol species identified in cerebral cortex samples of naive mice (n=8), grouped by fatty acyl 
chain components docosahexaenoic acid (DHA)/ arachidonic acid (AA)/ monounsaturated fatty acid (MUFA) and 
saturafted fatty acid (SFA) 
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Figure 3.10b Eleven phosphatidylinositol species were identified in mouse cerebral cortex samples using precursor ion 
scans of m/z 241 (equivalent to loss of the inositol headgroup,which has a mass of 241) The majority of PI in mouse 
cerebral cortex contained arachidonic acid (20:4) 
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3.4. Fragmentation studies of phospholipid species in mouse 
cerebral cortex 
 
Phospholipid ions identified with fragmentation scanning were further 
subjected to precursor ion scans in the negative (ES-) mode to identify the 
fatty acyl, plasmogen or ether groups that made up the remainder of the 
phospholipid‟s structure. The addition of 0.02% formic acid to the mass 
spectrometry solvent facilitated the production of negative fatty acyl ions from 
the phospholipid structure (Esch et al., 2007). 
 
The use of tandem mass spectrometry on the phosphatidylethanolamine, 
phosphatidylserine and phosphatidylinositol species identified in naïve mouse 
cerebral cortex sample resulted in the production of negative fatty acyl ions 
[R–H]– which can be definitively identified from their m/z values. However, 
phosphatidylcholine species did not readily form negative ions due to their 
positively-charged head group despite the addition of 0.02% formic acid to 
the chloroform/methanol solvent, and so for these lipids, positively-charged 
ions were used for identification of the fatty acyl chain. 
 
It is generally acknowledged that the fatty acyl group at the sn-2 position 
gives a stronger signal than that at the sn-1 position, due to the fact that the R 
group at sn-2 is more easily ionized than that at sn-1 (Han & Gross, 2005; 
Pulfer & Murphy, 2003; Taguchi et al., 2005).  Therefore, if more than one R 
group is identified on an MS/MS scan, it can be deducted that the R group 
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with the highest signal is located at the sn-2 position. Figure 3.11 is a 
representative MS/MS scan of a phosphatidylserine species. This 
phosphatidylserine species has an m/z of 838 and can be identified as PS 
18:0/22:4 from the m/z of the fatty acyl fragments yielded upon MS/MS 
analysis and the respective signal strength of these two fatty acyl ions. 
 
Tables 3.1–3.4 show the confirmed identities (using MS/MS analysis) of the 
phospholipid species that had previously been putatively identified in our 
studies on naïve mouse cerebral cortex using the lipid analyser software. 
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Figure 3.11 Representative MS/MS scan of a phosphatidylserine species with m/z 838 identifies its fatty acyl chains as 18:0 and 
22:4. The positioning of these two R groups can be deduced by looking at the spectrum; in general the R group at sn-2 has a stronger 
signal than that at sn-1 due to the fact that cleavage of the sn-2 acyl bond is easier than the sn-1 acyl bond 
135 
 
Table 3.1 Phosphatidylcholine and sphingomyelin species identified during 
MS/MS fragmentation scans of murine cerebral cortex lipid extract 
 [ M+ H] 
+
 m/z Species 
Identity: using 
ESI-MS data and 
lipid analyser 
software 
Identity: using 
ESI-MS/MS data 
834 PC40:6 PC18:0/22:6  
832 PC40a:0  PC 18:1/ 22:6 PC 18:1/ 22:6 
806 PC38:6 PC16:0/22:6  
810 PC38:4 PC 18:0/20:4  
782 PC36:4 PC16:0/20:4  
814 PC 38:2 PC18:0/20:2  
786 PC36:2 PC18:0/18:2  
758 PC 34:2 PC16:0/18:2  
816 PC 38:1 PC 18:0/20:1  
788 PC 36:1 PC18:0/18:1  
760 PC 34:1 PC16:0/18:1 PC16:0/18:1 
746 PC34a:1 PC16:0a/18:1 PC16:0/16:1 
732 PC 32:1 PC 16:0/16:1  
734 PC 32:0 PC16:0/16:0 PC16:0/16:0 
720 PC32a:0 PC 16:0a/16:0  
706 PC 30:0 PC 14:0/16:0  
    
729 SM 36:2 SM 18:1/18:1  
813 SM 42:1 SM 18:1/24:0  
731 SM 36:1 SM 18:1/18:0  
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Table 3.2 Phosphatidylethanolamine species identified during fragmentation 
MS/MS scans of murine cerebral cortex lipid extract 
[ M+ H] 
+ 
m/z 
Species 
Identity: using 
ESI-MS data 
and lipid 
analyser 
software 
Identity: using 
ESI-MS/MS 
data 
[M– H]- m/z 
790 PE 40:7 PE18:1/22:6 PE18:1/22:6 788 
792 PE 40:6 PE18:0/22:6 PE18:0/22:6 790 
778 PE 40a:6 PE18:0a/22:6 PE18:0/22:4 776 
764 PE 38:6 PE16:0/22:6  PE16:0/22:6 762 
750 PE 38a:6 PE16:0a/22:6  748 
794 PE 40:5 PE18:0/22:5 PE18:0/22:5 792 
766 PE 38:5 PE18:1/20:4 
PE16:0/22:5 
PE18:1/20:4 
764 
752 PE 38a:5 PE18:1a/20:4  750 
796 PE 40:4 PE18:0/22:4 PE18:0/22:4 794 
768 PE 38:4 PE18:0/20:4 PE18:0/20:4 766 
740 PE 36:4 PE16:0/20:4  738 
840 PE44a:3   838 
812 PE42a:3   810 
798 PE 40:3 PE18:0/22:3 PE18:0/22:3 796 
770 PE 38:3 PE18:0/20:3 PE18:0/20:3 768 
742 PE 36:3 PE18:1/18:2  740 
814 PE42a:2   812 
786 PE 40a:2 PE18:0a/22:2  784 
772 PE 38:2 PE18:0/20:2  770 
744 PE 36:2 PE18:0/18:2 
PE16:0/20:2 
PE18:1/18:1 
742 
816 PE42a:1   814 
788 PE 40a:1 PE18:0a/22:1  786 
774 PE 38:1 PE18:0/20:1  772 
746 PE 36:1 PE18:0/18:1 PE18:0/18:1 744 
718 PE 34:1 PE16:0/18:1 PE16:0/18:1 716 
776 PE 38:0 PE18:0/20:0  774 
762 PE 38a:0 PE18:0a/20:0 PE16:1/22:6 760 
748 PE 36:0 PE 18:0/18:0  746 
720 PE 34:0 PE16:0/18:0 PE16:0/18:0 718 
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Table 3.3 Phosphatidylserine species identified during fragmentation MS/MS 
scans of murine cerebral cortex lipid extract 
[M – H] -
m/z 
Species 
Identity: using ESI-MS 
data and lipid analyser 
software 
Identity: from ESI-MS/MS 
data 
882  PS22:4/22:6  
878  PS22:6/22:6  
832 PS 40:7 PS18:1/22:6 PS18:1/22:6 
834 PS 40:6 PS18:0/22:6 PS18:0/22:6 
836 PS 40:5 PS18:0/22:5 PS18:0/22:5 
838 PS 40:4 PS18:0/22:4 PS18:0/22:4 
810 PS 38:4 PS18:0/20:4 PS18:0/20:4 
840 PS 40:3 PS18:0/22:3  
812 PS 38:3 PS18:0/20:3 
PS18:0/20:3 
PS18:1/20:2 
814 PS 38:2 PS18:0/20:2  
786 PS 36:2 PS18:0/18:2 PS18:1/18:1 
872 PS 42:1  PS18:0/24:1 
844 PS 40:1 PS18:0/22:1 PS18:0/22:1 
816 PS 38:1 PS18:0/20:1 PS18:0/20:1 
788 PS 36:1 PS18:0/18:1 PS18:0/18:1 
760 PS 34:1 PS16:0/18:1 PS16:0/18:1 
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Table 3.4 Phosphatidylinositol species identified during MS/MS fragmentation 
scans of murine cerebral cortex lipid extract 
[M – H] - 
m/z 
Species 
Identity: using ESI-MS 
data and lipid analyser 
software 
Identity: from ESI-MS/MS 
data 
909 PI 40:6 PI18:0/22:6 PI18:0/22:6 
881 PI 38:6 PI16:0/22:6 PI16:0/22:6 
911 PI 40:5 PI18:0/22:5 PI18:0/22:5 
883 PI 38:5 PI18:1/20:4 PI18:1/20:4 
885 PI 38:4 PI18:0/20:4 PI18:0/20:4 
857 PI 36:4 PI16:0/20:4 PI16:0/20:4 
859 PI 36:3 PI18:1/18:2 PI16:0/20:3 
861 PI 36:2 PI18:0/18:2 PI18:1/18:1 
863 PI 36:1 PI18:0/18:1 PI18:1/18:0 
835 PI 34:1 PI16:0/18:1 PI16:0/18:1 
837 PI 34:0 PI16:0/18:0 PI16:0/18:0 
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3.5. Investigation of changes in cerebral cortex phospholipids 
produced by ALA 3, 24, 72 and 168 hours after its 
administration 
 
The phospholipid profiles of mice given intravenous injections of ALA or 
vehicle (0.05% volume ethanol) 3 hours, 24 hours, 3 days (72 hours) and 1 
week (168 hours) prior to sample collection were analysed using strictly the 
same MS/MS procedure. A general scan of each species was used to gain an 
overall picture of the species present in each sample. Following general 
scanning of each sample, neutral loss scans for 87 (PS species) and 141 (PE 
species) and precursor ion scans for 184 (PS and SM species) and 241 (PI 
species) were carried out on each sample to detect individual classes of 
phospholipids. The following graphs (figures 3.12 – 3.15 a-d) compares the 
brain phospholipid profile of naïve mice (CTL) compared to mice treated with 
vehicle (VEH) or α-linolenic acid (ALA) at four separate timepoints (3, 24, 72 
and 168 hours after tail vein injection). The effect on each phospholipid class 
at each timepoint is shown in separate graphs. Statistically significant 
(P<0.05) changes were observed in three phospholipid species three hours 
after fatty acid treatment and in two phospholipid at 24 hours after fatty acid 
injection. Species affected at t=3 hours were a sphingomyelin with m/z 813 
and phosphatidylethanolamine species with m/z 742 and m/z 746 At 24 
hours, a phosphatidylethanolamine with m/z 786 and phosphatidylserine with 
m/z 812 were affected. None of the species affected at either of these 
timepoints contained fatty acyl groups that were based on fatty acid 
substrates known to participate in the production of bioactive lipid mediators, 
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suggesting that changes in brain glycerophospholipid composition do not play 
a major role in the development of neuroprotection following PUFA treatment 
in rodent models of ischaemia. 
 
In addition, the temporal effect of ALA treatment on the phospholipid 
composition of the cerebral cortex was assessed using statistical analysis 
software (results shown in Figures 3.16–3.19). No significant differences  
(P<0.05) were seen between the brain phospholipid composition of naïve 
mice and mice treated with α-linolenic acid at any of the four tested timepoints 
(t= 3h, 24h, 72h, 168h post-injection), agreeing with our theory that changes 
in brain glycerophospholipid composition can not explain the neuroprotective 
effects of PUFA treatment in rodent models of ischaemia.  
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Figure 3.12a Effect of ALA on phosphatidylcholine and sphingomyelin species 3h 
post- injection (n=8 for CTL, n=4 for ALA and VEH groups, error bars ± SD.)  
 
 
Figure 3.12b Effect of ALA on phosphatidylcholine and sphingomyelin species 24h 
post- injection (n=8 for CTL, n=4 for ALA and VEH groups, error bars ± SD)  
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Figure 3.12c Effect of ALA on phosphatidylcholine and sphingomyelin species 72h 
post- injection (n=8 for CTL, n=4 for ALA and VEH groups, error bars ± SD)  
 
Figure 3.12d Effect of ALA on phosphatidylcholine and sphingomyelin species 168h 
post- injection (n=8 for CTL, n=4 for ALA and VEH groups, error bars ± SD)  
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Figure 3.13a Effect of ALA on phosphatidylethanolamine species 3h post- injection 
(n=8 for CTL, n=4 for ALA and VEH groups, error bars ± SD)  
 
Figure 3.13b Effect of ALA on phosphatidylethanolamine species 24h post- injection 
(n=8 for CTL, n=4 for ALA and VEH groups, error bars ± SD)  
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Figure 3.13c Effect of ALA on phosphatidylethanolamine species 72h post- injection 
(n=8 for CTL, n=4 for ALA and VEH groups, error bars ± SD)  
 
 Figure 3.13d Effect of ALA on phosphatidylethanolamine species 168h post- 
injection (n=8 for CTL, n=4 for ALA and VEH groups, error bars ± SD)  
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Figure 3.14a Effect of ALA on phosphatidylinositol species 3h post- injection (n=8 for 
CTL, n=4 for ALA and VEH groups, error bars ± SD)  
 
Figure 3.14b Effect of ALA on phosphatidylinositol species 24h post- injection (n=8 
for CTL, n=4 for ALA and VEH groups, error bars ± SD)  
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Figure 3.14c Effect of ALA on phosphatidylinositol species 72h post- injection (n=8 
for CTL, n=4 for ALA and VEH groups, error bars ± SD)  
 
Figure 3.14d Effect of ALA on phosphatidylinositol species 168h post- injection (n=8 
for CTL, n=4 for ALA and VEH groups, error bars ± SD)   
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Figure 3.15a Effect of ALA on phosphatidylserine species 3h post- injection (n=8 for 
CTL, n=4 for ALA and VEH groups, error bars ± SD)  
 
Figure 3.15b Effect of ALA on phosphatidylserine species 24h post- injection (n=8 for 
CTL, n=4 for ALA and VEH groups, error bars ± SD)  
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Figure 3.15c Effect of ALA on phosphatidylserine species 72h post- injection (n=8 for 
CTL, n=4 for ALA and VEH groups, error bars ± SD)  
 
 
Figure 3.15d Effect of ALA on phosphatidylserine species 168h post- injection (n=8 
for CTL, n=4 for ALA and VEH groups, error bars ± SD)  
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Figure 3.16. Temporal effect of ALA treatment on choline phospholipid species in mouse cortex, error bars ± SD. 
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Figure 3.17 Temporal effect of ALA treatment on  phosphatidylethanolamine species in mouse cortex, error bars ± SD. 
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Figure 3.18 Temporal effect of ALA treatment on phosphatidylinositol species in mouse cortex, error bars ± SD. 
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Figure 3.19 Temporal effect of ALA treatment on phosphatidylserine species in mouse cortex, error bars ± SD. 
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4. Analysis of lipid mediators in mouse cerebral 
cortex and plasma  
 
4.1. Profile of prostanoids in mouse cerebral cortex and 
plasma 
 
4.1.1. Preparation of calibration curves 
 
Twenty seven prostanoids were combined into a cocktail of standards, which 
was diluted into a series of mixed standard solutions containing 200, 160, 
120, 80, 40 and 20ng/ml of each prostanoid. Calibration curves were 
prepared using the diluted standards. Table 4.1 shows the MRM transitions 
and approximate retention times of each of the compounds in the cocktail of 
standards. 
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Table 4.1 Prostanoid standards used for quantification analysis using 
multiple-reaction monitoring (MRM). Isobaric species can be separated on the 
basis of their different retention times in the reverse-phase HPLC column 
(Masoodi et al., 2006). 
Species 
Mol. wt. 
of  
[M-H]
-
 
Structure of species 
Transition 
m/z 
Approx. 
retention 
time 
(min) 
15-deoxy-
Δ12,14-
PGJ2 
315 
O
COOH
 
315>271 18.10 
PGB2 333 COOH
OH
O
 
333>175 9.98 
PGJ2  
 
O
COOH
OH
 
333>271 9.17 
Δ12-PGJ2 333 
O
COOH
OH
 
333>271 9.80 
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Species 
Mol. wt. 
of  
[M-H]
-
 
Structure of species 
Transition 
m/z 
Approx. 
retention 
time 
(min) 
Internal 
Standard 
(PGB2-
d4) 
337 COOH
OH
O
D
D
D
D
 
337>179 9.96 
8-iso-15-
keto 
PGE2 
349 COOH
O
HO
O
 
349>113 5.68 
PGE3 349 
COOH
OH
O
HO
 
349>269 3.85 
PGD3 349 O
COOH
OH
OH
 
349>269 4.09 
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Species 
Mol. wt. 
of  
[M-H]
-
 
Structure of species 
Transition 
m/z 
Approx. 
retention 
time 
(min) 
PGF3α 349 
OH
COOH
OH
HO
 
351>193 3.30 
PGE2 351 
COOH
OH
O
HO
 
351>271 4.47 
PGD2 351 O
COOH
OH
OH
 
351>271 5.18 
8-iso-15-
keto 
PGF2α 
351 
OH
COOH
HO
O
 
351>315 4.09 
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Species 
Mol. wt. 
of  
[M-H]
-
 
Structure of species 
Transition 
m/z 
Approx. 
retention 
time 
(min) 
8-iso-
PGE2 
351 COOH
OH
O
HO
 
351>315 4.47 
13,14-
dihydro-
15-keto 
PGE2 
351 COOH
O
HO
O
 
351>333 6.98 
13,14-
dihydro-
15-keto-
PGF2α 
353 
OH
COOH
HO
O
 
353>113 8.12 
8-iso-
PGF2α 
353 
OH
COOH
OH
HO
 
353>193 3.38 
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Species 
Mol. wt. 
of  
[M-H]
-
 
Structure of species 
Transition 
m/z 
Approx. 
retention 
time 
(min) 
PGF2α 353 
OH
COOH
OH
HO
 
353>193 3.77 
PGE1 353 
COOH
OH
O
HO
 
353>317 4.47 
PGD1 353 O
COOH
OH
OH
 
353>317 4.79 
13,14-
dihydro-
15-keto 
PGE1 
353 COOH
O
HO
O
 
353>335 7.61 
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Species 
Mol. wt. 
of  
[M-H]
-
 
Structure of species 
Transition 
m/z 
Approx. 
retention 
time 
(min) 
13,14-
dihydro-
15-keto 
PGF1α 
355 
OH
COOH
HO
O
 
355>193 6.67 
PGF1α 355 
OH
COOH
OH
HO
 
355>311 3.69 
13,14-
dihydro-
PGF2α 
355 
OH
COOH
OH
HO
 
355>311 4.79 
13,14-
dihydro-
PGE1 
355 COOH
OH
O
HO
 
355>337 5.41 
160 
 
Species 
Mol. wt. 
of  
[M-H]
-
 
Structure of species 
Transition 
m/z 
Approx. 
retention 
time 
(min) 
13,14-
dihydro-
PGF1α 
357 
OH
COOH
OH
HO
 
357>113 4.94 
TXB3 367 
COOH
OH
O
OH
HO
 
367>169 3.06 
6-keto 
PGF1α 
369 
OH
COOH
OH
HO
O
 
369>163 2.83 
TXB2 369 
COOH
OH
O
OH
HO
 
369>169 3.46 
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Each of these 22 MRM channels yielded a chromatogram, on which the 
compounds undergoing that specific  transition could be detected. Figure 4.1 
illustrates representative chromatograms generated from the transition 
351>271. This transition can detect two compounds with different column 
retention times: PGE2, which has a retention time of approximately 4.9 min, 
and PGD2, which has a slightly longer retention time of approximately 5.8 
min.  
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Figure 4.1 Analysis of mixed prostaglandin standards following the transition 
m/z 351 > 271. Both PGE2 (retention time ≈ 4.9 mins) and PGD2 (retention 
time ≈ 5.8 mins) can be simultaneously detected. Integration of the peaks 
obtained can be used to produce calibration lines for these two prostanoids. 
 
 
 
  
163 
 
4.1.2. Lipid mediator profiling in naïve mice 
 
Out of the twenty seven prostanoid species that could be detected by this 
ESI/LC-MS/MS assay, twenty five species were detected in samples of 
mouse cerebral cortex and eighteen were detected in samples of mouse 
plasma.  
 
The most prominent prostanoid species in the cerebral cortex of untreated 
mice, each accounting for more than 10% of total prostanoids were PGE2, 
PGD2, 6-keto-PGF2α, PGF2α and PGE1. The most prominent prostanoid 
species in the plasma of untreated mice, each accounting for more than 10% 
of total prostanoids, were 15-deoxy-Δ12,14-PGJ2, PGB2 and TXB2. The 
prostanoid species detected in untreated mouse cerebral cortex and plasma 
are listed in Tables 4.2 and 4.3. 
 
Table 4.2 Table showing % total of prostanoids in naive mouse cerebral 
cortex 
Prostanoid species 
% total prostanoids in naïve mouse cerebral cortex 
(n=6) 
 
MEAN ± SD 
PGD2 33.65 ± 29.33 
PGF2α 25.22 ± 25.09 
6-keto PGF2α 14.04 ± 13.20 
PGE1 12.32 ± 19.55 
PGE2 10.54 ± 14.06 
PGD1 2.00 ± 4.91 
TXB2 1.75 ± 4.28 
Δ12-PGJ2 1.19 ± 2.31 
PGB2 0.73 ± 1.78 
15-deoxy-Δ12,14-PGJ2 0.66 ± 1.06 
13,14-dihydro-PGF2α 0.21 ± 0.51 
13,14-dihydro-15-keto PGE2 0.08 ± 0.14 
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Table 4.3 Table showing % total of prostanoids in naive mouse plasma 
Prostanoid species 
% total prostanoids in naïve mouse plasma (n=6) 
MEAN ± SD 
15-deoxy-Δ12,14-PGJ2 
 
33.25 ±  
TXB2 
 
31.90 ±  
PGB2 
 
22.35 ±  
8-iso-PGF2 
a 
8.41 ±  
PGE2 
 
2.01 ±  
Δ12-PGJ2 
 
1.12 ±  
PGF2α 
 
0.96 ±  
 
Figure 4.2 shows representative chromatograms acquired from analysis of 
naïve mouse cerebral cortex tissue. The transitions shown include the m/z 
351>271 transition, which is used to detect both PGD2 and PGE2, and the m/z 
351>315 transition, which detects 6-keto PGF2α. These three compounds are 
amongst the most abundant prostanoid species detected in our study on 
naïve mouse cerebral cortex. 
 
 
Figure 4.3 shows representative chromatograms acquired from analysis of 
naïve mouse plasma. The transitions shown include the m/z 369>269, which 
is used to detect TXB2. This compound is amongst the most abundant 
prostanoid species detected in our study on naïve mouse plasma. 
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Figure 4.2 Representative chromatograms acquired from analysis of cerebral 
cortex tissue taken from a naïve mouse. The transition m/z 351 > 271 shows 
two well-separated peaks, which are indicative of PGE2 (retention time 4.44 
min) and PGD2 (retention time 5.09 min). The transition m/z 351> 315 shows 
a distinctive peak for 6-keto PGF2α with a retention time of 5.09min. 
 
PGD2
PGE2
6-keto-PGF2alpha
 
 
Figure 4.3 Representative chromatogram acquired from analysis of plasma 
collected from a naïve mouse. The transition m/z 369>169 shows a defined 
peak at 3.70 min, which corresponds to TXB2. 
TXB2
  
166 
 
4.1.3. Effect of ALA treatment 
 
 
Mice which underwent different treatments had some similarities in the 
identities of the most abundant prostanoid species. For example, PGE2 and 
PGD2 accounted for more than 10% of total prostanoid species in the cerebral 
cortex of mice in the VEH3, VEH24 and ALA3 treatment groups. 6-iso-15-keto 
PGF2α was prominent in both the VEH3 and VEH168 groups and 8-iso-PGE3 
in the VEH3, ALA3 and ALA24 groups. Other prominent prostanoid species 
were PGB2 in the VEH72 and ALA168 groups, PGF2α in the VEH72 and 
VEH168 groups, 15-deoxy-Δ12,14-PGJ2 in the ALA72 and ALA168 groups, 
and TXB2 in the ALA3, ALA24 and ALA72 groups.  
 
Details of the abundance of prostanoid species detected in samples of mouse 
cerebral cortex and mouse plasma collected at various timepoints from 
animals divided into different treatment groups are shown in Tables 4.4 and 
4.5 respectively. 
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Table 4.4 Table showing the % abundance of prostanoids detected in samples of mouse cerebral cortex collected at various 
timepoints from animals divided into different treatment groups (CTL= naïve/untreated mice, VEH3= intravenous vehicle at 3h 
post-injection, ALA3= intravenous α-linolenic acid at 3h post-injection, VEH24= intravenous vehicle at 24h post-injection, 
ALA24= intravenous α-linolenic acid at 24h post-injection VEH72= intravenous vehicle at 72h post-injection, ALA72= intravenous 
α-linolenic acid at 72h post-injection, VEH168= intravenous vehicle at 168h post-injection, ALA168= intravenous α-linolenic acid 
at 168h post-injection, N/D= not detected) 
  
CTL 
n=6 
VEH3 
n=6 
ALA3 
n=7 
VEH24 
n=6 
ALA24 
n=4 
VEH72  
n=6 
ALA72 
n=4 
VEH168 
n=6 
ALA168 
n=6 
  MEAN SD MEAN SD MEAN SD MEAN SD MEAN SD MEAN SD MEAN SD MEAN SD MEAN SD 
PGD2 33.65 29.33 12.28 6.23 26.26 15.17 76.32 39.70 51.61 5.19 N/D N/D N/D N/D 12.04 8.76 N/D N/D 
PGF2α 25.22 25.09 3.83 9.39 5.80 13.62 5.59 10.40 N/D N/D 22.90 32.61 N/D N/D 17.31 8.53 N/D N/D 
6-keto PGF2α 14.04 13.20 11.71 2.05 2.58 2.71 N/D N/D N/D N/D 3.58 5.59 N/D N/D 24.09 24.53 N/D N/D 
PGE1 12.32 19.55 17.25 9.48 N/D N/D N/D N/D N/D N/D N/D N/D N/D N/D N/D N/D N/D N/D 
PGE2 10.54 14.06 14.18 5.68 17.15 18.86 2.12 5.19 N/D N/D N/D N/D N/D N/D N/D N/D N/D N/D 
PGD1 2.00 4.91 4.84 5.97 N/D N/D N/D N/D N/D N/D N/D N/D N/D N/D 6.89 3.43 N/D N/D 
TXB2 1.75 4.28 3.99 2.62 11.80 4.97 N/D N/D 10.80 4.37 N/D N/D 48.27 6.74 10.22 8.66 N/D N/D 
Δ12-PGJ2 1.19 2.31 N/D N/D 0.42 1.12 N/D N/D N/D N/D 5.46 4.27 N/D N/D N/D N/D 4.07 3.16 
PGB2 0.73 1.78 N/D N/D N/D N/D N/D N/D N/D N/D 94.44 59.53 N/D N/D N/D N/D 60.55 42.41 
15-deoxy-Δ12,14-PGJ2 0.66 1.06 N/D N/D 3.93 6.06 N/D N/D 2.89 5.78 3.18 4.11 45.81 7.65 N/D N/D 29.00 37.42 
13,14-dihydro-PGF2α 0.21 0.51 N/D N/D N/D N/D N/D N/D N/D N/D N/D N/D N/D N/D N/D N/D N/D N/D 
13,14-dihydro-15-keto PGE2 0.08 0.14 N/D N/D N/D N/D N/D N/D N/D N/D N/D N/D N/D N/D 10.60 5.80 N/D N/D 
8-iso-PGE N/D N/D 13.15 3.33 22.81 10.50 1.43 3.49 34.65 4.64 N/D N/D N/D N/D 10.71 5.66 N/D N/D 
13,14-dihydro-15-keto PGE1 N/D N/D 5.75 3.10 N/D N/D N/D N/D N/D N/D N/D N/D N/D N/D N/D N/D N/D N/D 
8-iso-15-keto PGE2 N/D N/D 3.11 2.65 N/D N/D N/D N/D N/D N/D N/D N/D N/D N/D 1.68 2.62 6.39 15.64 
PGF1α N/D N/D 2.36 3.65 N/D N/D N/D N/D N/D N/D N/D N/D N/D N/D 1.53 3.76 N/D N/D 
TXB3 N/D N/D 2.26 3.50 2.75 4.74 N/D N/D N/D N/D N/D N/D N/D N/D 1.64 4.02 N/D N/D 
6-keto PGF1α N/D N/D 1.98 3.23 N/D N/D N/D N/D N/D N/D N/D N/D N/D N/D 0.94 2.30 N/D N/D 
PGD3 N/D N/D 1.65 2.58 N/D N/D N/D N/D N/D N/D N/D N/D N/D N/D N/D N/D N/D N/D 
PGE3 N/D N/D 0.98 2.41 N/D N/D N/D N/D N/D N/D 6.80 11.63 N/D N/D N/D N/D N/D N/D 
13,14-dihydro-15-keto  
PGF2α N/D N/D 0.68 1.66 1.26 3.35 N/D N/D N/D N/D N/D N/D N/D N/D 1.81 2.82 N/D N/D 
13,14-dihydro-15-keto 
PGF1α N/D N/D N/D N/D 0.99 2.61 N/D N/D N/D N/D N/D N/D N/D N/D N/D N/D N/D N/D 
8-iso-PGF2α N/D N/D N/D N/D 0.91 2.40 N/D N/D N/D N/D N/D N/D 5.91 10.24 N/D N/D N/D N/D 
PGF3α N/D N/D N/D N/D 0.11 0.29 N/D N/D N/D N/D N/D N/D N/D N/D N/D N/D N/D N/D 
* In the presence of PGE2, the estimation of 8-iso-PGE2 is not reliable 
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Table 4.5 Table showing the % abundance of prostanoids detected in samples of mouse plasma collected at various timepoints 
from animals divided into different treatment groups (CTL= naïve/untreated mice, VEH3= intravenous vehicle at 3h post-
injection, ALA3= intravenous α-linolenic acid at 3h post-injection, VEH24= intravenous vehicle at 24h post-injection, ALA24= 
intravenous α-linolenic acid at 24h post-injection VEH72= intravenous vehicle at 72h post-injection, ALA72= intravenous α-
linolenic acid at 72h post-injection, VEH168= intravenous vehicle at 168h post-injection, ALA168= intravenous α-linolenic acid at 
168h post-injection, N/D= not detected). 
Prostanoid 
species 
CTL 
n=7 
VEH3 
n=6 
ALA3 
n=7 
VEH24 
n=6 
ALA24 
n=6 
VEH72 
n=6 
ALA72 
n=6 
VEH168 
n=6 
ALA168 
n=6 
MEAN SD MEAN SD MEAN SD MEAN SD MEAN SD MEAN SD MEAN SD MEAN SD MEAN SD 
15-deoxy-
Δ12,14-PGJ2 41.46 27.57 16.52 20.54 35.81 19.23 18.44 6.58 11.04 14.40 18.39 7.55 N/D N/D 30.54 30.79 N/D N/D 
PGB2 20.48 29.80 49.75 35.46 18.73 30.75 63.69 11.61 35.41 42.86 61.97 16.72 7.89 12.56 N/D N/D N/D N/D 
Δ12-PGJ2 0.96 2.54 13.13 23.85 1.49 2.93 8.81 2.60 2.93 3.72 9.14 6.81 N/D N/D N/D N/D 2.05 5.02 
8-iso-15-keto 
PGE2 N/D N/D 1.66 4.07 3.99 7.04 N/D N/D N/D N/D N/D N/D N/D N/D N/D N/D N/D N/D 
PGE3 N/D N/D 1.40 3.43 N/D N/D N/D N/D N/D N/D N/D N/D N/D N/D N/D N/D N/D N/D 
PGF3α N/D N/D N/D N/D N/D N/D N/D N/D 28.18 48.14 N/D N/D N/D N/D N/D N/D N/D N/D 
PGE2 N/D N/D N/D N/D 
  
N/D N/D 9.12 22.02 N/D N/D 57.16 31.02 N/D N/D 64.11 28.10 
PGD2 N/D N/D N/D N/D 0.46 1.23 N/D N/D 10.05 20.10 
  
5.04 9.17 14.50 29.28 7.13 11.10 
6-keto PGF2α N/D N/D N/D N/D 0.74 1.95 N/D N/D 10.13 20.26 1.74 4.27 N/D N/D N/D N/D N/D N/D 
8-iso-PGE2    N/D N/D N/D N/D 4.61 12.19 N/D N/D 0.69 1.38 5.78 14.15 N/D N/D N/D N/D N/D N/D 
13,14-dihydro-
15-keto PGE2 N/D N/D N/D N/D N/D N/D N/D N/D N/D N/D N/D N/D 7.53 15.15 N/D N/D 2.88 7.05 
8-iso-PGF2α 7.21 19.08 N/D N/D N/D N/D N/D N/D 0.20 0.52 N/D N/D 11.68 10.25 N/D N/D 7.34 6.36 
PGF2α 0.82 2.17 N/D N/D 15.48 26.13 9.07 15.46 1.65 4.37 0.76 1.87 1.15 2.83 13.20 32.33 N/D N/D 
PGE1 N/D N/D N/D N/D N/D N/D N/D N/D N/D N/D N/D N/D 0.74 1.81 N/D N/D N/D N/D 
PGD1 N/D N/D N/D N/D N/D N/D N/D N/D N/D N/D N/D N/D 1.78 4.36 4.47 10.95 1.67 4.10 
PGF1α N/D N/D 0.87 2.01 N/D N/D N/D N/D 0.19 0.51 N/D N/D 7.04 8.00 N/D N/D 4.66 3.88 
TXB2 27.34 38.61 N/D N/D 18.70 20.08 N/D N/D N/D N/D 2.21 5.42 N/D N/D 37.30 30.99 2.38 5.84 
  * In the presence of PGE2, the estimation of 8-iso-PGE2 is not reliable
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Statistical analysis of the percentage abundance of prostanoids between the 
different treatment groups at each timepoint was carried out using one-way 
ANOVA tests with post-hoc Dunnett‟s t tests. A P value of <0.05 was 
considered statistically significant, and a P value of <0.01 highly significant.  
 
Table 4.6 shows significant differences in the percentage abundance of 
prostanoids in cerebral cortex tissue samples of mice undergoing vehicle or 
ALA injection compared to naïve (untreated) mice in prostanoid species. 
Significant differences in the abundance of several prostanoids were seen at 
one or two timepoints but only one prostanoid species significantly increased 
in the cerebral cortex of mice at three timepoints after ALA injection. The 
effects of ALA at 3h, 24h and 72h post-injection on the cerebral cortex 
abundance of TXB2 are shown in figure 4.4. 
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Table 4.6 Statistical analysis of prostanoid abundance in cerebral cortex tissue of mice undergoing different treatments 
showed significant differences in the % abundance of several prostanoid species after VEH or ALA injection. 
Time after 
injection 
(h) 
VEH vs CTL 
(*P<0.05, ** P<0.01) 
Both VEH and ALA vs CTL 
(*P<0.05, ** P<0.01) 
 
ALA vs VEH 
(*P<0.05, ** P<0.01) 
 
3  CTL VEH   VEH ALA 
8-iso-15-
keto PGE 2  
NOT 
DETECTED 
3.11 ± 2.65* 
TXB2 3.99 ± 2.62 
11.80 ± 
4.97** 
13,14-
dihydro-15-
keto PGF2α 
NOT 
DETECTED 
0.66 ± 1.66* 
  
PGF2α 25.22 ± 
25.09 
3.83 ± 9.39* 
 
 
24   CTL VEH ALA  VEH ALA 
6-keto 
PGF2α 
14.04±13.20 11.71±2.05* 2.58±2.71* 
TXB2 
NOT 
DETECTED 
10.80 ± 
4.37** PGD 2 33.65 
±29.33 
76.32 ± 
39.70 * 
51.61±5.19* 
72  CTL VEH   VEH ALA 
PGB 2 
0.73 ± 1.73 
NOT 
DETECTED* 
 
15-deoxy-
Δ12,14-
PGJ2 
NOT 
DETECTED 
3.83 ± 
6.06* 
TXB2 NOT 
DETECTED 
48.27 ± 
6.74** 
168  CTL VEH  CTL VEH ALA  
13,14-
dihydro-15-
keto PGE2 
0.08 ± 0.14 
10.60 ± 
5.80* 
PGF 2 α 
25.22 ± 
25.09 
3.83 ± 9.39* 
NOT 
DETECTED* 
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Figure 4.4 Mice injected with α-linolenic acid (ALA) showed a significant 
difference in TXB2 abundance in cerebral cortex tissue samples at 3h, 24h 
and 72h post-injection compared to vehicle- injected (VEH) or naïve (CTL) 
mice.  
 
 
 
** P< 0.01 one-way ANOVA with post-hoc Dunnett’s t test 
 
 
Table 4.7 shows significant differences in the percentage abundance of 
prostanoids in plasma samples of mice undergoing vehicle or ALA injection 
compared to naïve (untreated) mice in prostanoid species. There were fewer 
species displaying significant differences in their abundance between naïve 
and treated mice, with only three species showing significant difference at 
72h post-ALA injection. These species were 15-deoxy-Δ12,14-PGJ2, PGE2 
and PGF1α. Of these species, only one showed significant differences at more 
than one timepoint post-ALA injection. 
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Table 4.7. Statistical analysis of prostanoid abundance in plasma of mice undergoing different treatments showed 
significant differences in the % abundance of three prostanoid species after VEH or ALA injection. 
 
Time after 
injection (h) 
VEH vs CTL  
(*P<0.05, ** P<0.01)  
Both VEH and ALA vs CTL 
(*P<0.05, ** P<0.01)  
ALA vs VEH (*P<0.05, ** P<0.01) 
3    
24  CTL VEH   
15-deoxy-
Δ12,14-PGJ2 
41.46 ± 
27.57 
16.52 ± 
20.54* 
72    VEH ALA 
15-deoxy-
Δ12,14-PGJ2 
18.39 ± 7.55 NOT 
DETECTED* 
PGE2 NOT 
DETECTED 
57.16 ± 
31.02* 
PGF1α NOT 
DETECTED 
7.04 ± 8.00* 
168    VEH ALA 
15-deoxy-
Δ12,14-PGJ2 
16.52 ± 
20.54 
NOT 
DETECTED* 
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4.2. Hydroxy fatty acids profiles in mouse cerebral 
cortex and plasma 
 
 
4.2.1. Preparation of calibration curves 
Twenty two standards were combined into a cocktail of hydroxy fatty acids, 
which was diluted into a series of standard solutions containing 160, 120, 80 
and 40 pg/µl. Calibration curves were prepared using diluted standards. Table 
4.8 records the transitions and approximate retention times of each of the 
compounds in the cocktail of standards. 
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Table 4.8 Hydroxy fatty acid standards used for quantification analysis using 
multiple-reaction monitoring (MRM). Isobaric species can be separated on the 
basis of their different retention times in the reverse-phase HPLC column 
(Masoodi et al., 2008). 
Species 
Mol. wt. 
of  
[M-H]
-
 
Structure of species 
Transition 
m/z 
Approx. 
retention 
time 
(min) 
9-HODE 295 
COOH
HO  
295>171 16.99 
13-HODE 295 
COOH
OH  
295>195 16.91 
5-HEPE 317 
COOH
OH
 
317>115 16.58 
18-HEPE 317 
COOH
OH
 
317>133 12.56 
9-HEPE 317 
COOH
OH
 
317>149 15.35 
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Species 
Mol. wt. 
of  
[M-H]
-
 
Structure of species 
Transition 
m/z 
Approx. 
retention 
time 
(min) 
15-HEPE 317 
COOH
OH
 
317>175 13.54 
12-HEPE 317 
COOH
OH
 
317>179 14.61 
5-HETE 319 
COOH
OH
 
319>115 24.94 
9-HETE 319 
COOH
OH
 
319>123 23.06 
8-HETE 319 
COOH
OH
 
319>155 21.42 
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Species 
Mol. wt. 
of  
[M-H]
-
 
Structure of species 
Transition 
m/z 
Approx. 
retention 
time 
(min) 
11-HETE 319 
COOH
OH
 
319>167 19.94 
15-HETE 319 
COOH
OH
 
319>175 18.55 
12-HETE 319 
COOH
OH
 
319>179 21.25 
12-HETE-
d8 
328 
COOH
OH
D
D
D
D
D
D
D
D
 
328>185 20.51 
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Species 
Mol. wt. 
of  
[M-H]
-
 
Structure of species 
Transition 
m/z 
Approx. 
retention 
time 
(min) 
LTB4 335 
COOH
OH
OH
 
335>195 7.80 
17S-
HDHA 
343 
COOH
OH  
343>281 19.61 
RvE1 349 
COOH
HO
OH
HO
 
349>195 2.57 
PD1 349 
COOH
HO
HO
 
359>206 6.90 
RvD1 375 
COOH
HO
OH
OH
 
375>141 3.62 
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Each MRM channel yielded a chromatogram, on which the compounds 
undergoing that specific transition could be detected. Figure 4.5 illustrates a 
representative chromatogram of the transition m/z 335> 195 for each of the 
diluted standard solutions. The same transition was also used in biological 
samples collected from mice in different treatment groups (naïve (CTL), and 
injected with α-linolenic acid (ALA) or vehicle (VEH) at various timepoints).  
 
Figure 4.5 Representative chromatograms of lipid mediator standards for 
transition m/z 335>195. Leukotriene B4 (LTB4) has a retention time of approx 
7min. 
 
 
LTB4 
LTB4 
LTB4 
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Figures 4.6 shows representative chromatograms of the transition m/z 
335>195 in cerebral cortex tissue and plasma respectively. In comparison to 
the standard solutions, there is a high level of background noise and there 
are no clearly defined peaks at approximately 7min, indicating that the 
compound was not present. 
 
Figure 4.6 Representative chromatogram of transition m/z 335>195 for 
mouse cerebral cortex (upper) and plasma (lower) samples. Note the 
absence of clearly defined peaks, indicating no compound was present. 
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5. Discussion 
 
5.1. Methodology considerations 
 
5.1.1. Importance of tissue sampling, storage and processing 
methods for the validity of lipidomic data 
 
The methods used for tissue sampling, sample storage and sample 
processing are important, and must be considered carefully in order to avoid 
artefacts, and to ensure that the lipidomic profile generated is an accurate 
representation of that in the living brain. Rapid post-mortem changes in brain 
lipids can occur, with changes observed as shortly as 90 seconds after death 
(Lee & Hajra, 1991)  
 
Hydrolysis of phospholipids decreases their concentration as they are 
converted to lysophospholipids and free fatty acids (FFA), The hydrolysis of 
phospholipids, whteher it is mediated by calcium–dependent phospholipases, 
UV irradiation, heat or plasticizers, leads to increased levels of free fatty acids 
(FFA), which serve as a substrate pool for bioactive lipid mediators, and 
lysophospholipids (Lee & Hajra, 1991). Tissue trauma can lead to the release 
of polyunsaturated fatty acids from the sn-2 position of phospholipids, 
providing another potential source of lipid mediators (Lee & Hajra ,1991). A 
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rapid killing method was chosen to minimize the risk of tissue trauma, and the 
tissue was frozen within seconds of death to avoid phospholipid hydrolysis by 
calcium–activated phospholipases.  
 
It has also been proposed that the metabolsm of free fatty acids released 
upon post-mortem ischaemia could lead to artificially elevated concentrations 
of eicosanoids, isoprostanes and docosanoids in samples of brain tissue 
unless tissue enzymes were inactivated, for example, by use of microwave 
irradiation (Farias et al, 2008). It has been reported that even a 1-minute 
post-mortem incubation of mouse brain could result in significant production 
of artifact PGE, and PGD2 (Golovko & Murphy, 2008). Previous lipidomic 
studies by our group used a different sample collection method, where an 
anaesthetized animal was decapitated and the brain dissected from an 
unfrozen skull kept on ice. However, since this sample collection method may 
not successfully inactivate brain enzymes, it can be asked whether all the 
prostaglandins detected in these brain samples were formed before death, or 
were they caused by post-mortem oxidation of free fatty acids released during 
brain ischaemia. Since the use of microwave irradiation to kill the mice could 
not be considered in this study for ethical and practical reasons, our method 
of brain tissue sample collection and dissection by rapidly freezing the 
cerebral cortex and keeping it frozen throughout the dissection process was a 
feasible alternative method of inactivating brain enzymes. 
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The process of dissecting a frozen brain is time-consuming, requiring 
approximately 20 minutes for dissection of the cortical grey matter from the 
whole head of the mouse. Extensive care was taken to ensure that the mouse 
brains were kept frozen during brain dissection, in order to minimize the risk 
of phospholipid degradation and lipid mediator oxygenation. Once dissected, 
samples of mouse cerebral cortex were stored at –80°C inside sealed 
cryogenic vials that had been pre-cooled with liquid nitrogen. These storage 
conditions have previously been used by our group to store samples of rodent 
brain and plasma for up to three years, with good recovery of phospholipids, 
prostaglandins and hydroxy fatty acids (Masoodi & Nicolaou, 2006; Little et 
al., 2007; Masoodi et al., 2008). 
 
Successful extraction of phospholipids from tissue samples requires both (i) 
the removal of phospholipids from the tissue pellet into the organic solvent 
phase, and (ii) the complete removal of the aqueous phase, which contains 
proteins and water-soluble metabolites. The incomplete extraction of lipids 
from the biological sample into the organic phase would lead to low ion 
counts, whilst the presence of proteins and water-soluble proteins in the 
extracted sample would lead to a low signal-to-noise ratio and the possibility 
of broad and non-specific peaks in the spectrum. Table 5.1 illustrates the 
effects of phospholipid extraction quality on MS/MS data quality. 
 
  
183 
 
Table 5.1 The quality of MS/MS data is highly-dependent on the phospholipid 
extraction process, which can be verified by inspecting specific criteria of the 
resulting spectra 
Good quality extraction Bad quality extraction 
High signal-to-noise ratio Low signal-to-noise ratio 
Spectrum contains narrow and well- 
defined peaks  
Spectrum contains broad peaks 
High ion count (> 1 x 107 for general 
scans, >1 x 104 for fragmentation scans, 
depending on species)  
Low ion count (< 1 x 106 for general 
scans, >1 x 103 for fragmentation 
scans, depending on species) 
 
 
Figure 5.1 Representative diagrams of a high-quality spectrum (above) and a 
poor-quality spectrum (below). A high signal-to-noise ratio and a good ion 
count is indicative of successful phospholipid extraction, whilst an 
unsuccessful extraction will show a low signal-to-noise ratio, undefined peaks 
and a low ion count. 
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The solid phase extraction of lipid mediators is performed using reversed 
phase SPE cartridges, and is dependent upon hydrophobic interactions 
between the silica beads packed inside the cartridge and the compounds to 
be extracted. The successful extraction of eicosanoids is dependent on 
adequate conditioning or priming of the SPE cartridge, appropriate pH 
adjustment of the sample to be analysed, correct washing of the packing and 
the elution of the compounds of interest. The total ion count for each sample 
can be used to deduce whether extraction of lipid mediators from the raw 
samples was successfully carried out. A low ion count indicates inadequate or 
unsuccessful extraction of lipid mediators, which could be explained by a 
number of reasons. For example, insufficient or inadequate priming of the 
SPE cartridges means that the silica-coated beads in the cartridge are not 
thoroughly wetted prior to addition of the sample. As a result, the lipid 
mediators might not be able to interact with the silica in the cartridge, and 
would be expelled from the cartridge before the addition of the elution solvent. 
Similarly, inaccurate pH adjustment of the biological sample prior to SPE 
could damage the cartridges by stripping away the silica on the surface of the 
beads, or reduce the binding of lipid mediators to the SPE cartridge. 
Eicosanoids are protonated and soluble in water at a low pH, so careful pH 
adjustment to pH 3.5 is crucial to avoid flushing out the eicosanoids from the 
SPE cartridge when rinsing with water. Finally, slow running of each solvent 
through the cartridge is crucial for successful extraction of eicosanoids. Each 
solvent should also be run very slowly (ideally drip-wise) through the SPE 
cartridges. Running solvents through cartridges at too rapid a pace runs a risk 
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that lipid mediators might be forcibly flushed out of the cartridge during the 
washing process. 
 
The methods used for the extraction purification, separation and detection of 
prostaglandins and other lipid mediators in this study were based on 
extensive previous work carried out by other members of our group (Masoodi 
& Nicolaou, 2006;; Masoodi et al., 2008; Nicolaou et al., 2009). Similar 
methods have also been used by other research groups, with successful 
extraction of lipid mediators (Marchellesi et al., 2003; Farias et al., 2008). 
However, previous studies carried out by our group used a different sample 
collection method, which may have influenced the lipid mediator profile 
obtained because of post-mortem metabolic changes.  
 
5.1.2. Evidence of quality and validity for the lipidomic data 
obtained in this study 
 
Phospholipid study 
 
The spectra obtained from general scans of the samples showed 
mass/charge (m/z) values that corresponded to the lipid species in the 
standards, which had been stored at –20 °C in glass vials, sealed with 
parafilm and kept in a dark environment. There was also only a low 
percentage abundance of lysophospholipids detected in all samples, 
indicating that the extent of phospholipid degradation had also been 
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minimized during sample collection and storage (Christie, 2003). Previous 
studies on brain phospholipids produced similar data on the number and m/z 
values of phospholipid species detected using MS in samples of rodent brains 
(Bang et al. 2007; Little et al. 2007; Hicks et al. 2006), suggesting that the 
sample collection, storage and extraction methods used in this study did not 
result in degradation of phospholipids before analysis.  
 
Spectra obtained from general scans and from the fragmentation spectra for 
phosphatidylcholine, sphingomyelin, phosphatidylinositol, phosphatidylserine, 
and phosphatidylethanolamine species all had a satisfactorily high ion count, 
indicating that phospholipid extraction was successfully carried out from the 
cerebral cortex tissue samples. The ion counts for phosphatidylinositol 
species tended to be rather lower than those for other phospholipid classes 
but this trend was observed for all samples, and the ion count for 
phosphatidylinositol standards were also lower than for other phospholipid 
classes. Since the phospholipid standards had not been exposed to UV 
radiation or to plasticizers during their storage, they would not be expected to 
show oxidative degradation. It can therefore be deduced that the lower ion 
count for phosphatidylinositol species was not caused by degradation of the 
sample or by inadequate sample extraction. Possible explanations for the 
lower ion counts observed for phosphatidylinositol species are that there may 
be a lower abundance of phosphatidylinositol lipids in the biological samples, 
or that these lipids are not as easy to ionize as the other phospholipid 
classes, resulting in a smaller signal under similar ionization conditions. This 
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is confirmed by literature (Wenk et al., 2003), with phosphatidylinositol 
species being considered minor phospholipids in brain tissue, where the 
majority of phospholipids comprise of phosphatidylethanolamines and 
phosphatidylserines (Christie, 2008; Vance & Vance, 2008). The lack of a 
highly polarized centre in the structure of inositol (in comparison to the acidic 
properties of serine, and the basic properties of choline, sphingosine and 
ethanolamine) could also account for the lower ion counts of 
phosphatidylinositols compared to the other phospholipid classes across all 
samples, despite optimization of the mass spectrometry conditions for each 
phospholipid class. 
 
Initial identification of the fatty acyl chains of phospholipids was based on the 
development of lipid analyzer software using samples of whole rat brain 
(Little, 2006; Little et al., 2007). Scans were carried out to detect phospholipid 
species in each class, and data from the fragmentation spectra of each 
detected species was used to calculate the most likely combination of fatty 
acyl chains for a phospholipid species with a certain m/z value. However, 
there is a possibility that there are inter-species differences in brain 
phospholipid composition, so in order to definitively identify the fatty acyl 
chains of each phospholipid species in the mouse brain, it is necessary to 
fragment each detected species in each phospholipid class using tandem 
mass spectrometry. The second part of this study used MS/MS to fragment 
each phospholipid species which had a percentage abundance of above 1% 
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in a fragmentation scan, in order to definitively identify the most abundant 
phospholipid species.  
 
The number of phospholipid species identified using MS/MS in this study 
differed considerably from earlier studies (Bang et al. 2007; Little et al. 2007; 
Hicks et al. 2006), although the number of species identified using MS 
general, precursor/fragment ion and neutral loss MS scans which were 
specific for different phospholipid classes (i.e. parent ion scan of m/z 184 for 
phosphatidyllcholines and sphingomyelins, neutral loss scan of m/z 141 for 
phosphatidylethanolamines, parent ion scan of m/z 241 for 
phosphatidylinositol lipids and neutral loss scan of 87 for phosphatidylserines) 
were comparable in number to a previous study by our group on whole rat 
brain (Little, 2006). Of all studied phospholipid classes, this is most notable 
for choline phospholipid species, where only four choline lipid species were 
successfully identified using MS/MS in this study, compared to over a dozen 
in earlier work using similar equipment and experimental methods (Little et 
al., 2007). This is in stark contrast to the part of this study that used MS and 
lipid analyser software to identify phospholipids, where sixteen 
phosphatidylcholine and three sphingomyelin species were identified in 
mouse cerebral cortex (described in further detail in Chapter 3.3.1).  
 
The fact that a similar number of choline lipids were identified in the MS part 
of this study as in previous work suggests that the reason for the discrepancy 
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in choline lipids identifiable using MS/MS was not due to a shortage of 
phospholipids in the extracted biological samples. Also, the method of sample 
collection in this study was developed in order to ensure that the hydrolysis of 
phospholipids caused by activation of PLA2 during post-mortem brain 
ischaemia was minimal. The low level of lysophospholipids observed during 
MS analysis of all phospholipid classes confirms that this was the case, and 
so we can rule out the possibility that incorrect sample collection, processing 
and extraction is the reason behind the low number of choline phospholipids 
identified using MS/MS in this study.  
 
However, there is a possibility that degradation of the extracted samples 
occurred after initial MS analysis and prior to MS/MS analysis. The extracted 
samples were stored at -20°C for some months between initial MS analysis 
and the MS/MS study, but the vials in which they were stored were sealed 
with parafilm and the extraction solvent also had added anti-oxidant (0.01% 
w/v BHT) in order to prevent oxidation or hydrolysis of sample lipids. 
Degradation of the extracted samples in between MS and MS/MS analysis is 
an unlikely explanation for the lesser number of choline phospholipids 
identified in this study using MS/MS, since the number of species identified 
using MS/MS in other phospholipid classes was comparable in this study to 
other work (see Section 5.2.1. Tables 5.2a-d for details).  
 
A more likely cause of the lack of identifiable choline phospholipids using 
MS/MS is that the experimental parameters had not been optimized to 
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generate fatty acyl anions from these positively-charged phospholipids. 
Higher collision energy was selected for MS/MS analysis in other lipidomic 
studies on phospholipids, with collision energies of >40eV being common 
(Bang et al., 2007; Hicks et al., 2006; Brügger et al., 2006). An attempt was 
made to facilitate the production of fatty acyl anions by the addition of formic 
acid to the sample dissolution solvent, and also increasing the collision 
energy from an initial 25eV to 30eV. The purpose of this work was to confirm 
the identity of a molecular ion with a certain m/z by fragmenting it and 
studying the fatty acyl ions liberated from the molecular ion. In order to ensure 
that the fatty acyl ions were indeed produced from the correct molecular ion 
rather than from a higher m/z parent ion which had partially degraded to form 
an intermediate ion with the m/z of interest, the collision energy was set as to 
allow the molecular ion to still be present. It was considered that further 
increasing the collision energy would result in excessive fragmentation of the 
molecular ion, which may have increased the amount of information on the 
side chain structures of the lipid species by producing fatty acyl ions, but this 
would have been at the expense of information on the molecular ion‟s m/z 
value. Despite an attempt to further optimize the production using formic acid 
to promote the production of [M+CH3COO]
- adduct anions, only limited 
success was achieved on identifying choline phospholipids using MS/MS in 
this study. 
 
In contrast, the number of phosphatidylethanolamine species detected using 
MS/MS in the ES- mode was comparable to that observed in previous studies 
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using MALDI tandem mass spectrometry, nanoflow LC-MS/MS and ESI-
MS/MS (Bang et al. 2007; Little et al. 2007; Hicks et al. 2006), suggesting that 
the analytical techniques used in this study were sensitive enough to enable 
detection and identification of phosphatidylethanolamine, phosphatidylinositol 
and phosphatidylserine species in mouse cerebral cortex samples. 
 
It has been previously noted that differences exist in the phospholipid 
composition of white matter and grey matter (Carrie et al., 2000; Xiao et al., 
2005). Our samples were essentially composed of grey matter, but samples 
of whole brain tissue containing both white and grey matter were used for the 
lipid analyzer software. A phospholipid species present at high percentage 
abundance in the white matter may mask the presence of another species 
with the same m/z value, but a different fatty acyl chain composition, found at 
a lower concentration in the grey matter. The use of MS/MS to identify the 
fatty acyl chains of each phospholipid species eliminates this possibility. 
 
Lipid mediator study 
 
The sensitivity of the analytical method is such that it is essential to ensure 
that both the column and the ESI source of the mass spectrometer are clean 
prior to starting LC-MS/MS analysis. To avoid a high level of background 
noise, thorough flushing out of the HPLC column is crucial, and to ensure that 
this was achieved, the HPLC column was flushed overnight prior to set-up of 
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calibration line runs. The signal-to-noise ratio was generally acceptable in 
most biological samples, although some samples displayed a high level of 
noise, implying that the extraction process was not successful in these 
samples. In order to avoid detoriation of data quality, any samples with a high 
noise-to-signal were discarded and the chromatograms were not used for lipid 
mediator profiling. 
 
The internal standard for the mixed prostaglandin assay (d4-PGB2) was 
detectable in each cocktail of standards and in each biological sample, 
indicating that the analytical equipment was set up in a satisfactory manner. It 
can also be deduced from the consistent peak area of the internal standard 
that the methods used in this study for storage and processing of samples did 
not result in their degradation. However, since the internal standard was not 
added to the samples prior to the extraction and purification process, it is 
possible that breakdown of prostaglandins may have occurred during sample 
collection and storage. The use of cold inactivation to instant freezing (freeze 
clamping) to inhibit all tissue enzymes can reasonably be expected to have 
prevented enzyme-mediated oxidation of lipid mediators. However, 
prostaglandins can also be oxidized by a non-enzymatic (free-radical) 
catalysed reaction, which may have occurred during to some extent during 
tissue storage at -80°C. A methodology study on brain prostanoid analysis 
reported that prostaglandin mass in brain powder stored at -80°C was 
reduced 2- to 4-fold within 4 weeks (Golovko & Murphy, 2008) and it was 
suggested that tissue samples should be immediately extracted and stored in 
193 
 
solvent with added antioxidant. The samples in this study were stored as 
pieces of tissue rather than as a powder, therefore would be less exposed to 
oxygen and UV radiation (which both generate free radicals), but the 
possibility that the levels of prostaglandins in the cerebral cortex tissue on the 
outer surface may have been reduced by the auto-oxidation of prostanoids 
can not be discarded. The difference in sample collection methods used 
between this study and previous work carried out by our group may also have 
influenced the levels of prostanoids detected in the analysed samples. 
 
The data obtained in this study showed that the retention times of the peaks 
of both the standard solutions and biological samples were similar to those 
described in previous studies by our group. It is well known that even slight 
changes in mobile phase composition or pH can have a considerable effect 
on the retention time of compounds, with shifts of ± 1 minute in retention 
times not being uncommon. The similar retention times observed in both the 
PG assay standards and biological samples indicate consistency between the 
standard solutions and the biological samples in terms of eluent pH, column 
temperature and mobile phase composition. The absence of shunting and 
shifting of LC peaks observed in biological samples, as well as the clear and 
sharp shape of the peaks, also indicate good quality data was collected on 
prostaglandin species in this study.  
 
A high degree of variability in brain and plasma prostanoid composition both 
within treatment groups and between different sample groups was seen in our 
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study, with some eicosanoid species being detected in some tissue samples 
within a treatment group, but not in other samples. This suggests that the 
assay we used is close to the limit of detection of lipid mediators, which 
means that slight variations in the abundance of species between two 
samples could result in detection in one sample and non-detection in the 
other. 
 
Genotyping of human volunteers has showed a high degree of genetic 
variation in the genes encoding prostaglandin synthase and receptor proteins, 
with over 20 allelic varieties of PGE synthase and prostanoid receptors 
observed in a sample of fewer than a hundred individuals (Bigler et al., 2007). 
Of these genotypes, several changes in amino acid sequence were observed, 
leading the authors to conclude that there is a wide variation in prostaglandin-
related enzymes between individuals. However, the inbred mouse strain used 
in this study (C57/BL6) is a well-established strain which is renowned for its 
genetic homozygosity (http://www.sanger.ac.uk), suggesting that genetic 
variation between individual animals is unlikely to be a major cause of the 
variability in lipid mediators within and between treatment groups. 
 
Differences in the levels of stress between individual mice may have led to 
differences in stress hormones and as a result, differences in inflammatory 
status in the mice. Chronic stress caused by in-cage fighting (male C57/BL6 
mice that are not littermates frequently fight when kept in the same cage) or 
acute stress caused by exposure to other stressors such as bright light, 
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handling, insertion into the tube restrainer or the injection process may vary 
from individual to individual, just as humans vary in their perception of stress. 
The pro-inflammatory effects of chronic stress should not be underestimated, 
since some groups of animals were housed together for up to three weeks 
between the acclimatization, injection and sample collection process, and 
visible signs of fighting were seen on some mice in the form of tail scratches.  
 
The HETE assay internal standard (d8-12(S)-HETE) was absent in some of 
the standards when setting up calibration curves for this assay, leading to 
delays between extraction of the samples and running of the assay while 
fresh standards were prepared. The same biological samples were used for 
both the PG and the HETE assay, with both assays being run back-to-back 
and the internal standard (as well as other standards used for set-up of 
calibration curves) for the HETE assay were stored under the same 
conditions as those used for calibration curves in the PG assay. However, the 
extreme sensitivity of hydroxy fatty acids to photo-oxidation and their 
susceptibility to auto-oxidation compared to prostanoid species means that 
that it is possible that the sample storage conditions used for the extracted, 
dried and reconstituted samples in this study may have been accountable for 
the low levels of hydroxy fatty acids detected in biological samples.  
 
Farias and co-workers (2008) reported the formation of prostanoid and 
docosanoid artefacts in rat brains subjected to global post-mortem ischaemia 
compared to control animals that were killed using high-powered microwave 
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irradiation focused on the head. Animals which were decapitated and 
incubated at 37°C for 5 minutes showed clear peaks for several hydroxy, di-
hydroxy and tri-hydroxy fatty acids, including 5-HETE, 12-HETE, resolvin D1 
(RvD1) and neuroprotectin D1 (NPD1). These lipid mediators were however 
not detectable in the brains of control animals, which had been killed by 
microwave irradiation. In contrast, the same lipid mediators were all 
prominent in a study by our group on rat brains, where the animals were killed 
by decapitation and their unfrozen brains dissected on ice, prompting the 
question of whether these species were caused by post-mortem artefacts 
rather than their presence in the living brain. This theory is supported by 
earlier work on post-ischaemia prostaglandin production in rodent brains 
(Spagnulo et al., 1979; Bosisio et al., 1976). 
 
In addition to the low signal-to-noise ratio, some of the peaks obtained for 
biological samples in the HETE assay also showed slight tailing. Tailing can 
occur as a result of column overload, but this is an unlikely scenario in our 
study, since the injection volume for biological samples was only 5µL. Tailing 
can also occur because of polar interactions between the hydrophobic C18 
phase and an acidic component, which is the more probable cause in this 
case. A possible method of eliminating tailing in this instance would be to use 
a polar C18 phase, or to lower the pH of the eluent. The use of a polar C18 
phase for the HETE assay would necessitate the use of two different columns 
for the mixed prostaglandin and HETE assays, increasing the cost and time 
requirements of the analytical work by eliminating the possibility of running 
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both assays back-to-back. A more suitable alternative would be to use a 
suitable buffer in the mobile phase used for the HETE assay to ensure that 
the pH of the eluent did not drop low enough to cause tailing.  
 
5.2. Discussion of analytical findings: phospholipid study 
 
5.2.1. Phospholipid profile of naïve mouse cerebral cortex 
 
The majority of phospholipid species identified using MS and MS/MS in this 
study had also previously been identified in previous studies on mouse and 
rat brain, suggesting inter-species similarities in brain phospholipid 
composition.  
 
Two novel species which had previously not been reported using either MS or 
MS/MS were identified in our study. These species were (i) a 
phosphatidylethanolamine with m/z 720, identified as PE 16:0-18:0 using 
MS/MS and (ii) a long-chain fatty acyl phosphatidylserine with m/z 872, 
identified as PS 18:0-24:1 using MS/MS. Although other PE species of 
comparable chain length were identified in other lipidomic studies on rodent 
phospholipids, PE 16:0-18:0 is usually linked to retinal phospholipids, most 
notably retinal stem cells, having been described as a “signature 
glycerophospholipids” of this cell type (Li et al., 2007). Very long-chain fatty 
acyl phospholipids with a chain length of ≥ C24 are usually linked with white 
matter and retinal tissues (Scott & Bazan, 1987; Suh & Clandinin, 2005), 
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prompting the question of whether these phospholipids could have been 
derived from contamination of the tissue samples. Our selected dissection 
method of cracking open the frozen skull along the central fissure and 
scooping out the cerebra whole does not lend itself to this possibility of retinal 
tissue being incorporated into the sample, and the absence of other very long 
chain phospholipid species in other phospholipid classes also suggests that 
contamination of cerebral cortex samples by white matter is also an unlikely 
source of PS 18:0-24:1. It can therefore be concluded that these two 
phospholipid species, although not detectable in lipidomic studies on whole 
mouse or rat brains, are enriched in grey matter compared to the rest of the 
brain. 
 
Some differences in the identities of the fatty acyl, alkyl or ether chains 
identified during fragmentation of phospholipid species were also observed 
between this study and previous work. The phosphatidylethanolamine with 
m/z 744 was identified as PE 16:0-20:2 and PE 18:1-18:1 rather than the PE 
18:0-18:2 species observed in studies on mouse and rat whole brain (Bang et 
al., 2007; Hicks et al., 2006; Little et al., 2007). Another instance where a 20:2 
species is featured in cerebral cortex lipids is the discovery of a PS species 
with m/z 812 which has the structure PS 18:1-20:2, as well as the more PS 
18:0-20:3 species with the same m/z value that has previously been reported 
in brain lipidomic studies (Bang et al., 2007; Hicks et al., 2006; Little et al., 
2007).. The presence of several novel phospholipids with a 20:2 component 
identified in this study implies that the grey matter may be enriched in 20:2, 
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which would appear to be an otherwise rare fatty acyl component of brain 
phospholipids.  
 
Finally, differences in the structure of phosphatidylinositol species identified in 
this study were observed compared to previous work. The 
phosphatidylinositol with m/z 861 had an identity of 18:1-18:1 rather than the  
PI 18:0-18:2 species described by Hicks and co-workers (2006) and the 
phosphatidylinositol with m/z 863 was identified as 18:1-18:0, not 18:0-18:1 
as reported by the same authors (Hicks et al., 2006). Since these are minor 
changes and only account for a small fraction of phosphatidylinositols, they 
can be assumed to not be of crucial importance.  
 
The phospholipid species that were identified using MS/MS in our study are 
listed in Tables 5.2a-d, with differences highlighted.  
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Table 5.2a Comparison of the phosphatidylcholines identified using MS/MS in 
mouse brain tissue in this study against previous literature; all differences are 
highlighted 
  Little et al. 
(2007) 
Hicks et al. 
(2006) 
Bang et al. 
(2007) 
This study 
m/z Species  
(no. of C atoms: 
no. of C=C bonds) 
RAT 
WHOLE 
BRAIN 
MOUSE 
WHOLE 
BRAIN 
MOUSE 
WHOLE 
BRAIN 
MOUSE 
CEREBRAL 
CORTEX 
706 30:0  14:0-16:0 14:0-16:1  
732 32:1 16:0-16:1 16:0-16:1 16:0-16:1 16:0-16:1 
734 32:0 16:0-16:0 16:0-16:0 16:0-16:0 16:0-16:0 
746 34:0 16:0p-18:0    
756   16:1-18:2   
758 34:2 16:0-18:2 16:0-18:2 16:0-18:2  
    
760 34:1 16:0-18:1 16:0-18:1 16:0-18:1 16:0-18:1 
762 34:0 16:0-18:0 16:0-18:0 16:0-18:0  
780   16:0-20:5 18:4-18:1  
 18:2-18:3   
782 36:4 16:0-20:4 16:0-20:4 16:0-20:4  
 18:2-18:2   
784 36:3  18:1-18:2 18:1-18:2  
 16:0-20:3 16:0-20:3  
786 36:2 18:0-18:2 18:0-18:2 18:1-18:1  
  18:0-18:2  
788 36:1 18:0-18:1 18:0-18:1 18:0-18:1  
790   18:0-18:0 18:0-18:0  
802   18:2-20:5   
804 38:7     
806 38:6 16:0-22:6 16:0-22:6 16:2-22:6  
 18:2-20:4   
808 38:5 18:1-20:4 18:1-20:4 18:1-20:4  
 16:0-22:5 16:0-22:5  
 18:0-20:5 18:0-20:5  
810 38:4 18:0-20:4 18:0-20:4 16:0-22:4  
 18:1-20:3 18:1-20:3  
  18:0-22:4  
812   18:0-20:3 18:0-20:3  
814 38:2  18:1-20:1 18:0-20:2  
826   18:0-21:3   
830   18:2-22:6   
832 40:7 18:1-22:6 18;1-22;6 18:1-22:6 18:1-22:6 
834 40:6 18:0-22:6 18;0-22;6 18:0-22:6  
836 40:5  18;0-22;5 18:0-22:5  
838 40:4  18;0-22;4 18:0-22:4  
840    18:0-22:3  
Species identified (n) 14 33 29 4 
Species matching this 
study (m) 
4 4 4 4 
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Table 5.2b Comparison of the phosphatidylethanolamines identified using 
MS/MS in mouse brain tissue in this study against previous literature; all 
differences are highlighted. (*ES- mode was used in our MS/MS work on PE 
species; molecular ions identified in this work were [M-H] – ions and had m/z = 
[M+H] + m/z values – 2) 
  Little et al. 
(2007) 
Hicks et al. 
(2006) 
Bang et al. 
(2007) 
This study 
m/z Species 
(no. of C atoms: no. 
of C=C bonds) 
RAT 
WHOLE 
BRAIN 
MOUSE 
WHOLE BRAIN 
MOUSE 
WHOLE 
BRAIN 
MOUSE 
CEREBRAL 
CORTEX* 
716 34:2  16:0-18:2   
718 34:1 16:0-18:1 16:0-18:1 18:0-16:1 16:0-18:1 
720 34:0    16:0-18:0 
738 36:5  16:0-20:5   
740 36:4 16:0-20:4 16:0-20:4 16:0-20:4 16:0-20:4 
742 36:3  16:0-20:3   
 18:1-18:2   
744 36:2 18:0-18:2 18:0-18:2 18:0-18:2 16:0-20:2 
   18:1-18:1 
746 36:1 18:0-18:1 18:0-18:1 18:0-18:1 18:0-18:1 
762 38:7 16:1-22:6  16:1-22:6 16:1-22:6 
764 38:6 16:0-22:6 16:0-22:6 16:0-22:6 16:0-22:6 
766 38:5 18:1-20:4 18:1-20:4 18:1-20:4 18:1-20:4 
 16:0-22:5  16:0-22:5 
768 38:4 18:0-20:4 18:0-20:4 18:0-20:4 18:0-20:4 
 18:1-20:3   
770 38:3 18:0-20:3 18:0-20:3  18:0-20:3 
772 38:2 18:1-20:1 18:1-20:1   
774 38:1 18:0-20:1    
784   18:0-21:3   
786 40:9 18:3-22:6    
788  18:2-22:6 18:2-22:6 18:2-22:6  
790 40:7 18:1-22:6 18:1-22:6 18:2-22:5 18:1-22:6 
792 40:6 18:0-22:6 18:0-22:6 18:0-22:6 18:0-22:6 
794 40:5 18:0-22:5 18:0-22:5  18:0-22:5 
796 40:4 18:0-22:4 18:0-22:4 18:0-22:4 18:0-22:4 
798  18:0-22:3   18:0-22:3 
812    20:4-22:6  
836    22:6-22:6  
 ether lipids     
750 38:5 18;1p-20;4    
754 38:3 18;0p-20;3    
778 40:5 18;0p-22;4   18:0p-22:4 
Species identified (n) 22 21 14 18 
Species matching this study 
(m) 
12 12 10 18 
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Table 5.2c Comparison of the phosphatidylinositols identified using MS/MS in 
mouse brain tissue in this study against previous literature; all differences are 
highlighted. 
  Little et al. 
(2007) 
Hicks et al. 
(2006) 
Bang et al. 
(2007) 
This study 
m/z Species 
(no. of C atoms: 
no. of C=C bonds) 
RAT  
WHOLE 
BRAIN 
MOUSE  
WHOLE 
BRAIN 
MOUSE  
WHOLE 
BRAIN 
MOUSE 
CEREBRAL 
CORTEX 
833 34:2  16:2-18:2 16:1-18:1  
835 34:1 16:0-18:1 16:0-18:1 16:0-18:1 16:0-18:1 
837 34:0  16:0-18:0  16:0-18:0 
855   16:0-20:5   
 18:2-18:3   
857 36:4 16:0-20:4 16:0-20:4 16:0-20:4 16:0-20:4 
 18:2-18:2   
859 36:3 18:1-18:2 18:1-18:2  16:0-20:3 
   16:0-20:3   
861 36:2  18:0-18:2  18:1-18:1 
863 36:1  18:0-18:1  18:1-18:0 
865 36:0  18:0-18:0   
877 38:8  18:2-20:5   
881 38:6 18:2-20:4 16:0-22:6 18:2-20:4 16:0-22:6 
 18:2-20:4 16:0-22:6  
883 38:5 18:1-20:4 18:1-20:4 18:1-20:4 18:1-20:4 
 16:0-22:5 18:0-20:5  
 18:0-20:5   
885 38:4 18:0-20:4 18:0-20:4 18:0-20:4 18:0-20:4 
 18:1-20:3   
887 38:3 18:0-20:3 18:0-20:3 18:0-20:3 18:0-20:3 
889 38:2 18:0-20:2 18:1-20:1   
905 40:8  18:2-22:6   
907 40:7 18:1-22:6 18:1-22:6   
909 40:6 18:0-22:6 18:0-22:6 18:0-22:6 18:0-22:6 
911 40:5  18:0-22:5  18:0-22:5 
913 40:4  18:0-22:4   
Species identified (n) 10 27 10 12 
Species matching this study 
(m) 
6 9 7 12 
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Table 5.2d Comparison of the phosphatidylserines identified using MS/MS in 
mouse brain tissue in this study against previous literature; all differences are 
highlighted. 
  Little et al. 
(2007) 
Hicks et 
al. (2006) 
Bang et 
al. (2007) 
This study 
m/z Species 
(no. of C atoms: no. of C=C 
bonds) 
RAT  
WHOLE 
BRAIN 
MOUSE  
WHOLE 
BRAIN 
MOUSE  
WHOLE 
BRAIN 
MOUSE 
CEREBRAL 
CORTEX 
760 34:1  16:0-18:1 16:0-18:1 16:0-18:1 
762 34:0  16:0-18:0 16:0-18:0  
780 36:5  16:0-20:5   
 18:2-18:3   
782 36:4  16:0-20:4   
 18:2-18:2   
784 36:3  18:1-18:2   
 16:0-20:3   
786 36:2 18:0-18:2 18:1-18:2 18:1-18:1 18:1-18:1 
788 36:1 18:0-18:1 18:0-18:1 18:0-18:1 18:0-18:1 
790 36:0 18:0-18:0 18:0-18:0 18:0-18:0  
804 38:7 18:2-20:5 18:2-20:5   
806 38:6  16:0-22:6 16:2-22:6  
 18:2-20:4   
808 38:5  18:1-20:4 18:1-20:4  
 16:0-22:5   
810 38:4 18:0-20:4 18:0-20:4 18:0-20:4 18:0-20:4 
 18:1-20:3   
812 38:3  18:0-20:3 18:0-20:3 18:0-20:3 
   18:1-20:2 
814 38:2 18:0-20:2 18:1-20:1 18:0-20:2  
816 38:1 18:0-20:1  18:0-20:1 18:0-20:1 
826   18:0-21:3   
830 40:8  18:2-22:6 18:2-22:6  
832 40:7 18:1-22:6 18:1-22:6 18:1-22:6 18:1-22:6 
834 40:6 18:0-22:6 18:0-22:6 18:0-22:6 18:0-22:6 
836 40:5 18:0-22:5 18:0-22:5 18:0-22:5 18:0-22:5 
838 40:4 18:0-22:4 18:0-22:4 18:0-22:4 18:0-22:4 
840 40:3 18:0-22:3  18:0-22:3  
842 40:2 18:0-22:2    
844 40:1 18:0-22:1  22:0-18:1 18:1-22:0 
854 42:10   20:4-22:6  
856 42:9   20:3-22:6  
862 42:6   20:0-22:6  
  18:0-24:6  
872 42:1    18:0-24:1 
878 44:12   22:6-22:6  
880 44:11   22:5-22:6  
882 44:10   22:4-22:6  
Species identified (n) 14 26 25 13 
Species matching this study (m) 7 8 8 13 
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5.2.2. Phospholipid profile of naïve mouse cerebral cortex – potential 
biological significance 
 
 
The vast majority of highly-unsaturated phospholipids detected in cerebral 
cortex tissue of naïve mice contained either arachidonic acid (denoted by 
20;4 in Tables 5.2a-d) or docosahexaenoic acid (denoted by 22;6 in Tables 
5.2a-d). Phospholipids containing arachidonic acid in their structure account 
for 14% of choline phospholipids, 18% of phosphatidylethanolamines, 9% of 
phosphatidylserines and 75% of phosphatidyl-inositols. In contrast, 
phospholipids containing docosahexaenoic acid in their structure account for 
11% of choline phospholipids, 60% of phosphatidylethanolamines, 64% of 
phosphatidylserines and 4% of phosphatidylinostols. 
 
Phosphatidylcholines make up a very high proportion of the outer leaflet of 
the plasma membrane and are also the principal phospholipids in plasma, 
where they are an essential component of high-density lipoproteins. The 
existence of phospholipases C and D specific for phosphatidylcholines 
suggest that diacylglycerols released from phosphatidylcholine may have a 
role in cell signalling (Vance & Vance, 2008). However, the majority of 
phosphatidylcholines are unsaturated or monounsaturated fatty acids, which 
yield diacylglycerols with much lower biological activity than highly 
unsaturated fatty acids, such as arachidonic acid (Christie, 2008). As a result, 
diacylglycerols formed from phosphatidylcholines would not be expected to 
show as much biological activity as those derived from phosphatidylinositols. 
205 
 
The plasmalogen form of phosphatidylcholine may also have a signalling 
function, with phospholipase A2 activity releasing arachidonic acid (a 
substrate for eicosanoid production) from the sn-2 position of plasmogen 
phosphatidylcholine species containing releasing this fatty acid (Gora et al., 
2006). 
 
Phosphatidylethanolamines are concentrated on the inner leaflet of the 
plasma membrane, along with phosphatidylserines. The ability of 
phosphatidylethanolamines to hydrogen bond to proteins through its ionizable 
amine group means that they exert a lateral pressure that can stabilize 
membrane proteins in their optimum conformations (Vance and Vance, 2008). 
Their cationic head group also neutralizes the negative charges on the 
anionic head groups of phosphatidylserines. Phosphatidylethanolamines do 
not naturally form a lipid bilayer due to their conical shape, and the high 
percentage of phosphatidylethanolamine species which contain highly-
unsaturated fatty acyl groups also means that membranes formed by this 
phospholipid class are highly-fluid. Phosphatidylethanolamines are involved 
in membrane fusion and fission, and can serve as a biosynthetic precursor for 
anandamide, an endocannabinoid neurotransmitter (Christie, 2008).  
 
In addition to functioning as negatively charged building blocks of 
membranes, inositol phosholipids can regulate the binding of proteins via 
non-specific electrostatic interactions with proteins, or through specific binding 
to „PH‟ domains of cellular proteins (Christie, 2008). They can also participate 
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in cell signaling through one of two ways. Firstly, they are the main source of 
inositol diacylglycerols (produced by phospholipase C) that act upon protein 
kinase C enzymes, which in turn control several key cell functions, including 
differentiation, proliferation, metabolism and apoptosis. Secondly, they are 
the primary source of the arachidonic acid required for the biosynthesis of 
eicosanoids, including prostaglandins (Farooqui & Horrocks, 2006; Vance & 
Vance, 2008). Phosphatidylinostiols containing arachidonic acid account for 
three quarters of all phosphatidylinositol species, and of these, sn-1-stearoyl-
sn-2-arachidonoyl-glycerophosphorylinositol (18;0-20;4), is by far the most 
common. The hydrolysis of sn-1-stearoyl-sn-2-arachidonoyl-
glycerophosphorylinositol (18;0-20;4) by phospholipase A2 releases 
arachidonic acid from the sn-2 position, producing substrate for the 
production of eicosanoids (Farooqui & Horrocks, 2006). The reverse reaction 
also occurs, which is a means by which free arachidonic acid and eicosanoid 
levels can be regulated.  
 
Phosphatidylserines are located entirely on the inner leaflet surface of the 
plasma membrane and other cellular membranes, although this distribution is 
disturbed during platelet activation and cell apoptosis (Martin et al., 1995). It 
is believed that a receptor on the surface of macrophages and other 
scavenger cells may recognize the phosphatidylserine and remove the 
apoptotic cells (Vance & Vance, 2008). A high concentration of 
phosphatidylserine in a region of a cellular membrane also results in an 
accumulation of negative surface charge, to which poly-cationic proteins can 
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bind. Some proteins also contain specific phosphatidylserine-binding 
domains, with which they can dock to membrane lipids, with the result that 
certain proteins can be re-directed from one target membrane to another 
(Christie, 2008). The ratio of n-3 to n-6 fatty acids in brain and retina 
phosphatidylserines is very much higher than in most other phospholipid 
classes and DHA accumulation has been shown to be important in the 
development and function of these tissues (Scott & Bazan, 1987; Birch et al., 
2010). It has also been suggested that phosphatidylserine may also act as a 
reservoir of DHA production for neuroprotection in neuronal tissue (Bazan, 
2009), and the fact that almost two thirds of phosphatidylserines in mouse 
cerebral cortex contained DHA would seem to agree with this theory, 
although it has not been confirmed.  
Figure 5.2 Different phospholipid classes have different biological functions, 
some of which overlap. For example, both plasmogen phosphatidylcholines 
and acyl phosphatidylinositols are rich sources of 20:4(n-6) when hydrolysed 
by PLA2, releasing a substrate for biosynthesis of many bioactive lipid 
mediators. 
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5.2.3. Identification of novel phospholipid species in naïve mouse 
cerebral cortex 
 
Our study detected several phospholipid species in mouse cortex which had 
previously not been reported in lipidomic studies on whole mouse or rat 
brains. These lipid species were PE 16;0-18;0, PE16;0-20;2, PE18;1-18;1, PI 
18;1-18;1, PS 18;1-20;2 and PS 18;0-24;1. The fatty acyl chains in the 
majority of these species are derived from either saturated fatty acids or from 
a monounsaturated fatty acid (oleic acid). However, two of the novel species 
detected in our studies contained an eicosadienoic acid (20:2) fatty acyl 
chain. 
 
Two eicosadienoic acid species have been previously been recorded in 
mammalian tissue. These are (i) 8, 11-eicosadienoic acid (20:2n-9), which is 
commonly derived from oleic acid by Δ-6 desaturation followed by chain 
elongation, and (ii) 11, 14- eicosadienoic acid (20:2n-6), which is commonly 
derived from linolenic acid by chain elongation (Beermann et al., 2005; Diau 
et al., 2003; Li et al., 2007). Eicosadienoic acid generally has a low 
prevalence in body tissues, although it can be detected using advanced 
analytical methods. For example, 8,11-eicosadienoic acid has been detected 
at low concentrations (<1% of all fatty acids) in the retina of infant baboons 
(Diau et al., 2003), and 11,14-eicosadienoic acid has been found amongst 
phosphatidyl-ethanolamine and phosphatidylserine species of human 
erythrocyte phospholipids (Beermann et al., 2005). 11,14-eicosadienoic acid 
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is widely considered a „dead-end product‟ i.e. one which is not converted into 
other long-chain fatty acids, although it has recently been shown to be a 
substrate of the FADS-2 gene product (Park et al., 2009). Its role as a 
substrate for Δ-8 desaturation by the FADS2 gene product has led to 
speculation that 20:2(n-6) may play a part in the production of eicosanoids 
derived from 20:3(n-6), such as prostaglandins E1 and F1α, thromboxane B1 
and hydroxy-eicosatrienoic acids (Park et al., 2009). Yeast cells transfected 
with the baboon FADS2 gene showed Δ-8 desaturation activity on both n-6 
and n-3 fatty acids, including the conversion of 20:2n-6 to 20:3n-6 and of 
20:3n-3 to 20:4n-3 (Park et al., 2009). Δ8-desaturation of 8,11-eicosadienoic 
acid to 11,14-eicosadienoic acid (20:2n-6 to 20:3n-6) has previously been 
reported in both rat and human tissue (Albert & Coniglio, 1977; Albert et al., 
1979) and polymorphisms in the FADS2 gene have been linked to changes in 
the lipid profile of human serum and erythrocyte phospholipids of heart 
patients, including eicosadienoic acid (Malerba et al., 2008). Figure 5.3 
illustrates the biosynthesis and metabolism of both eicosadienoic acid 
species, and the bioactive lipid products to which they can give rise.  
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Figure 5.3 Biosynthesis and metabolism of eicosadienoic acid 
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Novel phosphatidylethanolamine species with m/z 720 (PE 16:0-18:0) 
 
The PE species with m/z 720 (PE 16:0-18:0) has previously been identified 
as a „signature glycerophospholipid‟ of rat retinal stem cells in a lipidomic 
study using ESI-MS/MS (Li et al, 2007), and by extension this lipid species 
may also be present in other neural stem cells. The presence of the novel 
phospholipid species PE 16:0-18:0 (1-palmitoyl 2-stearoyl 
phophatidylethanolamine) is consistent with the emerging hypothesis that 
neural stem cells are present in the cerebral cortex. Neural stem cells have 
previously been identified and located in three regions of the brain in adult 
rodents, namely: (i) the ventricular and subventricular zone, (ii) the 
hippocampus, and (iii) tissue connecting the lateral ventricles and the 
olfactory bulb (Li et al., 2007). These three regions all contain grey matter 
(Bear et al., 2001) and so tissue from them may have been included in the 
samples of mouse cerebral cortex that were subjected to phospholipid 
extraction and analysis.  
 
The low prevalence of this species in the cerebral cortex tissue samples is in 
accordance with the theory that this phospholipid is primarily present in neural 
stem cells, although the prevalence of PE 16:0-18:0, although low, accounted 
for >1% of total cortex phosphatidylethanolamines, which may not be 
expected from a cell population which is located in only small, discrete brain 
regions. It has not been documented in literature that neural stem cells have 
a widespread presence in the cerebral cortex, although the detection of the 
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neural stem cell „signature glycerophospholipid‟ PE 16:0-18:0 in mouse 
cerebral cortex by this study might imply that neural stem cells may be more 
numerous or account for a greater proportion of the cerebral cortex than 
initially expected.  
 
It has been suggested that stem cell therapy may provide a manner in which 
neuronal damage mediated during cerebral ischaemia could be reversed (Liu 
et al., 2009). Latent stem cells located in the hippocampus have also been 
reported to be activated by neural excitation (Walker et al., 2008) and neural 
progenitor cells in the subventricular zone showed an increase in proliferation 
rate following stroke in mice (Zhang et al., 2004). More recently, Lai and co-
workers (2008) showed functional differentiation of neural progenitor cells in 
the subventricular zone following a simulated stroke in animals, supporting 
the possibility of stem cell therapy for stroke. Delivery of neural stem cells to 
the infarct site can be successfully carried out by injecting scaffold particles 
made of poly(D,L,lactic-co-glycolic) acid (PLGA) with neural stem cells into 
the ventricles (Bible et al., 2009), although it has not been clarified whether 
this strategy would provide long-term success. Our study also supports the 
theory that neural stem cells are already present in the cerebral cortex under 
physiological conditions, and that these cells may be involved in neuronal 
repair following an ischaemic challenge.  
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Novel phosphatidylserine species containing a very long chain fatty 
acid (PS 18:0-24:1) 
 
We also detected and identified a novel PS species containing a very long 
chain fatty acid (PS 18:0-24:1). There is generally an absence of PS species 
containing fatty acyl chains longer than C22 in other lipidomic studies on 
whole mouse or rat brain. However, Bang and colleagues also recorded a 
C24 fatty acyl chain in their analysis of whole mouse brain, where PS18:0-
24:6 was identified (Bang et al., 2007). Very long chain fatty acid 
phospholipids (chain length ≥C24) have been identified in retinal tissue, where 
there is an abundance of phospholipids containing very long chain fatty acids, 
and 24:1n-9 (nervonic acid) has also been associated with myelin (Martinez & 
Mougan, 2004). The method of brain dissection used in our studies, where 
the skull was cracked open along the central fissure and the cerebra scooped 
out of the frozen head before further dissection and removal of the white 
matter was carried out, means that it is highly unlikely that mouse eye tissue 
was accidentally incorporated into the sample. The careful removal of white 
matter from the cerebra, and the fact that no common myelin lipids (22:1 and 
24:1) were detected in any other phospholipid classes, also implies that 
contamination of cerebral cortex samples with white matter is an unlikely 
source of this PS species. It can therefore be concluded that murine grey 
matter contains a small, yet detectable, amount of longer-chain fatty acyl 
chains within structural phospholipids.  
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Phosphatidylserine 18:1-20:2 species with m/z 812  
 
Our fragmentation study identified two PS species with an m/z of 812, 
identified as PS 18;1-20;2 and PS 18;0-20;3, in contrast to previous studies 
which only found one PS species with this m/z value (PS 18;0-20;3). Although 
in the past, eicosadienoic acid was widely considered a „dead-end, its 
recently discovered role as a substrate for Δ-8 desaturation by the FADS2 
gene product has led to speculation that 20:2(n-6) may play a part in the 
production of eicosanoids derived from 20:3(n-6), such as prostaglandins E1 
and F1α, thromboxane B1 and hydroxy-eicosatrienoic acids (Park et al., 2009). 
The 1-series prostaglandins have been reported to exert an anti-inflammatory 
effect by direct competition for binding with the pro-inflammatory 2-series 
prostaglandins, and this competive effect partally blocks the activation of 
prostanoid receptors.  
 
5.2.4. Effects of alpha linolenic acid (ALA) treatment on mouse 
cerebral cortex phospholipid profile  
 
Intravenous injection of ALA did not produce widespread changes in the fatty 
acid composition of phospholipid and sphingomyelin species in mouse 
cerebral cortex. No significant differences in the percentage abundance of 
phosphatidylcholine and sphingomyelin species were observed at any 
timepoint between ALA-treated, vehicle-treated or naïve mice. Similarly, there 
were no differences in the abundance of phosphatidylinositol species at 24, 
72 or 168 hours following ALA or vehicle treatment, phosphatidylserine 
species at 3, 72 and 168 hours after ALA or vehicle injection, or in 
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phosphatidylethanolamine species at 3 and 168 hours after ALA or vehicle 
injection. However, there were discrete changes in the relative abundance of 
a few phospholipid species at different time points (see Table 5.3).  
 
Table 5.3. Discrete changes were observed in the relative composition of 
phospholipid species in cerebral cortex in ALA- treated mice (P<0.05 ANOVA 
with post-hoc Dunnett t test, control group = naïve mice). R1 and R2 fatty acyl 
chains were definitively identified using MS/MS. 
 
Phospholipid species Timepoint 
affected 
Change in 
phospholipid 
abundance 
Phospholipid 
class 
m/z of 
[M– H]- 
ion 
R1 R2 
SM 813 18:0 24:1 3 +1.04% 
PE 740† 18:1 18:2 3 + 0.01% 
PE 744†† 18:0 18:1 3 + 1.38% 
PE 784††† 18:0a* 22:0* 24 +0.67% 
PS 812 18:0 20:3 24 -0.308% 
 
† [M+ H] + m/z value of 742 
†† [M+ H] + m/z value of 746 
††† [M+ H] + m/z value of 786 
* Data from studies on rat brain  
 
 
These changes were: 
 
(i) An increase in the the relative abundance of the sphingomyelin 
species with m/z 813 at 3 hours. This species was identified as SM 
18:0/24:1 using MS/MS data.
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(ii) An increase in the relative abundance of the 
phosphatidylethanolamine species with m/z 742 (identified as 
PE18:1/18:2 by MS/MS), at 24 hours after ALA injection.  
(iii) An increase in the abundance of the phosphatidylethanolamine 
species with m/z 746 at 72h post-ALA injection. This species was 
identified as PE18:0/18:1 using MS/MS data. 
(iv) An increase in the abundance of the phosphatidylethanolamine 
species with m/z 786 at 72h post-ALA injection. This species was 
identified as PE18:0a/22:0 using MS/MS data.  
(v) A decrease in the relative abundance of the phosphatidylserine 
species with m/z 812 at 24 hours. This species was identified as 
PS18:0/20:3 using MS/MS 
 
It had been expected that ALA treatment of mice would lead to either (a) 
direct effects on brain lipid composition, whereby ALA or n-3 fatty acids 
derived from ALA would be incorporated into brain phospholipids, or (b) 
indirect effects, where changes in the homeostasis of lipids in the brain or in 
the biosynthesis of lipids lead to neuroprotection.  
 
However, despite the use of appropriate statistical analysis to determine 
whether changes in phospholipid composition were statistically significant or 
not, the large number of phospholipids detected in the mouse cerebral cortex 
(75 species detected at >1% abundance in mouse cerebral cortex samples 
using MS, and 47 phospholipids definitively identified using MS/MS) and the 
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fact that none of the differences observed were significant at the P<0.01 level, 
means that it possible that the changes observed were due to chance. 
Indeed, probability theory would suggest that at least three of these five 
significant changes are likely to be due to chance rather than an actual 
difference in cerebral cortex composition.  
 
Previous studies have shown a direct effect by a single dose of essential fatty 
acid on brain and plasma lipids. A tracer study on rats fed single 20mg doses 
of deuterated LA and ALA (Liu & Salem, 2007) showed accumulation of 
radiolabelled LA and ALA metabolites over a 25-day period. The animals 
showed only minimal accumulation of radiolabelled ALA itself in the brain, but 
its metabolites did gradually accumulate in the brain, with maximum 
concentrations of 20:5n-3, 22:5n-3 and 22:6n-3 in the brain reached at 8h, 
96h and 600h after ALA dosing. LA could be incorporated more readily into 
the brain than ALA, with its concentration in the brain peaking 8h after dosing. 
However, the metabolites of LA accumulated in the brain at a comparable 
rate to those of ALA metabolites, with 20:3n-6, 20:4n-6, 22:4n-6 and 22:5n-6 
reaching maximal concentrations at 96h, 240h, 600h and 168h respectively, 
following the radiolabelled lipid dose. Both 22:4n-6 and 22:6n-3 differed from 
the other PUFA metabolites studied in that they appeared to still be 
continuously accumulating in the brain at the end of the experiment, and so 
we cannot be certain whether their concentrations in the brain would increase 
further had an additional timepoint been included in the experiment. This 
study demonstrates the far-reaching effects of even a single dose of essential 
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fatty acid on lipid accumulation in the brain. The same study also examined 
the plasma concentrations of n-3 and n-6 lipids following dosing of LA and 
ALA and reported peaks of 18:3n-3 at 4h, and 20:5n-3, 22:5n-3 and 22:6n-3 
at 96h. Maximum plasma concentration of 18:2n-6 and 18:3n-6 was reached 
at 8h, 20:3n-6 and 20:4n-6 at 24h and 22:4n-6 and 22:5n-6 at 96h. The length 
of time required to reach peak plasma concentrations of many of these PUFA 
metabolites correspond to the “window of neuroprotection” (Dirnagl & 
Hallenbeck, 2004; Blondeau et al., 2002; Lauritzen et al., 2000) in 
preventative stroke therapy, which means that the production of 
neuroprotective compounds from essential fatty acids or their metabolites is a 
possibility. 
 
Pawlosky and colleagues (2001) carried out a tracer study following the 
metabolic fate of radiolabelled ALA in the plasma of human volunteers. 
Plasma concentrations of radiolabelled ALA, EPA and DHA were measured 
at time intervals between 0 – 120 hours after ingestion of a meal containing 
radioactive ALA. Plasma concentrations of ALA, EPA and DHA peaked at 
approximately 10, 40 and 72 hrs after intake of radioactive ALA respectively. 
Once again, elevated plasma concentrations of EPA and DHA coincide with 
the “window of neuroprotection” (Dirnagl & Hallenbeck, 2004), which means 
that the production of neuroprotective PUFA metabolites from substrates 
available in the circulation cannot be discounted.  
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Several metabolites of ALA have bioactive properties themselves, or are 
precursors to lipid mediator compounds, including pro–resolution and/or 
neuroprotective polyhydroxylated derivatives of EPA and DHA such as the 
resolvins and neuroprotectins (Chen & Bazan, 2005, Hong et al., 2003, 
Marcheselli et al., 2003, Mukherjee et al., 2004, Serhan et al., 2000). For 
example, 10,17S-docosatrienoic acid, a metabolite of DHA, is produced by 
many cell types including microglia and Th2 helper T cells (Levy et al., 2007) 
under a range of pathophysiological conditions, including rodent models of 
ischaemia (Hong et al., 2003). 10,17S-docosatrienoic acid has been shown to 
reduce inflammation in a mouse model of asthma by reducing the production 
of pro-inflammatory lipid mediators (Levy et al., 2007; Serhan et al., 2002). 
Direct intra-cerebroventricular infusion of 10,17S-docosatrienoic acid resulted 
in the reduction in infarct size in mice subjected to MCAO in comparison to 
untreated controls (Belayev et al., 2005; Marcheselli et al., 2003; Mukherjee 
et al., 2004), implying that the neuroprotective effects of PUFA seen in rodent 
models of ischaemic stroke may be mediated by PUFA metabolites rather 
than the injected PUFA itself. If this is the case, then the composition of the 
free fatty acid pool in brain or plasma may be of more importance than the 
phospholipid composition. 
 
However, changes in brain phospholipid and free fatty acid homeostasis have 
been reported in mice subjected to hypoxic preconditioning. A study reported 
changes in the amounts of four phospholipid classes and several fatty acids 
in mice subjected to one run of hypoxia compared to untreated mice and mice 
220 
 
subjected to repeated runs of hypoxia (Duan et al., 1999). Phospholipid 
classes were detected using thin layer chromatography, while FFA were 
derivatised to fatty acid methyl esters (FAME) and analysed using gas 
chromatography. It was noted that levels of choline phospholipids (PC and 
SM) were decreased and those of PE and PS lipids were increased in mice 
that underwent one run of hypoxia compared to mice in the control group. All 
of these changes, except for the decrease in SM, were counter-acted in mice 
subjected to a higher number of hypoxic runs. In addition, free fatty acid 
levels were increased in mice subjected to one run of hypoxia compared to 
control mice, but near-control levels of fatty acids were detected in the group 
of mice that had undergone four periods of hypoxia.  
 
It is plausible that repeated runs of hypoxia lead to no detectable changes in 
FAME because the preconditioning process invokes an adaptive 
cytoprotective response upon subsequent exposure to harmful stimulus, 
reducing influx of calcium ions, minimizing the activation of PLA2 and 
subsequent autolysis of membrane phospholipids. Some free fatty acids 
released from structural phospholipids by PLA2 activity, such as arachidonic 
acid, are substrates for the production of pro-inflammatory lipid mediators. For 
example, prostaglandins, which are produced from arachidonic acid, have 
neurotoxic effects (Farooqui & Horrocks 2006) and inhibitors of prostaglandin 
production are known to have a neuroprotective effect in animal models of 
stroke (Ahmad et al., 2009). As a result, the inhibition of free fatty acid release 
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by the inhibition of PLA2 would be expected to be neuroprotective, since it 
reduces the amount of substrate available for prostaglandin synthesis. 
  
The release of the free fatty acids located at the sn-2 position of the majority 
of the phospholipid species which were increased in ALA-treated mice would 
not result in additional substrate for the production of bioactive lipid 
mediators. The two exceptions are to this rule are the 
phosphatidylethanolamine with m/z 742 (identified as PE 18:1/18:2 using 
MS/MS) and the phosphatidylserine with m/z 812 (identified as PS 18:0/20:3) 
using MS/MS. The hydrolysis of PE18:1/18:2 would release linolenic acid 
from the sn-2 position, which is a precursor for the pro-inflammatory hydroxy 
octadienoic (HODE) acids 9-HODE and 13-HODE or can alternatively be 
metabolised to produce arachidonic acid, which can then be converted either 
enzymatically or by free radical-catalysed reactions into a wide range of 
bioactive lipid mediators, including prostaglandins, thromboxanes and 
hydroxy fatty acids. Work using radioactive tracers showed long-term 
accumulation of radiolabelled LA and ALA metabolites in rat brain tissue 
following a single dose of deuterated LA and ALA (Liu & Salem, 2007, which 
provides support for the possibility that an increase in PE18:1/18:2 may lead 
to the production of LA and its metabolites upon instigation of the 
phospholipase A2 signalling cascade. However, the length of time required 
for metabolites of LA to accumulate in the brain during tracer studies means 
that it is unlikely that any neuroprotective effect caused by a change in brain 
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phospholipids can be attributed to the production of long-chain LA-derived 
metabolites. 
 
Preconditioning has been defined as a procedure where a noxious stimulus 
near to but below the threshold of damage is applied to a tissue (Dirnagl et 
al., 2009), following the principles of the adage “what doesn‟t kill one makes 
one stronger”. However, it can be assumed that the threshold at which tissue 
injury would occur may differ from region to region of the brain, or from 
individual to individual. For instance, age may be a factor which affects the 
threshold at which tissue damage occurs upon a noxious stimulus. Research 
on elderly stroke patients showed that patients who had experienced 
transient ischaemic attacks (TIA), commonly known as “mini-strokes”, did not 
show improved neurological outcome compared to patients of the same age 
who had not experienced TIA prior to an ischaemic stroke (Della Morte et al., 
2008), leading to the question whether differences in age could lead to 
differences in susceptibility in brain injury, meaning that even TIA could cause 
tissue damage in the elderly rather than acting as a noxious stimulus below 
the threshold of tissue injury. Stroke is rare in young adults, but 1,000 people 
under the age of 30 suffer a stroke every year in the UK, which means that 
the development of ischaemic tolerance through preconditioning warrants 
investigating, even if it is suggested that it is a phenomenon which only 
occurs in young adults. 
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5.3. Interpretation of analytical findings: lipid mediators study 
 
5.3.1. Prostanoid profiling of mouse cerebral cortex and plasma – 
potential biological significance 
 
Prostaglandins, isoprostanes and thromboxanes act upon members of a 
family of prostanoid receptors conserved from rodents to humans (Narumiya 
& FitzGerald, 2001; Narumiya et al., 1999). They can be activated under both 
physiological and pathophysiological conditions by a range of bioactive lipids, 
many of which were identified in mouse plasma and cerebral cortex samples 
in this study. Each member of the prostanoid receptor family has a specific 
distribution in the body and their expression varies between tissue types, as 
shown in Figure 5.4 (Narumiya et al., 1999). 
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Figure 5.4 Members of the prostanoid receptor family have a specific distribution in the body  
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Members of the prostanoid receptor family have been shown to play roles in 
the development of ischaemia-reperfusion injury, and the fact that fatty acid 
treatment of mice led to significant changes in several lipid mediator species 
that can act upon these receptors, lends itself to the possibility that fatty acid 
neuroprotection is mediated by the modulation of prostanoid receptor activity. 
Table 5.5 summarizes the changes observed in lipid mediators in both mouse 
cerebral cortex and plasma, and also which prostanoid receptors are affected 
by the lipid mediators in question.   
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Table 5.5 Fatty acid (ALA) treatment caused significant differences in the 
abundance of lipid mediators in both cerebral cortex and plasma, of which 
some can activate prostanoid receptors. Prostanoid receptors may play a role 
in the development of tissue injury in animal models of ischaemia. 
Prostanoid 
changes in 
CEREBRAL 
CORTEX 
RECEPTOR 
BINDING? 
ROLE OF RECEPTOR ACTIVATION  
IN ANIMAL MODELS OF ISCHAEMIA 
15-deoxy-Δ12,14-
PGJ2 
INCREASED at 
72h 
PPARγ? Unknown 
TXB2 REDUCED 
at 3h, 24h and 
72h 
TP (via its 
biologically 
active precursor 
TXA2) 
Increases blood flow in models of myocardium 
ischemia 
   Prostanoid 
changes in 
PLASMA 
RECEPTOR 
BINDING? 
ROLE OF RECEPTOR ACTIVATION  
IN ANIMAL MODELS OF ISCHAEMIA 
15-deoxy-Δ12,14-
PGJ2 REDUCED 
at 72h and 168h 
PPARγ? Unknown 
PGE2 
INCREASED at 
72h and 168h 
EP1 
 
 
 
 
 
EP2 
 
 
 
 
EP3 
 
 
EP4 
Knockout reduces neuronal death in in vitro 
ischaemia model (Saleem et al., 2007) and 
blockade of EP1 receptor results in reduced 
infarct volume & better neurological function in 
mouse model of focal ischaemia (Abe et al., 
2009) 
 
Increased neuronal death in EP2-/- tissues 
compared to wild-type controls, and blockade of 
EP2 receptors resulted in increased infarct size 
(McCullough et al., 2004) 
 
Knockout EP3-/- mice showed a reduced infarct 
volume following MCAO compared to wild-type 
animals (Saleem et al., 2009) 
Activation of EP4 protects against ischaemia-
reperfusion injury in rat hearts (Xiao et al., 
2004). 
PGF3α 
INCREASED at 
24h  
FP Blockade reduces neuronal injury (Saleem et al., 
2009) 
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5.3.2. Effects of alpha-linolenic acid treatment on the prostanoid profile 
of mouse cerebral cortex  
 
There were several differences in the prominent prostanoid species detected 
in mouse cerebral cortex of animals in different treatment groups. Table 5.6 
shows the most abundant prostanoid species (i.e. have a percentage 
abundance of >10% in the tissue sample) in naïve mice (CONTROL) and 
animals subjected to α-linolenic acid (ALA) or vehicle (VEH) injection at 
various timepoints (3h, 24h, 72h and 168h post-treatment). 
 
Table 5.6 Differences in prominent lipid mediator species (i.e. comprise of 
>10% abundance of all prostanoids) in mouse cerebral cortex samples of 
animals from various treatment groups and time points. 
Treatment 
group 
Most prominent prostanoid species 
(>10 % of total prostanoids) 
CONTROL  PGD2  PGE2  PGE1 PGF2α 6-keto 
PGF2α 
  
VEH3  PGD2 PGE2 8-
iso-
PGE2 
PGE1  6-keto 
PGF2α 
  
VEH24  PGD2        
VEH72 PGB2     PGF2α    
VEH168      PGF2α 6-keto 
PGF2α 
  
ALA3  PGD2  PGE2 8-
iso-
PGE2 
    TXB2 
ALA24  PGD2   8-
iso-
PGE2 
    TXB2 
ALA72 PGB2     PGF2α    TXB2 
ALA168 PGB2       15-
deoxy-
D12,14-
PGJ2 
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Several significant differences (P<0.05, two-way ANOVA and post-hoc 
Dunnett‟s t-test) were observed between the eicosanoid composition of 
cerebral cortex in ALA-treated animals compared to naïve mice or those 
injected with vehicle. Here, we will outline these differences and consider the 
biological significance of these changes. 
 
Increase in 15-deoxy-Δ12,14-PGJ2 
The percentage abundance of 15-deoxy-Δ12,14-PGJ2 was increased in ALA-
treated mice compared to VEH-injected or naïve (CTL) animals 72h following 
ALA administration. This compound has been identified as an activator of the 
PPARγ receptor, and has been reported to reduce angiogenesis in tumour 
cells and to inhibit the expression of many inflammatory proteins such as 
iNOS, COX-2 and NFκB in vitro and in vivo (Powell, 2003; Sasaguri & Miwa, 
2004). However, these anti-inflammatory effects have only been observed at 
micromolar concentrations, considerably higher than the usual physiological 
range of prostaglandins (Bell-Parikh et al., 2003), prompting doubts whether 
15-deoxy-Δ12,14-PGJ2 is of biological importance or whether it should be 
regarded as only a metabolite of PGD2. If the latter is the case, then the 
increase in 15-deoxy-Δ12,14-PGJ2 at 72h post-injection in the cerebral cortex 
of ALA-treated animals compared to VEH-injected or naïve animals, can be 
viewed as a reflection of the levels of PGD2 in the cerebral cortex and 
plasma.  
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Reduction in TXB2 
TXB2 levels in ALA-treated animals were reduced at 3h, 24h and 72h 
compared to vehicle-injected or naïve animals. TXB2 is not itself a bioactive 
lipid, but a stable and physiologically inactive metabolite of TXA2 (which is 
synthesized in vivo from PGH2 and has a very short half-life). The short half-
life of TXA2 means that it can‟t be detected in its active form in tissue 
samples, but TXB2 is a reliable indicator of TXA2 concentration and activity in 
biological systems. The biological functions of TXA2 include vasoconstriction, 
platelet aggregation and bronchoconstriction, and its effects are mediated via 
a specific thromboxane (TP) receptor. The reduction in TXB2 in mouse 
cerebral cortex at 3h, 24h and 72h following ALA injection could result in 
decreased activity of the TP receptor during this time period, owing to a 
reduction in the rate of production of TXA2, the biologically active precursor of 
TXB2. However, this reduction may be counter-acted by an increase in 8-iso-
PGE2 binding to TP receptors. These two seemingly counter-productive 
changes in the concentration of TP receptor ligands imply that changes in TP 
receptor activity may not be the most important factor in the development of 
fatty acid-induced neuroprotection 
 
5.2.3. Effects of alpha-linolenic acid treatment on the prostanoid profile 
of mouse plasma 
 
There were some differences in the prominent prostanoid species detected in 
mouse plasma of animals in different treatment groups. Table 5.7 shows the 
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most abundant prostanoid species (i.e. have a percentage abundance of 
>10% in the sample) in naïve mice (CONTROL) and animals subjected to α-
linolenic acid (ALA) or vehicle (VEH) injection at various timepoints (3h, 24h, 
72h and 168h post-injection). 
 
Table 5.7 Differences in prominent lipid mediator species (i.e. comprise of 
>10% abundance of all prostanoids) in mouse plasma samples of animals 
from various treatment groups and time points. 
Treatment 
group 
Most prominent prostanoid species 
(>10 % of total prostanoids) 
CONTROL PGB2        15-
deoxy-
D12,14-
PGJ2 
TXB2 
VEH3 PGB2       D12-
PGJ2 
15-
deoxy-
D12,14-
PGJ2 
 
VEH24 PGB2  PGE2     D12-
PGJ2 
  
VEH72 PGB2        15-
deoxy-
D12,14-
PGJ2 
 
VEH168  PGD2  PGE1 PGF3α    15-
deoxy-
D12,14-
PGJ2 
TXB2 
ALA3 PGB2     PGF2α   15-
deoxy-
D12,14-
PGJ2 
TXB2 
ALA24   PGE2  PGF3α    15-
deoxy-
D12,14-
PGJ2 
 
ALA72   PGE2    8-iso- 
PGF2α 
   
ALA168 PGB2  PGE2        
231 
 
Several significant differences (P<0.05, two-way ANOVA and post-hoc 
Dunnett‟s t-test) were observed between the eicosanoid composition of 
plasma in ALA-treated animals compared to naïve mice or those injected with 
vehicle. These differences could in turn lead to modulation of prostanoid 
receptor activity in the mouse, leading to systemic effects.  
 
Reduction in 15-deoxy-Δ12,14-PGJ2 
The percentage abundance of 15-deoxy-Δ12,14-PGJ2 was decreased in ALA-
treated mice compared to vehicle-injected or naïve animals at 72h and 168h 
following ALA administration. Although this lipid species has been identified 
as a PPARγ ligand and found to play a role in certain animal models of 
inflammation, such as asthma, the lack of information on the actions of 15-
deoxy-Δ12,14-PGJ2 within the physiological concentration range of 
prostaglandins has led to doubts as to whether this species is of any 
biological importance, or whether it should be regarded solely as a metabolite 
of PGD2. The decrease in 15 -deoxy-Δ12,14-PGJ2 at 72h and 168h post-ALA 
injection may then reflect a drop in circulating PGD2, and the biological 
functions of this species should be considered. Although previous lipidomic 
studies by our group have found considerable amounts of PGD2 in the brain, 
the distribution of the DP receptor does not reflect an important role in the 
CNS and to date, there is a lack of information on the role, if any, that the DP 
receptor plays in the development of post-ischaemic injury.  
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Increase in PGE2 
Plasma PGE2 concentration is also elevated in ALA-treated mice at 72h and 
168h compared to untreated or vehicle-injected mice. It is plausible that the 
elevated levels of circulating PGE2 in the plasma following ALA treatment 
may lead to modulation of one or more of the EP receptor subtypes, which in 
turn mediates a neuroprotective effect upon ischaemic challenge. 
 
Both EP2 and EP4 have protective effects in rodent models of ischaemia 
(McCullough et al., 2004; Xiao et al., 2004) but the EP1 and EP3 receptors 
were both implicated in the development of ischaemia-reperfusion injury in 
mouse models of focal cerebral ischaemia (Saleem et al., 2007; Abe et al., 
2009; Saleem et al.,2009).  
 
Transgenic animals lacking the EP1 receptor gene (EP1-/-) displayed a higher 
rate of cerebral blood flow during MCAO than wild-type animals and neuronal 
cultures from EP1-/- mice also showed greater resistance to oxidative stress 
than wild-type neurons (Saleem et al., 2007), leading to speculation that the 
EP1 receptor is a potential pharmacological target for the treatment of 
ischaemic stroke. These deductions were confirmed by a more recent study 
on the use of the selective EP1 receptor antagonist SC51089 in a mouse 
model of focal ischaemia. This compound proved to be neuroprotective in 
both male and female C57/BL6 mice over a wide time window (Abe et al, 
2009). Infarct volume was significantly reduced in drug-treated mice 
compared to control animals, and performance in neurological tests was also 
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better in drug-treated mice than in controls, leading to speculation that the 
EP1 receptor is a potential pharmacological target for the treatment of 
ischaemic stroke (Abe et al, 2009). Another transgenic animal study showed 
that EP3 receptor knockout (EP3-/-) mice also showed a reduced infarct 
volume in knockout mice following MCAO compared to wild-type animals 
(Saleem et al., 2009).  
 
All four EP receptor subtypes can be found in the rodent brain, but the most 
abundant subtype in the brain is the EP3 receptor, which is widely-distributed 
in the CNS, including the neurons of the cerebral cortex and hippocampus. 
These two areas of the brain are particularly vulnerable to tissue damage 
following a period of ischaemia, which implies that the EP3 receptor in 
particular may have a role to play in the development of neuronal injury in 
stroke. It is possible that the increase in plasma PGE2 results in down-
regulation of the activity of all EP receptor subtypes, which has the positive 
effect of preventing EP3 receptor activation in the brain and subsequent 
neuronal injury following an ischaemic episode. Alternatively, there is the 
possibility that increased activity of the EP1 and EP3 receptor in the brain 
caused by a temporary period of elevated plasma PGE2 following ALA 
treatment acts as a noxious stimulus, leading to the development of 
ischaemic tolerance. 
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Increase in PGF3α 
The relative abundance of PGF3α was increased in ALA-treated mice 
compared to untreated animals or those injected with vehicle at 24h following 
treatment. PGF3α is a 3-series analogue of the biologically active compound 
PGF2α, which regulates vasoconstriction through its action upon the FP 
receptor and also plays a key role in both physiological and 
pathophysiological control of smooth muscle contraction. PGF3α is a partial 
agonist of the FP receptor, competing directly with its more biologically active 
2-series analogue for FP binding space (Wada et al., 2007). The increase in 
PGF3α at t=24h in ALA-treated animals may have resulted in decreased 
activation of the FP receptor by the partial agonist effects of PGF3α on this 
receptor reducing the biological effects mediated by PGF2α through the FP 
receptor. The FP receptor has been reported to contribute to brain injury in a 
mouse model of focal ischaemia and blocking FP receptor activity results in a 
reduction in neuronal injury (Saleem et al., 2009), implying that this 
prostanoid receptor also plays a role in ischaemia- reperfusion injury. The 
increase in plasma PGF3α 24h after PUFA injection may contribute to 
protection against tissue damage in the event of an ischaemic challenge by 
partially blocking the deleterious effects of FP receptor activation.  
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5.4. New issues emerging from this study 
 
Methodological issues 
The refinement of the methodology for the HETE assay (for example, the use 
of a buffer or more refined pH adjustment during the extraction process) in 
order to produce sharper peaks which had minimal tailing would provide 
increased information on the fatty acids. The lack of detected HETEs in this 
study compared to earlier work by our group may have been due to 
differences in sample collection, but there is a possibility that extracted 
samples may have degraded during storage prior to analysis. The risk of UV 
degradation or oxidation of HETEs could be eliminated by storage of 
extracted samples that are to undergo LC-MS/MS analysis of HETEs and 
other related compounds at -80°C in a non-polar solvent with added 
antioxidant. The addition of resolvins and the neuroprotectins to the MRM 
channels studied would also make the assay for hydroxy fatty acids more 
comprehensive, and provide a clearer picture of whether these 
neuroprotective compounds are endogenously produced following 
intravenous PUFA administration. 
 
Total tissue changes vs. redistribution(s) within the tissue 
Our chosen analytical methods only permitted the analysis of lipids of the 
whole tissue rather than at a cellular or sub-cellular level, meaning that the 
possibility of redistribution of phospholipid species between different cellular 
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components, or extracellular changes in brain lipids cannot be ruled out. 
There is also a possibility that statistically significant changes in bioactive 
lipids may have occurred in discrete brain cell populations which were not 
detectable at a whole tissue level. This possibility is particularly important 
when considering changes in the concentration of bioactive lipid mediators in 
the brain, where the levels of relevant species may only be elevated or 
depressed in specific areas of the brain, for instance, perhaps those areas 
which are most vulnerable to injury following brain ischaemia.  
 
Are changes in brain phospholipid composition the most important? 
Fatty acyl chains containing highly-unsaturated fatty acids in phospholipids 
are regarded as a potential pool of substrates for enzymes such as cyclo-
oxygenase and lipo-oxygenase. However, these highly-unsaturated fatty 
acids within the phospholipid structure can only made available for these 
enzymes by hydrolysis at the sn-2 position, which is tightly regulated by 
calcium-dependent enzymes. Under normal physiological conditions, the rate 
of free fatty acid production by PLA2 is counteracted by phospholipid 
synthesis from diacylglycerols and fatty acids, and the amount of free fatty 
acids in the brain remains low. However, the biological actions of hydrolysed 
or oxidised PUFA products such as 10,17S-docosatrienoic acid are apparent 
even at low concentrations (Belayev et al. 2005, Marcheselli et al. 2003, 
Mukherjee et al. 2004), implying that even a small change in the production of 
certain PUFA metabolites could have an effect in rodent models of ischaemic 
stroke. If this is the case, then the composition of the free fatty acid pool in 
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brain or plasma may be of more importance than the phospholipid 
composition.  
 
A study using GC or GC-MS to investigate free fatty acid composition of 
mouse cerebral cortex and plasma would show whether PUFA injection has a 
significant effect on the free fatty acid pool in the circulation, or a more local 
effect on the free fatty acid pool in the brain. This work could provide insight 
into whether the production of neuroprotective PUFA metabolites in the brain 
prior to an ischaemic event could account for the neuroprotective effects of 
intravenous PUFA prior to or immediately after focal ischaemia in rodents. 
 
Assessing the inflammatory status of the animal following fatty acid 
treatment 
It is also unclear whether the process of intravenous PUFA injection exerts its 
neuroprotective effects through “true preconditioning”, where exposure to 
cellular stress results in the development of tolerance to other stressful stimuli 
i.e. cross-tolerance, or by modulation of the post-ischaemic inflammatory 
cascade. A method of investigating whether intravenous PUFA results in 
inflammation following its administration would be to study the expression of 
known biomarkers of inflammation in mice undergoing PUFA treatment. For 
example, the presence of systemic inflammation in mice could be detected by 
studying the expression levels of C-reactive protein or interleukin-6 in plasma. 
Similarly, localised inflammation of the brain could be assessed by 
immunoblotting for inflammatory protein biomarkers such as interleukin-6 or 
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NFκB in brain tissues. An alternative method of assessing brain inflammation 
would be to develop and run a GC-MS or an LC-MS/MS assay for F3–
isoprostanes and F4–neuroprostanes, which are 20:5n-3 and 22:6n-3 
analogues of F2–isoprostanes. F4–neuroprostanes have been suggested as 
biomarkers of brain inflammation in neurodegenerative diseases such as 
Alzheimer‟s disease (Montuschi et al., 2004; Roberts & Fessel, 2004). A 
significant increase in the level of neuroprostanes in mice treated with PUFA 
compared to those undergoing vehicle administration would imply that PUFA 
administration is a stress event, and that PUFA neuroprotection is a form of 
“true preconditioning”. Alternatively, the development of an assay for 
isofurans or neurofurans, which are both indicative of oxidative stress, would 
provide information on whether the administration of PUFA causes tolerance 
to ischaemic conditions through cellular adaptation caused by prior exposure 
to cellular stress. 
 
Expression and function of bioactive lipid receptors 
 
This study showed changes in the relative composition of some bioactive lipid 
mediators in both plasma and cerebral cortex samples, but the results of 
these changes on the expression and the functional activity of receptors in 
both the brain and the circulatory system have not been assessed. The 
observed increases in plasma PGE2  and  PGF3 creates potential for a further 
study on the expression of the EP1, EP3 and FP receptors in brain tissue and 
also on the functional activity of these receptors following fatty acid treatment.  
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Detection and quantification of neural stem cells in adult mice 
 
The detection of a glycerophospholipid which is exclusively linked to neural 
stem cells in the cerebral cortex of adult mice leads to questions as to 
whether enrichment of neural stem cells could result in a more favourable 
neurologiical outcome following MCAO due to self-repair of the ischeamia-
damaged tissue. Several methods of neural stem cell enrichment have been 
described in literature, including exercise, social contact, BDNF and DN-3 
agonists. The presence of the signature phospholipid PE 16:0;20:0 may 
provide a method in which to quantify the relative population of neural stem 
cells in enriched compared to non-enriched animals.  
 
 
5.5 Conclusions 
 
Advanced lipidomic analysis – A new powerful tool for neurochemistry 
Our study detected several phospholipid species in mouse cortex which had 
previously not been reported in lipidomic studies on whole mouse or rat 
brains (see section 5.2.3.). The fatty acyl chains at both sn-1 and sn-2 in the 
majority of these newly identified species are derived from either saturated 
fatty acids or from the monounsaturated fatty acid, oleic acid. However, two of 
the novel species identified in our study contained an eicosadienoic acid 
(20:2) fatty acyl chain at the sn-2 position. They were identified using MS/MS 
as PE16;0-20;2 and PS 18;1-20;2. The phosphatidylethanolamine with m/z 
720 (identified as PE 16:0-18:0 using MS/MS) has been described as a 
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„signature glycerophospholipid‟ of rat retinal stem cells, but had not been 
previously detected in whole brain lipidomic studies. In other terms, lipidomic 
analysis allowed us to demonstrate the presence of a neural stem cell lipid in 
the cerebral cortex.  
 
 
We also detected and identified a novel PS species containing a very long 
chain fatty acid (PS 18:0-24:1), typical of retinal tissue (where fatty acyl 
chains ≥ C24 are common) and myelin (a rich source of 24;1). The method of 
brain dissection used in our studies precludes the accidental incorporation of 
eye tissue into the biological samples and the absence of common myelin 
lipids from other phospholipid classes implies that no contamination of 
cerebral cortex samples with white matter occurred. It can therefore be 
concluded that murine grey matter contains a small, yet detectable, amount of 
longer-chain fatty acyl chains within structural phospholipids. 
 
How ALA treatment may induce adaptive cytoprotection in the CNS (i.e. 
brain preconditioning)? 
 
Structural changes in the plasma membrane are unlikely to have a 
central role  
No widespread changes in the phospholipid composition of mouse cerebral 
cortex were observed following ALA treatment, suggesting that structural 
changes in the plasma membrane are not the cause of fatty acid-induced 
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neuroprotection in mouse models of focal ischaemia. However, the discrete 
changes observed in cerebral cortex lie within the “window of 
neuroprotection”, which lends itself to the theory that changes in the 
composition of brain phospholipids could lead to changes in cell signalling, in 
particular the inflammatory cascade mediated by sn-2 hydrolysis of structural 
brain phospholipids that leads to release of free fatty acids which serve as 
substrates for bioactive lipid mediator compounds. 
 
 
 
Interactions with inflammatory signalling pathways 
The majority of the phospholipid species changed in their relative abundance 
in ALA-treated mice contained fatty acyl or fatty alkyl groups derived from 
unsaturated or monounsaturated fatty acids. These lipids, in contrast to 
highly-unsaturated fatty acids, generally do not give rise to bioactive lipid 
compounds when released from the sn-2 position by phospholipid hydrolysis. 
However, changes observed in eicosadienoic acid-containing species could 
lead to an increase in the rate of production of eicosatrienoic acid, which is a 
substrate for the production of 1-series prostaglandins and hydroxytrienoic 
acids. These lipids can directly compete with the more biologically active 2-
series prostaglandins and hydroxytetraenoic acids respectively, partially 
blocking pro-inflammatory cell signalling pathways. 
 
A potential role for prostanoid receptors in the development of ischaemic 
preconditioning was confirmed by work on lipid mediator profiling in fatty-acid 
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treated mouse cerebral cortex and plasma. Significant changes were 
observed in the composition of eicosanoid species in the cerebral cortex and 
plasma of ALA-treated mice compared to vehicle-injected or naive mice. 
Observed changes in lipid mediators in ALA-treated cerebral cortex were a 
decrease in TXB2 at 3h, 24h and 72h. The systemic effects of ALA 
administration differed from localized effects on cerebral cortex prostanoids, 
with the most notable differences being increases in plasma PGF3α at 24h 
and in plasma PGE2 at 72h and 168h after injection.  
 
The pharmacological activities of isoprostanes such as 8-iso-PGE2 have not 
been confirmed, although it has been suggested that isoprostanes could 
activate both the thromboxane receptor as well as specific isoprostane 
receptors. Activation of the TP receptor by 8-iso-PGE2 could result in 
increased cerebral blood flow through vasodilation, which may at least in part 
counter-act the harmful effects of focal cerebral ischaemia. Cerebral blood 
flow could be assessed using a laser Doppler probe to confirm this theory. 
However, no cloning studies on isoprostane receptors have been reported to 
date and the effect of isoprostane receptors on the development of 
neuroprotection or neuronal injury in models of ischaemia remains unknown. 
  
A reduction in TXB2 would appears to counteract the effects of TP receptor 
activation caused by an increase in 8-iso-PGE,, but it is possible that a 
reduction in the rate of production of TXA2 (the biologically active precursor of 
TXB2) results in upregulation of the TP receptor. However, on the whole, the 
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seemingly counter-productive changes in the concentration of TP receptor 
ligands imply that changes in TP receptor activity may not be the most 
important factor in the development of fatty acid-induced neuroprotection.  
 
The increase in plasma PGE2 at 72h and 168h in ALA-treated animals 
compared to vehicle-injected or naïve mice also supports the theory that fatty 
acid-induced neuroprotection is mediated by effects on the inflammatory 
cascade. Many subtypes of EP prostanoid receptors which are activated by 
PGE2 have been linked to animal models of ischaemia, most notably the EP1 
and the EP3 receptor, both which have been shown to have a deleterious 
effect on post-ischaemia rodent brain. Knockout studies on these genes 
showed that EP1-/- mice and EP3-/- mice both showed a smaller infarct 
volume after MCAO compared to wild-type mice and pharmacological 
blockade of either receptor had a neuroprotective effect. A prolonged 
increase in the levels of circulating PGE2 may result in down-regulation of this 
receptor, or alternatively, the presence of high levels of PGE2 may act as a 
cellular stress event, resulting in the development of cross-tolerance. The lack 
of an obvious phenotype in EP1-/- and in EP3-/- mice may point towards 
these two EP receptor subtypes as a possible pharmacological target for 
stroke therapy. 
 
Finally, the increase in PGF3α observed in mouse plasma after ALA injection 
suggests that FP receptor activity is modulated following ALA injection. PGF3α 
binds to the same prostanoid receptor as its 2-series analogue, but has a 
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lower rate of biological activity than the corresponding 2-series species, 
resulting in partial blockade of the FP receptor. Blocking FP receptor activity 
resulted in a reduction in neuronal injury in a rodent model of focal cerebral 
ischaemia, implying that this prostanoid receptor may play a role in 
ischaemia-reperfusion injury and be a possible pharmacological target in 
stroke therapy. 
 
The changes in prostanoid composition in both cerebral cortex tissue as well 
as in plasma samples suggest that the effects of PUFA treatment are 
widespread, having both systemic and localised effects. The localised 
decrease in cerebral cortex TXA2 may exert a neuroprotective effect by 
causing changes in cerebral blood flow or in modulation of the expression or 
activity of the TP receptor. However, the rise in plasma 8-iso-PGE2 would 
appear to have a seemingly counter-productive effect on TP receptor activity. 
it would appear that changes in in systemic bioactive lipid mediator 
production appear to provide more promising routes for development of a 
prophylactic stroke therapy Increases in plasma PGE2 and PGF3α, both of 
which act on prostanoid receptors that have been shown to play a role in the 
development of ischaemia-reperfusion neuronal injury in rodent models of 
cerebral ischaemia, may provide potential pharmacological targets.  
 
To conclude, the lipid profile changes observed in mice following intravenous 
PUFA treatment arise primarily from systemic effects, although a localised 
effect on one bioactive lipid mediator was also observed. Although subtle 
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differences in brain structural lipid composition was observed between PUFA 
treated animals and vehicle-injected or untreated mice, these changes were 
minor and discrete, suggesting that structural changes in the plasma 
membrane are not the cause of fatty acid-induced neuroprotection in mouse 
models of focal ischaemia. 
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Appendix 1.1 Phospholipid analysis in mouse cerebral cortex 
using MS 
Representative general scan mass spectrum of mouse cerebral cortex in VEH3 group
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Representative general scan mass spectrum of mouse cerebral cortex in VEH24 group 
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Representative general scan mass spectrum of mouse cerebral cortex in VEH72 group 
269 
 
Representative general scan mass spectrum of mouse cerebral cortex in VEH168 
group 
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Representative general scan mass spectrum of mouse cerebral cortex in ALA3 group 
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Representative general scan mass spectrum of mouse cerebral cortex in ALA24 group 
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Representative general scan mass spectrum of mouse cerebral cortex in ALA72 group 
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Representative general scan mass spectrum of mouse cerebral cortex in ALA168 
group 
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Representative neutral loss and precursor ion scanning mass spectra of cerebral 
cortex in VEH3 group mouse 
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Representative neutral loss and precursor ion scanning mass spectra of cerebral 
cortex in VEH24 group mouse 
276 
 
Representative neutral loss and precursor ion scanning mass spectra of cerebral 
cortex in VEH72 group mouse 
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Representative neutral loss and precursor ion scanning mass spectra of cerebral 
cortex in VEH168 group mouse 
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Representative neutral loss and precursor ion scanning mass spectra of cerebral 
cortex in ALA3 group mouse 
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Representative neutral loss and precursor ion scanning mass spectra of cerebral 
cortex in ALA24 group mouse 
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Representative neutral loss and precursor ion scanning mass spectra of cerebral 
cortex in ALA72 group mouse 
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Representative neutral loss and precursor ion scanning mass spectra of cerebral 
cortex in ALA168 group mouse 
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Appendix 1.2 – MS/MS scans of phospholipid species in mouse cerebral cortex 
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Appendix 2 - Lipid mediator analysis in mouse cerebral cortex 
using LC-MS/MS 
Representative chromatograms of 22 MRM channels for naïve mouse cerebral cortex
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Representative chromatograms of 22 MRM channels for naïve mouse cerebral plasma
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